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ABSTRACT 
Cell-cell communication, and specifically epithelial-mesenchymal signalling, is a 
key factor determining normal tissue development and organisation in hollow 
organs such as gastrointestinal tract. Mechanisms governing normal epithelial-
mesenchymal communication have been studied for many years, but the changes 
occurring during tissue damage, infection and inflammation, and in cancer, 
remain unclear. Myofibroblasts are recognised as key mesenchymal cells 
involved in this communication in health and in disease. Myofibroblasts produce 
and secrete many proteins responsible for the assembly of extracellular matrix 
(ECM), tissue organisation and morphogenesis. Initial studies from this 
laboratory suggested that myofibroblasts might exhibit regulated secretion. The 
aim of this project was to determine the secretory mechanisms of myofibroblasts 
from the upper gut of normal and cancer tissues, and to address their significance 
in cancer. 
Gastric myofibroblasts were shown to exhibit calcium-dependent secretion of the 
small ECM protein, Transforming growth factor-β inducible protein or TGFβig-
h3, in response to acute stimulation (30 min) with insulin-like growth factor 
(IGF)s. Inhibitors of protein synthesis (actinomycin D and cycloheximide) and of 
protein transport from endoplasmic reticulum (ER) to Golgi (brefeldin A) 
inhibited basal, but not IGF-stimulated secretion, as seen from Western blot 
analyses of media. These observations support the idea that evoked secretion 
occurs from a pre-formed pool of vesicles. 
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Myofibroblasts from the upper gut showed differences in their secretory 
phenotype; specifically normal myofibroblasts from stomach exhibited regulated 
secretion, but their counterparts from oesophagus did not. Moreover, gastric 
cancer-associated myofibroblasts (CAMs) from patients with poor survival tend 
not to exhibit regulated secretion. These findings suggest a role for the tissue 
microenvironment in determining the secretory phenotype of myofibroblasts. 
Secretome-wide analysis of myofibroblasts media collected after IGF stimulation 
revealed that about 85% of the secretome exhibits evoked release. The relevant 
proteins belonged to different classes including ECM proteins, ligands, binding 
proteins, carbohydrate-binding proteins, proteases and protease inhibitors. These 
data indicate that myofibroblasts may contribute to tissue organisation by rapid 
release of substances involved in re-modelling the tissue microenvironment.    
The regulated secretory phenotype of myofibroblasts was associated with the 
expression of the chromogranin-like protein, secretogranin II. Knock-down of 
secretogranin II inhibited regulated secretion, whereas over-expression in 
myofibroblasts that lacked regulated released - induced it. Expression of 
secretogranin II by myofibroblasts coincided with the expression of dense core 
secretory vesicles that were similar to those found in neuroendocrine cells.  
This work indicates that there is a neuroendocrine-like secretory phenotype in 
myofibroblasts, as illustrated by the expression of neuroendocrine cell protein 
secretogranin II and the presence of regulated secretion. However, not all normal 
myofibroblasts exhibit the regulated phenotype, and in gastric cancer the 
phenotype correlates with early stage of disease. These findings may be 
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exploitable both in the development of novel therapies and in understanding 
cancer progression.   
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1.1 Mechanisms of cell-cell communication  
1.1.1 Overview 
In multicellular organisms, communication between cells is crucial in 
maintaining normal health and development. The concept of an internal balance 
within complex organisms emerged from the idea of the “milieu de l’intérieur” 
introduced by the French physiologist Claude Bernard in 1854 (Gross, 1998). 
Initially, “milieu de l’intérieur” was considered to relate to the chemical 
composition of the blood, but later Bernard extended the principle to other areas 
e.g. temperature. The American physiologist Walter Bradford Cannon expanded 
on Bernard’s view of “milieu de l’intérieur” and introduced the term homeostasis 
in his book The Wisdom of the Body, first published in 1932. To maintain 
homeostasis within the body it was anticipated that tightly controlled 
communication mechanisms existed at different levels of organisation within an 
organism including cell-cell communication.  
 
1.1.2 Signal transduction 
It is now well recognised that cell-cell communication occurs both by soluble 
secreted factors, by cell-matrix interactions and by interactions between 
membrane proteins. Water-soluble cell-cell signalling molecules generally act by 
binding to cell surface receptors to trigger changes in intracellular messenger 
molecules, which are followed by execution of the appropriate physiological 
responses; an early example of this process was elucidated by Rodbell who used 
the term signal transduction (Rodbell, 1980) to describe binding of the hormone 
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glucagon to a receptor on rat liver cell membranes which activated a G-protein 
that subsequently triggered a signalling cascade leading to changes in cell 
metabolism.  
 
1.1.3 The first hormone 
The first clear example for cell-cell communication was provided by the 
discovery of communication via soluble factors released into the blood stream 
and exerting their effects at a distance. In 1902, Bayliss and Starling discovered 
the first hormone, which they termed secretin (Bayliss and Starling, 1902).  They 
showed that a substance was secreted by epithelial cells of the small intestine 
after stimulation with acid and was transported through the blood stream to the 
pancreas, where it stimulated the secretion of the pancreatic juice. The term 
hormone was then introduced in 1905 to describe the class of substances acting 
in this way (Starling, 1905). The process is now also termed endocrine regulation 
and a distinction is recognised between this and paracrine regulation, where 
secreted molecules influence local, or nearby, cells; similarly, in autocrine 
regulation secreted molecules act on the cell that released them in the first place.    
 
1.1.4 Discovery of neurotransmitters 
Prior to the discovery of hormones, the neuroanatomist Ramón y Cajal described 
the anatomy of junctions between neurons (Cajal., 1888), which afterwards were 
termed synapses by Sherrington to stress the functional importance of these 
structures in neuronal communication (Sherrington, 1897). Slightly later, the idea 
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of chemical transmission at synapses was developed independently by Loewi 
(Loewi, 1921) and by Dale who identified the first neurotransmitter, 
acetylcholine (Dale, 1914; Loewi, 1924). 
 
1.1.5 Other types of signalling molecule  
Although hormones (endocrine regulation) and neurotransmitters (neuronal 
regulation) were the first mediators of cell-cell communication to be studied in 
detail, it has been clear for several generations that there are many other 
examples including locally active substances such as cytokines, chemokines and 
growth factors.   
Cytokine is a broad term for signalling molecules applied initially to proteins 
modulating immune cell function. However, it is now known that cytokines exert 
their effects on many different cell types. The unexpected discovery by Nowell 
in the 1960s that a plant lectin stimulated T-lymphocyte proliferation in culture 
triggered studies leading to identification of the first of the family of T-cell 
growth factors (Nowell, 1960), later identified as interleukin-2 (Morgan et al., 
1976).  
Chemokines are a large group of proteins that are released by cells to act as lures 
for other cells in acute and chronic inflammation, during infection and in cancer. 
The first chemokine to be described was interleukin-8, synthesised by various 
cell types including macrophages (Koch et al., 1992) and endothelial cells (Wolff 
et al., 1998) and acting as chemoattractant for memory T cells and monocytes 
(Schall et al., 1990). 
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Growth factors are substances that mediate cell growth and differentiation (Ray 
and Melmed, 1997). In the early 1960s, Levi-Montalcini and Cohen described 
the first growth factor, nerve growth factor (Levi-Montalcini, 1965). This was 
followed by the discovery of epidermal growth factor (EGF) by Cohen, while 
working in Levi-Montalcini’s lab (Carpenter et al., 1978). Many other types of 
growth factor have since been characterised including, for example, platelet 
derived growth factor (PDGF), transforming growth factor (TGF)-α (which is 
chemically related to EGF) and TGF-β (which is chemically unrelated to EGF 
and TGF-α) and the insulin-like growth factors (IGFs).  
 
1.1.6 The insulin-like growth factor system 
1.1.6.1 IGFs 
Insulin-like growth factors illustrate the relationship between hormones and 
growth factors. They were originally identified in 1957 by Daughaday (Salmon 
and Daughaday, 1957) and then chemically characterised as belonging to the 
same group as the islet hormone insulin, although unlike insulin they consist of a 
single aminoacid chain (Daughaday and Rotwein, 1989). In 1977, a family of 
IGF-binding proteins was described (Hintz and Liu, 1977). At the moment, the 
IGF system includes two IGFs (IGF-I and IGF-II), two receptors (IGF-IR and 
IGF-IIR/mannose-6-phosphate receptor) and several IGF binding proteins 
(IGFBPs) (see below) (Ye et al., 2007).  
The mature IGF polypeptides consist of A, B, C and D domains, A and B of 
which are homologous to insulin (Duan and Xu, 2005). Both IGFs are widely 
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expressed in fetal and prenatal stages in different body tissues, however hepatic 
IGF-I production is the major source of circulating IGF-I, regulated by growth 
hormone secretion (Duan and Xu, 2005). The IGFs regulate cell growth and 
development through endocrine, paracrine and autocrine mechanisms (Le Roith 
et al., 2001) via binding to IGF-IR, which is linked to activation of two major 
cellular signalling pathways: mitogen-activate protein kinase (MAPK) and 
phosphatidylinositol-3-kinase(PI3K)-Akt (Coolican et al., 1997).  
 
1.1.6.2 IGFBPs 
IGF-binding proteins regulate the bioavailability and effects of the IGFs. 
Depending on the stability of the bond when complexed with IGF, there are six 
IGFBPs with high affinity and ten with low affinity, which are also known as 
IGFBP-related proteins (Burger et al., 2005). The different IGFBPs are expressed 
in a tissue- and developmental stage-specific manner (Jurgeit et al., 2007). 
Although there is a high structural resemblance, each IGFBP has distinct features 
and specific roles. For example, IGFBP-3 and IGFBP-5 are found in the 
circulation in complex with IGFs (Guler et al., 1987; Twigg and Baxter, 1998), 
thereby mediating their systemic effects. Except for IGFBP-1 that is mainly 
expressed in liver, other IGFBPs are expressed by different cell types, including 
fibroblasts and myofibroblasts, in various organs where they are thought to exert 
their effects locally (Duan and Xu, 2005). Moreover, some IGFBPs inhibit 
(IGFBP-4 and -6), while the rest can either potentiate or inhibit IGF actions 
(Duan and Xu, 2005). In addition, IGFBPs may exhibit IGF-independent effects. 
The IGFBP-related proteins exhibit 20- to 100-fold lower affinity in comparison 
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with IGFBPs toward IGFs (Oh et al., 1996) and they too are believed to have 
IGF-independent effects (Hwa et al., 1998).  
Two IGFBPs were identified in the current project: IGFBP-5 and IGFBP-7. The 
former was described about 20 years ago. In addition to its systemic IGF-related 
effects via the circulation, IGFBP-5 binds to IGF-IR on the cell surface and 
different extracellular matrix (ECM) proteoglycans that can lead to both 
inhibitory and stimulatory IGF effects depending on the cell type, method of 
administration or experimental conditions (Beattie et al., 2005; Yin et al., 2004). 
Besides IGF-related effects, IGFBP-5 exhibits some IGF-independent effects 
such as activation of the plasminogen system associated with tissue remodelling 
(Sorrell et al., 2006). Also, IGFBP-5 is reported to bind a specific cell surface 
IGFBP-5 receptor, followed by cellular uptake and activation of cellular 
pathways of growth and apoptosis (Andress, 1995; Andress, 1998). Moreover, 
IGFBP-5 is identified in the nucleus of different cell types, where it possibly acts 
as a signalling molecule (Schedlich et al., 2000). Multiple studies demonstrate 
that IGFBP-5 induces apoptosis (Hung et al., 2008), inhibits tumour growth and 
tumour vascularisation both in vitro and in vivo (Butt et al., 2003; Rho et al., 
2008).  
Insulin-like growth factor binding protein-7 (IGFBP-7) is the first member of the 
IGFBP-related proteins, and hence it is also called IGFBP-related protein-1 (Hwa 
et al., 1999). It acts as a tumour suppressor to inhibit tumour growth in a breast 
cancer cell line (Amemiya et al., 2011) and to induce apoptosis in prostate cancer 
cells (Mutaguchi et al., 2003).  
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1.1.6.3 The IGF system and the gut 
The local role of the IGF-system is well illustrated by mechanisms in the 
gastrointestinal (GI) tract (Lund, 1999). A local or paracrine action of IGFs 
predominantly produced by mesenchymal cells (fibroblasts and myofibroblasts) 
determines epithelial cell turnover (Williams et al., 2002). The high turnover of 
gut epithelial cells i.e. the process of cell renewal, is determined in part by IGFs 
acting in a paracrine way on cell growth, proliferation and differentiation 
(Williams et al., 2002). In addition, IGF-I may also influence intestinal transport 
of sugar (Castilla-Cortazar et al., 1997) and normalise aberrations in ion transport 
(Peterson et al., 1996). Previous work from our laboratory identified IGF-II as an 
autocrine growth factor from colonic and gastric myofibroblasts (Hemers et al., 
2005). Subsequent unpublished work from the laboratory showed that IGF-II 
increases intracellular calcium in gastric myofibroblasts (McCaig, Burdyga & 
Varro, unpublished observations), thereby raising questions as to whether there 
might not be other effects on cellular function besides mitogenic effects. 
 
1.2 Biology of protein secretion  
1.2.1 Secretion – classical and unconvential pathways  
For many years after their discovery, hormones and neurotransmitters were 
considered to be part of quite different biological processes. It was recognised, 
however, that both were released by cells in response to stimulation and with the 
elucidation of cellular mechanisms of secretion it became clear that similar 
cellular events were involved. The so-called classical pathway of secretion 
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(exocytosis) of proteins from eukaryotic cells was largely elucidated by Palade 
and his colleagues working on enzyme secretion from pancreatic acinar cells 
(Caro and Palade, 1964; Jamieson and Palade, 1967; Palade, 1956) and later 
shown to apply to peptide hormones. In 1978, Tartakoff and Vassalli suggested 
that there are two types of secretory process: constitutive and regulated 
(Tartakoff et al., 1978). Constitutive secretion involves the release of newly 
synthesised protein within minutes and is unregulated, whereas regulated 
secretion involves storage of secretory product, often in large quantities, in 
secretory vesicles with dense cores that are released after stimulation through a 
mechanisms involving increased intracellular calcium (Douglas and Rubin, 1961; 
Douglas and Rubin, 1963) (Figure 1.1). Although some cases of calcium-
independent secretion were reported, even in these systems calcium remained an 
obligatory element in the regulated secretion mediated by other secondary 
messengers (Hutton, 1986).  
Additionally, neurons exhibit calcium dependent exocytosis from small clear 
synaptic vesicles docked near the presynaptic membrane and involved in rapid 
release of small, nonprotein, neurotransmitters such as acetylcholine, glutamate 
and gamma-aminobutiryc acid (GABA) (Kelly, 1993). Unlike dense core 
secretory vesicles, synaptic vesicles do not originate from Golgi, as they are 
recycled and refilled near the pre-synaptic membrane (Heuser and Reese, 1973).  
There are some examples of cells specialised for regulated secretion, which are 
not of neuronal, endocrine or exocrine origin. For instance, juxtaglomerular cells 
                                                Chapter 1 - Introduction 
30 
 
 
Figure 1.1 Secretion pathways. Cells release substances via two main secretion 
pathways: constitutive and regulated. Proteins are synthesised on ribosomes of 
the rough ER, transported through Golgi cisternae and sequestered within 
constitutive secretory vesicles labelled with membrane proteins for the 
constitutive pathway, or within dense core secretory vesicles containing core 
made of granins for the regulated pathway. Regulated secretion requires an 
extracellular stimulus or secretagogue and increased intracellular calcium. 
However, some proteins (eg FGF-2, IL-1β, galectin-3) leave the cell via 
unconventional secretion, i.e. not via the ER-Golgi pathway. 
 
of the kidney secrete renin (Friis et al., 2000), endothelial cells secrete Weibel-
Palade bodies (Birch et al., 1992), and non-neuronal cells of the CNS (astrocytes) 
may secrete neurotransmitters (Volterra and Meldolesi, 2005).   
More recently, it was discovered that some proteins may leave cells through 
routes that do not involve the ER-Golgi pathway, termed unconventional 
secretion (Figure 1.1). The first proteins shown to exhibit unconventional 
secretion were the cytokine interleukin-1β (Rubartelli et al., 1990) and the 
carbohydrate-binding protein galectin-1(Cooper and Barondes, 1990). However, 
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over the last two decades the list has grown to include other proteins such as 
fibroblast growth factor-1 (Jackson et al., 1992), fibroblast growth factor-2 
(Mignatti and Rifkin, 1991) and galectin-3 (Sato and Hughes, 1994). Also, there 
are a number of membrane-anchored precursors that are released on stimulation 
through mechanisms involving cleavage (or shedding) converting them into 
soluble forms for example members of the EGF family such as heparin-binding 
EGF-like growth factor (Goishi et al., 1995; Higashiyama et al., 1991). 
 
1.2.2 Mechanism of secretion  
The classical secretory pathway can be dissected into a number of functional 
stages (Burgess and Kelly, 1987). It starts with synthesis, i.e. addition of 
aminoacids, at ribosomes attached to the rough ER where the protein is passed 
through the membrane of the ER to the lumen; some post-translational 
modifications can occur at this stage including signal peptide cleavage, 
glycosylation and folding even before protein synthesis is complete. Secretory 
proteins entrapped within transport vesicles then leave the ER and are directed to 
the Golgi apparatus, where they fuse with Golgi membranes and their cargo 
passes into the Golgi lumen. The Golgi apparatus consists of three functionally 
distinct regions cis-, medial- and trans-, the latter also giving rise to the terminal 
compartment the trans-Golgi network (TGN). Within the Golgi apparatus 
proteins are modified by glycosylation and in the TGN there may be 
phosphorylation or sulphation, followed by sorting and packing within secretory 
vesicles. Sorting of proteins to the appropriate pathway depends on multiple 
factors, and those with relevance to this study are discussed later. Proteins 
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packaged into secretory vesicles pass through the cytosol to the plasma 
membrane for release via exocytosis. The process of membrane fusion involves 
multiple stages, including tethering, docking, fusion and release (Burgoyne and 
Morgan, 2003). Although constitutive and regulated secretory pathways share the 
basic cellular exocytotic machinery, there is specificity in the molecular 
mechanisms most notably there is an obligatory calcium-dependent mechanism 
involved in regulated exocytosis.  
 
1.2.3 Cellular machinery for regulated secretion  
1.2.3.1 Regulated secretory proteins 
A number of proteins have been shown to be involved in the formation and 
maturation of the dense core secretory vesicles, most notably members of the 
chromogranin family. These are acidic, soluble secretory proteins present in cells 
exhibiting regulated secretion from dense core secretory vesicles of neuronal and 
endocrine lineages (Wiedenmann and Huttner, 1989). The first members of the 
group to be identified were the “classic” granins, namely chromogranin A which 
was initially isolated from chromaffin cells of the adrenal medulla (Banks and 
Helle, 1965; Helle, 1966), chromogranin B (or secretogranin I) which was 
isolated from a rat pheochromocytoma cell line (Lee and Huttner, 1983) and 
secretogranin II, previously known as chromogranin C which was initially 
described in anterior pituitary (Fischer-Colbrie et al., 1995; Rosa and Zanini, 
1981). Six other acidic soluble proteins, which are less well known, have since 
been identified including secretogranins III (1B1075)(Ottiger et al., 1990), IV 
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(HISL-19 antigen)(Neuhold and Ullrich, 1993), V (neuroendocrine secretory 
protein 7B2)(Seidah et al., 1983), VI (NESP55)(Ischia et al., 1997), VII (the 
nerve growth factor inducible protein VGF)(Levi et al., 1985) and pro-SAAS 
(Fricker et al., 2000).  
The Chromogranin A and B, and secretogranin II genes, contain cAMP-response 
elements within their proximal promoters, which play a crucial role in 
neuroendocrine-specific gene expression (Mahapatra et al., 2000; Mahata et al., 
1999; Wu et al., 1995). Granin synthesis seems also to respond to agents like 
steroid hormones and neurotrophin growth factors (Taupenot et al., 2003).  
The primary structure of granin molecules consist of a single polypeptide chain 
with an amino-terminal signal peptide sequence and a similar carboxy-terminal 
motif. Chromogranin A and B also share a highly-homologous structure in their 
amino-terminal region, namely a disulfide-bonded loop (Benedum et al., 1987). 
There are multiple sites for proteolytic processing (i.e. pairs of basic amino acid 
residues) suggesting that these molecules act as precursors for smaller secreted 
peptides. Thus cleavage of the granins by prohormone convertases-1 and -2 
(Eskeland et al., 1996; Laslop et al., 1998), and plasmin (Jiang et al., 2001), leads 
to generation of biologically active products such as pancreastatin (Tatemoto et 
al., 1986) and vasostatin from chromogranin A (Aardal et al., 1993; Ratti et al., 
2000) and secretoneurin from secretogranin II (Fischer-Colbrie et al., 1995), 
which can act as autocrine, paracrine or endocrine factors.  
The granins bind calcium with low affinity, but high capacity and tend to 
aggregate at low pH and in the presence of calcium, a process believed to 
determine aggregation in the TGN and thought to be part of a sorting mechanism 
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for secretory vesicles of the regulated pathway, so-called “sorting by retention” 
(Gerdes et al., 1989; Reiffen and Gratzl, 1986; Yoo and Albanesi, 1991). 
Through condensation and aggregation at low pH and high calcium, the granins 
are believed to be an essential component of the dense core of secretory vesicles 
of the regulated secretory pathway by controlling vesicle biogenesis. Also, 
granins serve as chaperones in the sorting of other regulated secretory proteins 
into dense core secretory vesicles (Gerdes et al., 1989; Gorr et al., 1989; Huttner 
and Natori, 1995). Thus the  granins have been suggested to serve as markers of 
dense core secretory granules in neurons and endocrine cells in both normal and 
neoplastic tissues (Huttner et al., 1991). Immunoreactivity for chromogranins A 
and B, and to some extent of secretogranin II and other granins, has been linked 
with different neuroendocrine tumours and their circulating levels may reflect the 
secretory activity of these tumours (Taupenot et al., 2003).  
While chromogranin A and B have been quite intensively studied, secretogranin 
II is somewhat less well understood. It exhibits relatively weak homology with 
chromogranins A and B (Taupenot et al., 2003). Nevertheless, recent reports 
have shown that both N- and C-terminal regions of the polypeptide structure 
contain independent sorting signals that are sufficient to direct secretogranin II 
into the dense core granules of the regulated pathway (Courel et al., 2010).  
 
1.2.3.2 Membrane fusion proteins 
A central role in membrane fusion events is played by the membrane-bound 
SNAP receptor proteins (SNAREs) (Sollner et al., 1993b). SNARE proteins are 
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receptors for N-ethylmaleimide-sensitive fusion protein (NSF) and α-soluble 
NSF attachment protein (α-SNAP) (Burgoyne and Morgan, 2003). All SNARE 
proteins have a characteristic heptad repeat sequence, termed the SNARE motif 
(Kloepper et al., 2007). Of the many SNAREs in the human genome only a 
dozen or so are fusogenic (Sudhof and Rothman, 2009). Individual SNARE 
proteins are unfolded, but they spontaneously assemble into a stable four-helix 
bundle (Sutton et al., 1998) that forms between the two membranes and catalyzes 
fusion by forcing membranes together as they  zipper up (Hanson et al., 1997). 
SNAREs can be separated in two groups: present on the vesicle (donor) 
membrane i.e. v-SNAREs (vesicle-associated membrane proteins such as VAMP 
and synaptobrevin), and present on the target (acceptor) membrane i.e. t-
SNAREs (such as syntaxin and SNAP-25) (Gerst, 1999). According to the 
SNARE hypothesis, v-SNAREs and t-SNAREs form a stable complex that 
targets the vesicle to the correct destination at the plasma membrane (Rothman 
and Orci, 1992). Subsequent binding of the core SNARE complex to α-SNAP 
and adenosine triphosphate(ATP)ase NSF, which brings a significant energy 
input associated with ATP, disassembles the SNARE complex (Sollner et al., 
1993b).  
Synaptobrevin/VAMPs are small membrane proteins of about 120 amino acids, 
that exhibit extended or two short amphipathic α-helical segments, able to form 
coiled-coil structures (Gerst, 1999). Synaptobrevin/VAMPs are components of 
synaptic vesicle membranes (Baumert et al., 1989) and bind α-SNAP (Sollner et 
al., 1993a). They are substrates for clostridial neurotoxins, i.e. botulinum and 
tetanus toxins, which block synaptic transmission at the presynaptic membrane 
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(Montecucco and Schiavo, 1993). There are at least four known 
synaptobrevin/VAMP isoforms, associated with secretory granule and synaptic 
vesicle release in mammalian cells (Gerst, 1999). It has been discovered that the 
toxin-sensitive VAMP2, and the toxin-insensitive VAMP1A, are present in 
secretory granules, dense core vesicles and synaptic vesicles (Baumert et al., 
1989). Other VAMP isoforms are thought to be related to the constitutive 
pathway (Gerst, 1999).  
Syntaxins are t-SNARE proteins of around 300 amino acids with at least three 
putative coiled-coil forming regions (sites for protein binding) and a single 
transmembrane domain (Bennett et al., 1993). There are at least four known 
syntaxins (syntaxin 1A, B and possibly C, syntaxins 2 to 4) present in the plasma 
membrane and associated with exocytosis (Bennett et al., 1993). Syntaxins have 
roles in the earlier steps of the secretory pathway (Gerst, 1999), they can interact 
with calcium-sensing protein synaptotagmin (Shao et al., 1997) and the t-SNARE  
SNAP-23 associated with the constitutive secretion (Wang et al., 1997).  
SNAP-25 is expressed by neurons (Oyler et al., 1989) and by many non-neuronal 
cells exhibiting regulated secretion (Kannan et al., 1996; Sadoul et al., 1995). 
Like other SNAREs, SNAP-25 has heptad repeats, is able to form coiled-coils 
and α-helices (Gerst, 1999) with synaptobrevin/VAMP and syntaxin (Chapman 
et al., 1994). SNAP-25 is linked to calcium-sensing via binding to synaptotagmin 
(Schiavo et al., 1997) and via interaction with the calcium channels (Wiser et al., 
1996).  
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1.2.3.3 Calcium-sensing proteins 
Many different proteins with calcium-binding properties have been described. 
For example, specific C2 domains in the primary structure of protein kinase C, 
synaptotagmin, rabphilin 3A, calmodulin, calcyclin and annexin allow them to 
bind phospholipids in a calcium-dependent manner (Burgoyne and Morgan, 
1998). One of the best characterised families of putative calcium sensors is the 
family of 13 proteins called synaptotagmins (Brose et al., 1992). Synaptotagmins 
also bind other molecules involved in regulated exocytosis including calcium-
channels (Leveque et al., 1992), SNARE complex (Sollner et al., 1993a) and 
calmodulin (Fournier and Trifaro, 1988).  
 
1.2.3.4 Other regulated secretory proteins 
SNAREs have been identified as essential components for the fusion event, but 
they are far from being the only proteins involved. For example, Rab GTPases 
have been long known to play a role in regulated secretion by regulating the 
transport of vesicles through the actin cytoskeleton and by regulating the 
assembly of the tethering proteins between vesicle and target membrane (Zerial 
and McBride, 2001). Other important regulators belong to the SM 
(Sec1/Munc18) protein family, where Sec1 is a yeast protein and Munc18 stands 
for the Munc18 mammalian proteins (Burgoyne et al., 2009). SM proteins have 
been extensively studied in relation to membrane fusion events. They consist of 
around 600 amino acids that fold into an arch-shaped “clasp” structure (Misura et 
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al., 2000) and are capable of interacting with SNAREs and either inhibiting 
(Sudhof and Rothman, 2009) or promoting fusion (Yamaguchi et al., 2002).  
Other regulators of SNARE assembly and disassembly may act to activate or 
inhibit fusion depending on the conditions. These include “grappling” proteins 
involved in membrane fusion, i.e. they keep the cell machinery in a “ready-to go” 
state so that a small stimulus can trigger the fusion event (Sudhof and Rothman, 
2009). Synaptotagmin and complexins are the best described grappling proteins, 
which are responsible for the precise timing and place of release (Rizo and 
Rosenmund, 2008). SNAREs complexes are clamped by complexins in an 
activated state (Tang et al., 2006). Increases in intracellular calcium, followed by 
binding to synaptotagmin serve as a trigger to release the clamp and for the 
SNARE complex to proceed to fusion (Pang et al., 2006).  
Other protein families described as SNARE function regulators include 
synaptophysin (for v-SNAREs), DOC2 (modulator of syntaxin-MUNC18 
interaction), protein kinase C (a calcium-dependent tyrosine kinase); moreover, 
there is a large group of proteins implicated in regulated secretion including 
syncollin, Hrs-2, SV2, CAPS and VAP33 (Gerst, 1999).  
 
1.3 The gastrointestinal tract and epithelial-mesenchymal communication  
1.3.1 Epithelial-mesenchymal communication in health 
Tissue organisation in hollow organs (e.g. gastrointestinal tract, airways, 
urogenital system) is maintained by interactions between epithelial cells and 
underlying mesenchymal (stromal) cells that are the source of growth factors 
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such as IGF and TGF-β (Powell et al., 1999a). Epithelial-mesenchymal cell 
communication is recognised to be crucial in normal development and 
differentiation, and in wound healing, inflammation and cancer (Castro and 
Arntzen, 1993; Perdue and McKay, 1994).  
There is a common pattern of organisation along the length of the gastrointestinal 
tract or the gut, although each region has its own characteristic structure. 
Typically there is: mucosa, consisting of an epithelial layer facing the lumen; the 
underlying lamina propria; a thin layer of smooth muscle (muscularis propria); a 
dense irregular layer of connective tissue called submucosa that includes a nerve 
plexus (the submucosal plexus); two layers of smooth muscule (inner circular 
and outer longitudinal) with a nerve plexus (the myenteric plexus) between them; 
and adventitia or serosa consisting of several layers of connective tissue (Lund, 
1999).  
Each compartment of the gut wall consists of characteristic cell types, but in 
recent years myofibroblasts have emerged as a key component of sub-epithelial 
tissues that play a role in determining tissue organisation (Figure 1.2). These 
cells can be divided into two sub-groups depending on their exact localisation: 
subepithelial myofibroblasts are found in the lamina propria, and interstitial cells 
of Cajal are in the muscularis propria and in the submucosa (Powell et al., 
1999b). There is a tight perycriptal sheath of myofibroblasts of the lamina 
propria in the intestine (Pascal et al., 1968), which forms a syncytium extending 
throughout lamina propria (Joyce et al., 1987). In the stomach, myofibroblasts do 
not form a tight sheath (Mutoh et al., 2005), but they are found scattered within 
the gastric mucosa (Wu et al., 1999), and represent one of the major cell types 
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producing factors influencing the organisation, development and differentiation 
within the mucosa. 
 
1.3.2 Epithelial-mesenchymal communication in disease 
1.3.2.1 H. pylori infection and other gastric inflammatory conditions  
Changes in tissue architecture such as occurring in inflammation and wound 
healing are associated with increased proliferation and migration of cells in both 
epithelial and subepithelial compartments, and include changes in myofibroblast 
numbers and activity (Figure 1.2). 
In the case of the upper gastrointestinal tract, the point is well illustrated by the 
changes that occur with Helicobacter pylori infection. Originally identified in 
1982 by Barry Marshall and Robin Warren, H.pylori infection is associated with 
chronic gastritis and peptic ulcer (Marshall and Warren, 1984). It is now known 
that H.pylori infection is related to changes in the tissue microenvironment 
including changes in gene expression in gastric epithelial cells (Mills et al., 2001) 
and increased gastrin secretion (Levi et al., 1989). Increased gastrin secretion 
leads to increased acid secretion and activates local defence systems e.g. 
increasing epithelial cell migration and cell renewal, and growth factor secretion 
(Kirton et al., 2002; Noble et al., 2003).  
Prolonged elevation of plasma gastrin is also associated with other conditions 
such as achlorhydria e.g. pernicious anaemia (Dockray et al., 2005; Jensen, 
2002). Pernicious anaemia is a condition of chronic inflammation in the stomach, 
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which develops on the basis of atrophic gastritis and is associated with 
generation of auto-antibodies to gastric parietal cells, leading eventually to their 
 
 
Figure 1.2 Epithelial-mesenchymal signalling in health and disease, and in 
cancer. Myofibroblast is a key cell type in epithelial-mesenchymal cross-talk, 
determining normal tissue organisation (A). In H.pylori infection and other 
gastric inflammatory conditions there is increased secretion of growth factors and 
matrix proteases, i.e. normal epithelial-mesenchymal signalling is impaired, 
leading to cell growth and proliferation and ECM degradation (B). Transition 
from normal conditions to cancer is associated with changes in epithelial-
mesenchymal signalling, including changes in the genome, proteome and 
secretome of myofibroblasts e.g. decreased secretion of ECM protein TGFβig-h3 
(C).  
 
loss. Gastric acid, produced by parietal cells, inhibits G-cell function, so 
following atrophy there is increased G-cell numbers and increased plasma 
gastrin. Elevated plasma gastrin causes hyperplasia of the histamine-secreting 
enterochromaffin-like cells (ECL) in the gastric corpus (Bordi et al., 1995), and 
in some cases this may lead to dysplasia and formation of ECL carcinoid 
tumours (Dockray et al., 2005; Gibril et al., 2004; Peghini et al., 2002). 
Importantly, elevated gastrin also stimulates production of MMP-7, which in turn 
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stimulates proliferation of gastric myofibroblasts and epithelial cells via cleavage 
of IGFBP-5 and liberation of IGF-II (Varro et al., 2007) (Figure 1.2). 
 
1.3.2.2 Gastric cancer and tumour microenvironment 
Many reports associate chronic inflammation with H.pylori in the stomach with 
an increased risk of gastric cancer (Parsonnet et al., 1991). Gastric cancer is one 
of the most common malignancies of the gastrointestinal tract. Despite its 
declining incidence, 5-year overall survival is generally accepted as <15% for 
patients diagnosed in late stages (Gao et al., 2008; Siewert et al., 1998), which 
has been attributed to its late clinical onset and rapid progression (Jemal et al., 
2009; Lochhead and El-Omar, 2008). A multistep model for progression to 
gastric cancer was proposed by Correa, starting with chronic gastritis, through 
atrophy, metaplasia and dysplasia leading to carcinoma (Correa, 1992).  
Most gastric cancers (~95%) are adenocarcinomas of intestinal, diffuse or mixed 
type according to the Lauren histological classification (Lauren, 1965). The other 
5% are rare cancers of the smooth muscle (leiomyosarcomas), lymph 
(lymphomas), neuroendocrine (carcinoids) or stromal tissue (gastrointestinal 
stromal tumours or GIST) (Rotterdam, 1989). Beside gastric cancer another 
malignancy of the upper gut is the oesophageal cancer. Oesophageal cancers 
predominantly are squamous cell carcinomas (in the upper or middle part of the 
oesophagus) and adenocarcinomas (in the lower part of oesophagus) (Daly et al., 
2000).   
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Increasingly, a role for the microenvironment in promoting preneoplastic tissue 
remodelling has been recognised. The idea that tumour development requires an 
appropriately supportive tissue microenvironment, can be found in the “soil and 
seed hypothesis” first discussed by Paget in 1889 (Paget, 1889). The term 
“tumour microenvironment” was introduced in the late 1970s to stress the 
importance of the microenvironment (Cunha and Matrisian, 2002). The tumour 
microenvironment consists of the interconnected host cells of the cancer stroma 
including connective tissue cells, blood vessels and inflammatory cells, and the 
surrounding ECM, as well as cancer cells themselves (Figure 1.2). It is 
recognised that the tissue microenvironment can exert dual effects both 
protecting the host from cancer cell expansion and promoting cancer cell growth.  
In some solid tumours the stromal compartment can account for more than 90% 
of the tumour mass (Ronnov-Jessen et al., 1996). Myofibroblasts have been 
recognised as a particularly abundant cell type in the tumour stroma, and more 
recently were identified as an active contributor in carcinogenesis (Bhowmick et 
al., 2004).  
 
1.4 Myofibroblasts 
1.4.1 The origin of myofibroblasts 
Myofibroblasts are derived from fibroblasts which are non-vascular, non-
epithelial and non-inflammatory cells that constitute the principal cellular 
component of connective tissue (Kalluri and Zeisberg, 2006). Various stimuli, 
including tissue injury and inflammation, and mediators such as TGFβ and 
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PDGF (Desmouliere et al., 2003), convert fibroblasts to myofibroblasts 
(sometimes called activated fibroblasts). Similar processes are thought to occur 
during cancerogenesis (De Wever and Mareel, 2002), and are associated with 
changes in gene expression including increased expression of α-smooth-muscle 
actin (Gabbiani et al., 1971). However, another hypothesis suggests that 
myofibroblasts share some common features with, and may arise from, smooth 
muscle cells. For example, intestinal myofibroblasts were described to originate 
histologically from the thin layer of smooth muscle of the muscularis mucosae 
(Powell, 2005). This was also the case for at least part of the cancer-associated 
myofibroblasts (CAMs) in the invasive gastric carcinoma (intestinal type) (Jiang 
et al., 2008).  
Recent data has shown that bone marrow-derived mesenchymal stem cells 
(MSCs) may contribute to the development of inflammation-based gastric cancer 
(Houghton et al., 2004), and that these cells may also to be transformed into 
CAMs at the tumour site (Quante et al., 2011). Notably, 15-25% of CAMs in the 
tumour stroma of mouse gastric cancers exhibited markers of bone marrow-
derived MSCs (Direkze et al., 2004).  
Adult bone-marrow is a source of two different pluripotent cell populations: 
haematopoietic stem cells (Lewis and Trobaugh, 1964) and MSCs (Beresford, 
1989; Caplan, 1991). MSCs under appropriate conditions are able to differentiate 
into different cell lineages, including fibroblast/myofibroblasts, osteoblasts 
(Haynesworth et al., 1992), chondrocytes (Johnstone et al., 1998) and adipocytes 
(Pittenger et al., 1999). By doing so, stem cells are efficient in maintaining tissue 
and organ homeostasis through regeneration (Urbanek et al., 2005). In addition, 
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however, during the multi-step lineage progression, MSCs respond to a spectrum 
of stimuli via synthesis and secretion of a number of growth factors and 
cytokines so that they also have both direct and indirect effects on other cells in 
their proximity (Haynesworth et al., 1996).  
 
1.4.2 Role in health  
Myofibroblasts are usually found in relatively low density. They regulate 
epithelial morphogenesis (Bhowmick et al., 2004) and maintain the structural 
integrity of the ECM by secreting many of its components including collagen 
type I, III and V and fibronectin (Rodemann and Muller, 1991; Tomasek et al., 
2002). By secretion of type IV collagen and laminin they also contribute to the 
formation of basement membrane (Chang et al., 2002). They produce and secrete 
many growth factors including TGF-β (Border and Noble, 1994), PDGF 
(Bostrom et al., 1996; Leveen et al., 1994), HGF (Goke et al., 1998), IGF-I and 
IGF-II (Lund, 1999), growth factor binding proteins, proteases and protease 
inhibitors (Kalluri and Zeisberg, 2006). Myofibroblasts are found in increased 
numbers during the repair processes involved in the response to tissue injury, 
damage or infection (De Wever and Mareel, 2002) when they release increased 
amounts of ECM proteins and ECM-degrading proteases such as matrix 
metalloproteinases (MMP)-2, MMP-3 and MMP-9, implicated in increased ECM 
turnover (Rodemann and Muller, 1991). Additionally myofibroblasts participate 
in local immune response, via secretion of cytokines, such as IL-1, and 
chemokines (Rollins et al., 1989; Strieter et al., 1989).  
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Following wound healing, the number of myofibroblasts decreases and they 
regain their resting phenotype or undergo apoptosis (Tomasek et al., 2002). 
However, in some circumstances myofibroblasts remain activated leading to 
tissue fibrosis (Kalluri and Zeisberg, 2006) and their contraction accounts for the 
distorted architecture of scar tissue. 
Besides their phenotypic and functional similarities, myofibroblasts from 
different tissues may exhibit degrees of specificity e.g. intestinal subepithelial 
myofibroblasts participate in electrolyte transport (Valentich, 1994) and 
interstitial cells of Cajal are implicated in the control of motility throughout the 
gut (Sanders, 1996).   
 
1.4.3 Role in cancer 
Recent work emphasises that CAMs differ from normal tissue myofibroblasts in 
number, cellular architecture, localisation, and in functional properties (De 
Wever and Mareel, 2002). Nevertheless, like normal myofibroblasts they 
participate in paracrine and autocrine control mechanisms involving secretion of 
signalling molecules such as growth factors and their binding proteins, proteases 
and protease inhibitors, and multiple ECM proteins, that collectively support 
cancer development (Kalluri and Zeisberg, 2006). In addition to secretion of 
soluble factors, myofibroblasts participate in the recruitment of other stromal cell 
types including macrophages, pericytes and endothelial cells (Rodemann and 
Muller, 1991), however in the later stages they support cancer progression 
simply by blocking immune and inflammatory cells from the tumour site 
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(Lieubeau et al., 1999). Also, myofibroblasts contribute to cancer progression by 
facilitating the invasiveness, i.e. metastasis, of otherwise non-invasive cancer 
cells (Dimanche-Boitrel et al., 1994). Further, myofibroblasts in the metastatic 
site support cancer cell growth similar to the myofibroblasts in the initial tumour 
site (Olaso et al., 1997).  
A significant body of the work on myofibroblasts in cancer, has come from 
studies of breast and prostate cancer and by comparison much less is known of 
gastric cancer. Even so, however, recent work has shown that gastric 
myofibroblasts contribute to tumour development (Yuhiko Fuyuhiro  and 
Hirakawaawaawa, 2010) and angiogenesis (Guo et al., 2008). Moreover, 
unpublished work from this laboratory has shown that gastric CAMs unlike 
normal gastric myofibroblasts can stimulate cancer cells proliferation, invasion 
and migration both in vitro and in vivo (Charlotte Woodcock, MPhil thesis); and 
a myofibroblasts-derived ECM protein TGFβig-h3 acts to inhibit these effects 
(Kumar & Varro, unpublished observations).  
 
 
1.4.4 The myofibroblast secretome 
Previous studies on colon and gastric myofibroblasts, showed that IGFBP-5 was 
a target of matrix metalloprotease-7 (MMP-7) and that following cleavage there 
was release of IGF-II (Hemers et al., 2005) which in turn stimulated proliferation 
and migration of both epithelial cells and gastric myofibroblasts (Hemers et al., 
2005; McCaig et al., 2006). Other proteins identified as secreted by 
myofibroblasts in these studies included collagen α1 types I, III and VI, and 
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fibronectin. Subsequently, a number of differentially secreted proteins in CAMs 
compared to normal myofibroblasts were identified including e.g. TGFβig-h3, 
which was decreased in the media of CAMs from patients with advanced disease 
compared with myofibroblasts from early stage disease, or normal cells 
(Holmberg & Varro, unpublished observations). However, these studies leave 
unanswered the question of the mechanism of secretion by myofibroblasts and of 
the changes occurring in cancer. The following sections briefly introduce some 
of the main protein groups known to be released by myofibroblasts and so 
potentially accounting for the difference between CAMs and normal 
myofibroblasts. 
 
1.4.4.1 Matrix proteases and their inhibitors 
Myofibroblasts produce and secrete a range of matrix proteases and protease 
inhibitors including members of zinc superfamily of proteases (containing Zn2+ 
ion in the catalytic centre): matrix metalloproteases (MMPs) and desintegrin and 
metalloproteases (ADAMs) (Powell et al., 1999a). The MMPs are a family of 23 
zinc-dependent endopeptidases, and they are separated into two major groups: 
soluble and membrane-anchored (Klein and Bischoff, 2011). In turn, soluble 
MMPs are characterised according to their substrate specificity as collagenases, 
gelatinases, stromelysins and a heterogenous group including for example MMP-
7. Initially, MMPs were believed to modulate and regulate ECM turnover by 
directly degrading ECM proteins such as collagen, proteoglycans and fibronectin 
(Woessner, 1991). However, MMPs also degrade other components of the ECM 
including growth factors, cytokines, adhesion molecules and protease inhibitors 
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such as serine protease inhibitors (Nagase and Woessner, 1999). Also, MMPs 
liberate active forms of growth factors, cytokines and chemokines from their 
membrane-anchored pro-forms, a process termed shedding (Klein and Bischoff, 
2011).  
Most MMPs are produced by subepithelial cells such as myofibroblasts, but 
MMP-7 is an exception that is predominantly synthesised by epithelial cells, 
including those of the gastrointestinal tract (Lopez-Boado et al., 2000). Recent 
reports suggest that MMP-7 mediates responses to bacteria in different systems 
including in H. pylori infection in the stomach (Crawford et al., 2003; 
Wroblewski et al., 2003), is elevated in hypergastrinaemia (Varro et al., 2007); as 
noted above, liberates IGF-II by cleavage of IGFBP-5 and it has been suggested 
to play a role in mucosal remodelling (Hemers et al., 2005).  
Tissue inhibitors of matrix metalloproteases (TIMPs) are the natural inhibitors of 
MMPs (Gomez et al., 1997). There are four known members of the family 
(TIMPs 1-4), numbered depending on the order of discovery, that exhibit 
similarities but with specific structure and functional roles (Greene et al., 1996). 
TIMPs were described to exhibit effects on cell growth and apoptosis 
independent from their protease inhibitor properties. Data on their role in cancer 
is controversial: some studies show that lower secretion rate of TIMPs is 
conducive for the development of distant metastases or tumour growth (Sakata et 
al., 2000; Vizoso et al., 2007), while others show that higher TIMP expression 
correlates with poor prognosis (Egeblad and Werb, 2002). It is believed that 
these effects may depend on the type and stage of disease, however the exact 
mechanisms are still unclear.   
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MMPs are secreted as inactive precursor molecules proteolytically activated by 
different matrix proteases and non-proteolytic agents (Nagase and Woessner, 
1999). Two proteases that can activate pro-MMPs are urokinase type (uPA) and 
tissue type (tPA) plasminogen activators (Carmeliet et al., 1997; Yepes and 
Lawrence, 2004; Zhao et al., 2007). Both plasminogen activators convert 
plasminogen into its active form plasmin (Robbins et al., 1967) that in turn 
digests fibrin and other ECM proteins (Andreasen et al., 1997; Blasi et al., 1987; 
Robbins et al., 1967). The plasminogen activation system also includes three 
inhibitors: plasminogen activator inhibitor (PAI)-1, -2 and protease nexin, and 
the uPA receptor (uPAR). 
Increased expression of the uPA system is associated with different tissues 
responses to injury and infection (Andreasen et al., 1997). For example, infection 
with H.pylori is associated with increased expression of uPA, uPA receptor, PAI-
1 and PAI-2 in the gastric mucosa (Kenny et al., 2008; Varro et al., 2004). 
Moreover, increased expression of members of the uPA system was reported in 
gastric cancers with poor prognosis (Ito et al., 1996; Kaneko et al., 2003). 
Although little information is available about protease nexin, there is evidence 
for promoting the invasive phenotype of pancreatic and breast cancer cells via 
modifying ECM environment (Buchholz et al., 2003; Candia et al., 2006), and it 
is suggested to be a poor prognostic marker (Gao et al., 2008). 
Different organisation of tPA molecule determines its high affinity for plasma 
fibrin (van Zonneveld et al., 1986a), and therefore, tPA is primarily studied as a 
thrombolytic agent (van Zonneveld et al., 1986b), although other functions are 
known. 
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1.4.4.2 Extracellular matrix proteins   
Formation and remodelling of ECM is essential in tissue growth, wound healing 
and fibrosis, and in cancer. ECM consists of very many different components 
including a large group of protein-polysaccharide complexes called 
proteoglycans and protein fibrils (e.g. collagens, fibronectin, and laminin), both 
synthesised and secreted by specialised cells of the connective tissue like 
myofibroblasts.  
Small leucine-rich proteoglycans (SLRPs) are a family of nine proteoglycans 
divided according to their gene and protein structure in three classes (Iozzo, 
1998). Class I comprises of two proteins: decorin and biglycan, class II includes 
fibromodulin, lumican, keratocan, and PRELP, and class III consists of 
epiphycan and osteoglycin. 
Decorin is the best known SLPR. Decorin has roles in the assembly of ECM via 
binding to collagen I, II and VI fibrils, and fibronectin in vivo (Iozzo, 1998), and 
in physiological process like inflammation and wound healing (Ferdous et al., 
2007). Also, decorin is one of the major SLRPs of the human sclera and its 
expression is directly related with the maintenance of corneal transparency (Rada 
et al., 2000).  
Reduced expression of decorin has been found in many epithelial tumours 
including colon, pancreas, breast (Iozzo and Cohen, 1993) and has been 
associated with carcinogenesis (Bi et al., 2008). Moreover, it has been shown that 
decorin inhibits tumour growth via different mechanisms: down-regulation of 
epidermal growth factor receptor (EGFR) (Iozzo et al., 1999), ErbB2 (Santra et 
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al., 2000) and hepatocyte growth factor (HGF or Met) receptor (Goldoni et al., 
2009), as well as neutralising TGF-β signalling (Yamaguchi et al., 1990) and up-
regulating cell cycle inhibitors p21 and p27 (Xaus et al., 2001). Decorin may 
therefore act as an extracellular tumour suppressor (Augoff et al., 2008). In 
addition, altered decorin expression in the stroma was reported in breast cancer 
(Kelemen et al., 2008). In vivo experiments linked altered decorin gene 
expression in the stroma with cancer-host cell signalling (Adany et al., 1990). 
Lumican is another SLRP which, similarly to decorin, is a potent regulator of 
collagen fibrillogenesis (Rada et al., 1993) in dermal and muscle connective 
tissue (Chakravarti et al., 1998). Also, lumican in the human sclera and cornea is 
crucial for the maintenance of corneal transparency (Rada et al., 1993; Young et 
al., 2003). Vuillermoz et al. reported that lumican inhibits melanoma cell growth 
both in vitro and in vivo (Vuillermoz et al., 2004). It is has been reported that 
reduced expression of both decorin and lumican was associated with poor 
outcome in invasive breast cancers (Troup et al., 2003). 
 
1.4.4.3 Small ECM proteins 
Initial proteomic studies identified increased abundance of the small ECM 
protein TGFβ-inducible protein (TGFβig-h3, TGFBI, BIGH3, BIG-H3, RGD-
CAP or kerato-epithelin) in the media of gastric myofibroblasts after treatment 
with MMP-7 (Duval & Varro, unpublished observations). TGFβig-h3 was first 
identified as a secreted protein in human adenocarcinoma cell lines after 
treatment with TGF-β (Skonier et al., 1992). TGFβig-h3 is believed to play a role 
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in  cell adhesion, proliferation and migration through interaction with a number 
of  ECM molecules like collagens, fibronectin, laminin, and also functioning as a 
ligand for several integrins (Kim et al., 2000). In the cornea, TGFβig-h3 co-
aggregates with decorin in complexes with collagen VI (Reinboth et al., 2006). It 
is expressed in various cells, and mutations of the gene are associated with 
multiple forms of hereditary corneal distrophies (Zamilpa et al., 2009).  
Down-regulation or loss of expression of TGFβig-h3 has been reported in 
primary tumours and cancer cell lines from lung and breast, hence it was 
described as a tumour suppressor and proposed as a diagnostic marker (Calaf et 
al., 2008; Zhang et al., 2009; Zhao Y., 2006). However, there are studies 
showing that TGFβig-h3 supports tumour growth and metastasis, suggesting that 
its pro- or anti-oncogenic effects may depend on tissue type and experimental 
conditions (Ma et al., 2008; Tang et al., 2007).  
 
1.4.4.4 Carbohydrate-binding proteins  
Galectins are a family of lectins binding β-galactoside through an evolutionary 
preserved carbohydrate-recognition domain (CRD) in their structure (Barondes et 
al., 1994). Based on the number and organisation of CRDs they are classified in 
three subtypes (Hirabayashi and Kasai, 1993). Galectin-3 has a unique structure 
amongst the vertebrate galectins, as it contains proline- and glycine-rich N-
terminal domain (Houzelstein et al., 2004). Galectin-3 is known to lack an N-
terminal signal peptide sequence directing a protein to ER-Golgi secretory 
pathway and thus it is released via an unconventional secretion pathway 
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(Hughes, 1999). Galectin-3 is ubiquitously expressed and can be localised to the 
nucleus and cytoplasm, or be secreted depending on various factors (Dumic et 
al., 2006). Intra- and extracellular localisation of galectin-3 is associated with 
specific biological functions in cell communication, development, in the immune 
response, in disease and in carcinogenesis.  
 
1.5 Studies of secretome and SILAC 
There is increasing evidence, including from this laboratory, that myofibroblasts 
undergo multiple changes in the transition to cancer and that these include 
changes in the secretome, i.e. the total of all secreted proteins (excluding 
membrane-bound proteins). In part these studies have been made possible 
through the recent technological advances in the proteomic techniques, notably 
the development of mass spectrometry, and the availability of well annotated 
gene and genome databases that made possible proteomic characterisation of 
complex protein samples.  
One widely used mass-spectrometry based method that is applicable in secretome 
studies is stable isotope labelling by amino-acid in culture or SILAC (Alvarez-
Llamas et al., 2007; Greco et al., 2010). In SILAC, cells are cultured in media 
supplemented with normal amino-acids (Light label), or with amino-acids 
labelled with stable isotopes (Heavy label). Thus light and heavy peptides in two 
or more samples can be identified and relatively quantified. Also, SILAC makes 
it possible (a) to exclude serum contaminants, which is not possible with some 
other proteomic methods; (b) to reduce sources of error introduced during sample 
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preparation prior to mass spectrometry; and (c) provides more accurate 
quantification of low signal-to-noise samples (Ong et al., 2002). Therefore, 
SILAC is routinely used in the assessment of protein expression as a function of 
time or stimulus (Ong and Mann, 2005). Moreover, SILAC can be used in the 
evaluation of mechanisms controlling protein secretion (Greco et al., 2010), for 
example, in myofibroblasts, where they are poorly understood.  
 
1.6 Aims and objectives 
The primary objective of this thesis was to determine the mechanisms by which 
myofibroblasts from normal tissue or cancers of upper gastrointestinal tract 
secrete proteins that might influence the cellular microenvironment. This study 
therefore investigated the secretion by primary myofibroblasts from normal 
tissue, cancers of stomach and oesophagus, and tissue adjacent to these cancers; 
for comparison studies were also made on human MSCs. The specific aims were: 
1. To establish a model system for studying calcium-dependent secretion of 
myofibroblasts. 
2. To assess the influence of the tissue microenvironment in determining the 
secretory phenotype of myofibroblasts. 
3. To identify and study putative secreted proteins with potential as biomarkers. 
4. To identify and characterise the molecular mechanisms determining regulated 
secretion by gastric myofibroblasts. 
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2.1 Primary cell cultures 
2.1.1 Primary human myofibroblasts  
Many of the primary human myofibroblasts used for these studies had been 
isolated from stomach or oesophagus obtained during surgery for cancer 
resection. In these cases, tissue had been taken from the tumour (CAM) and 
usually from an immediately adjacent, macroscopically normal, region within 
10mm of the resection border (ATMs). 
In addition, some myofibroblasts (NTM) were obtained from normal stomach or 
oesophagus of transplant donors, and some from the antrum of patients with 
pernicious anaemia undergoing antrectomy for treatment of ECL cell 
neuroendocrine tumours. A list of all the cell lines used is provided in Table 2.1. 
The cultures had been initially prepared by either Dr Peter Hegyi (First 
Department of Medicine, University of Szeged, Hungary) or by Dr Islay Steele 
within this research group. In all cases, the method used to prepare 
myofibroblasts was that described by (Mahida et al., 1997; Wu et al., 1999). 
Ethical Committee approval was provided by both the University of Szeged and the 
Royal Liverpool University Hospital; written consent was obtained.  The cells had 
in each case been previously characterised in the laboratory by 
immunocytochemistry showing positive staining for α-SMA and vimentin, and 
negative for cytokeratin and desmin. 
 
 
 
Patient 
No. Origin  Type  Age Gender Survival (Mo) 
Tumour 
location Classification 
Regional lymph 
nodes (N) 
Adjacent 
Tissue 
1 gastric 
ATM 
72 M >59 antrum, corpus, border medullar N0 
intestinal metaplasia, 
atrophy CAM 
2 gastric 
ATM 
82 M 3 antrum intestinal N2 intestinal metaplasia, 
chronic gastritis CAM 
3 gastric 
ATM 
66 F 5 antrum, corpus, border mixed N4 chronic gastritis CAM 
4 gastric 
ATM 
50 F 22 antrum, corpus, border diffuse N1 chronic gastritis CAM 
5 gastric 
ATM 
76 M 25 antrum intestinal N0 intestinal metaplasia, 
chronic gastritis CAM 
6 gastric 
ATM 
77 M >34 antrum intestinal N0 intestinal metaplasia, 
chronic gastritis CAM 
7 gastric 
ATM 
76 M 15 antrum intestinal N2 
intestinal metaplasia, 
atrophy, chronic 
gastritis CAM 
8 gastric ATM 72 M >34 corpus mixed N1 chronic gastritis 
CAM 
9 gastric 
ATM 
84 F >31 antrum, corpus, border intestinal N0 chronic gastritis CAM 
10 gastric 
ATM 
59 F 17 antrum and corpus diffuse N2 chronic gastritis 
CAM 
11 gastric 
ATM 
51 M 9 antrum, corpus, border mixed N3 chronic gastritis CAM 
12 gastric 
ATM 
67 M >31 antrum intestinal N1 chronic gastritis 
CAM 
13 gastric CAM 39 F >43 antrum, corpus, border intestinal N2 No adjacent tissue 
 14 gastric CAM 54 M >45 antrum, corpus, border diffuse N0 No adjacent tissue 
15 gastric ATM 61 M n.a. n.a. n.a. n.a. Normal 
16 gastric ATM 65 M n.a. n.a. n.a. n.a. intestinal metaplasia, 
chronic gastritis 
17 
gastric corpus 
NTM 44 F n.a. n.a. n.a. n.a. n.a. gastric antrum 
oesophagus 
18 
gastric corpus 
NTM 45 M n.a. n.a. n.a. n.a. n.a. gastric antrum 
oesophagus 
19 
gastric corpus 
NTM 52 F n.a. n.a. n.a. n.a. n.a. gastric antrum 
oesophagus 
20 
gastric corpus 
NTM 60 M n.a. n.a. n.a. n.a. n.a. gastric antrum 
oesophagus 
21 
gastric corpus 
NTM 52 F n.a. n.a. n.a. n.a. n.a. gastric antrum 
oesophagus 
22 
gastric corpus 
NTM 41 M n.a. n.a. n.a. n.a. n.a. gastric antrum 
oesophagus 
27 oesophagus 
ATM 
72 M 18 oesophagus adenocarcinoma n.a. Barrett’s oesophagus 
 CAM 
28 cardia 
ATM 
70 F >36 cardia adenocarcinoma n.a. chronic gastritis 
 CAM 
29 cardia 
ATM 
63 M 19 cardia adenocarcinoma n.a. chronic gastritis, intestinal metaplasia CAM 
30 gastric antrum PA 49 F n.a corpus ECL cell carcinoids n.a. n.a 
31 gastric antrum PA 43 M n.a corpus ECL cell carcinoids n.a. n.a 
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32 gastric antrum PA 71 F n.a corpus ECL cell carcinoids n.a. n.a 
33 bone marrow MSC 19 M n.a. n.a. n.a. n.a. n.a. 
34 bone marrow MSC 43 M n.a. n.a. n.a. n.a. n.a. 
35 bone marrow MSC 22 F n.a. n.a. n.a. n.a. n.a. 
36 bone marrow MSC 36 M n.a. n.a. n.a. n.a. n.a. 
37 bone marrow MSC 21 M n.a. n.a. n.a. n.a. n.a. 
38 bone marrow MSC 19 M n.a. n.a. n.a. n.a. n.a. 
Table 2.1 Primary human myofibroblasts and MSC with corresponding patient data. Patient No, type of cells generated, origin of cells, age, gender, tumour 
location, tumour classification, post-operative survival and pathology assessment of tissue taken adjacent to the tumour are presented. A post-operative survival 
indicates survival at the time of thesis submission. (Key: PA-Pernicious anaemia, ECL cell-Enterochromaffin-like cell, MSC-Mesenchymal stem cell, NTM-
Normal tissue myofibroblasts, CAM-Cancer, ATM-Adjacent tissue, N-Regional lymph nodes: N0-No regional lymph node metastasis, N1-Metastasis in 1 to 6 
regional lymph nodes, N2-Metastasis in 7 to 15 regional lymph nodes, N3-Metastasis in more than 15 regional lymph nodes).  
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2.1.2 Human mesenchymal stem cells 
Six human bone-marrow derived mesenchymal stromal (stem) cell (MSC) types 
were purchased from Lonza, USA and PromoCell, UK (Table 1). These cells had 
been routinely characterised by the producer as positive for surface antigens CD29, 
CD44, CD105 and CD166, and negative for CD14, CD34 and CD45, and by 
functional in vitro assays for differentiation into adipocytes, chondrocytes and 
osteocytes.  
 
2.1.3 Tissue culture 
Primary myofibroblasts were used at passages 4 to 15. Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, Poole, Dorset, UK) 
supplemented with 10% v/v fetal bovine serum (FBS, BioWhittaker, Lonza, 
Belgium), 1% v/v antibiotic-antimycotic solution (Sigma), 1% v/v penicillin-
streptomycin (Sigma) and 1% v/v non-essential amino acids (Sigma). Media was 
prepared fresh and changed every 48 – 72 h. Human MSCs were cultured in a 
special media containing Mesenchymal Stem Cell Basal Medium and 
SingleQuots® kit (MSCBM, Lonza, Belgium). The kit includes mesenchymal 
cell growth supplement, L-glutamine and gentamicin sulphate/amphotericin-B. 
Media was prepared and changed every 72 - 96 h. All cells were incubated at 
370C in an atmosphere of 5.0% v/v CO2. At about 90% confluence, cells were 
split into new flasks. 
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2.1.4 Release assay  
Cells were washed twice with 10ml sterile phosphate buffered saline (PBS, 
Invitrogen, Paisley, Renfrew, UK) and harvested with 0.25% w/v trypsin (Sigma) 
or trypsin-EDTA in the case of MSCs. Trypsin was inactivated with media 
containing serum, and cells were counted with a haemocytometer (Weber 
Scientific International Ltd, Middlx, England). Two 10cm dishes were plated for 
each condition and were left overnight for cells to attach. Media was removed the 
following day and cells were washed 3 times with 10ml sterile PBS. Afterwards, 
cells were starved in 5ml serum-free media for 1 h, which was then replaced. 
Cells were stimulated, as appropriate, with 100ng/ml rhIGF-II (R&D Systems 
Inc., Oxfordshire, UK), 50ng/ml rhIGF-I (Calbiochem, Merck4Bioscheinces, 
Beeston, UK), 2µg/ml rhMMP-7 (Calbiochem) and 1µM ionomycin calcium salt 
(Sigma-Aldrich). Preincubations with 10µg/ml brefeldin A (Epicentre 
Biotechnologies, Cambio Ltd, Cambridge, UK), 10µg/ml cycloheximide 
(Sigma), 2µg/ml actinomycin D (Sigma), 3.2µM AG1024 (Calbiochem) and 
5µM marimastat (Calbiochem) were performed in particular experiments. After 
stimulation for 30 min, media was collected and centrifuged (800g 40C, 7 min) to 
remove cell debri.  
 
2.2 Protein chemistry 
2.2.1 Protein extraction from media and cell lysates 
Media was concentrated to a volume of about 100µl using Amicon Ultra-15 
3kDa centrifugal filter devices (Millipore, Watford, UK). For proteomic studies 
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(subsequently performed by Dr Chris Holmberg), proteins in the media were 
extracted using StrataClean™ Resin (Agilent Technologies, USA) following the 
manufacturer’s protocol. To recover cellular protein, cells were washed with 
10ml sterile PBS on ice, scraped and cell protein was extracted using 100µl/dish 
RIPA cell lysis buffer (Upstate, USA) (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 
1% w/v NP-40, 1% w/v sodium deoxycholate and 0.1% w/v sodium dodecyl 
sulfate), containing 1% v/v Phosphatase Inhibitor Cocktail set II, EDTA-Free 
(Calbiochem, USA) and 1% v/v Protease Inhibitor Cocktail Set III, EDTA-Free 
(Calbiochem, USA). Cell suspensions were sonicated (Sonicor, Sonicor 
Instrument Corporation, USA) for 5 min to break down membranes, incubated 
on ice for 30 min for the membranes to sediment and centrifuged (12 000g 40C, 3 
min);  supernatants were transferred into clean tubes and stored at -800C until 
further processed.  
 
2.2.2 Protein assays 
Total protein was determined using the Dc Protein Assay kit (Bio-Rad Lab Inc., 
Life Science Group, USA), containing alkaline copper tartrate (Reagent A), 
surfactant solution (Reagent S) and diluted Folin reagent (Reagent B) (Lowry et 
al., 1951). Standard solutions of bovine serum albumin (BSA, Jackson Immuno 
Research Lab., Suffolk, UK) at concentrations of 0 mg/ml, 0.0625 mg/ml, 0.125 
mg/ml, 0.25 mg/ml, 0.5 mg/ml, 0.75 mg/ml and 1 mg/ml were used to generate a 
standard curve. Cell protein samples were diluted 1:5 or 1:10 in RIPA buffer to 
ensure that absorbance at 750 nm would fall within the range of the standard 
curve. Media samples were assayed undiluted. Absorbance at 750nm was 
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measured with a SpectraCount spectrophotometer (Packard Bioscience 
Company, software: PlateReader v3.0) and the values were then used for the 
quantification of total protein using MSOffice Excel. 
 
2.2.3 Western Blot analysis 
Depending on the molecular weight of protein (kDa) different percentages of 
SDS polyacrylamide gel were run (Laemmli, 1970; Shapiro et al., 1967). 
PageRuler™ Plus Prestained Protein Ladder (Fermentas, York, UK) was used as 
a protein size marker. Depending on protein abundance, different quantities of 
total protein were loaded (10 µg to 60 µg). Protein extracts were mixed with 
Laemmli Buffer (4% w/v SDS, 2mM EDTA, 10% w/v sucrose, 125mM HEPES, 
1% v/v 2-mercaptoethanol, 10% v/v glycerol, Bromophenol Blue) and heated for 
4 min at 1000C (except for the media treated with StrataClean™ Resin). Gel 
electrophoresis was conducted at 100 V in running buffer, prepared from a 5X 
stock buffer with a pH 8.3, containing 25mM tris base, 192mM glycine and 
0.01% w/v SDS. Proteins were transferred onto nitrocellulose membranes 
(Hybond™-ECL Nitrocellulose membrane, GE Healthcare Limited, UK) 
(Towbin et al., 1979) for 1h at 100 V in transfer buffer, containing 0.2mM tris 
base, 150mM glycine and 20% v/v methanol. Membranes were washed 3 times 
for 10 min in 0.1% Tween 20 (Sigma) in tris buffered saline (TBS, Sigma) 
(450ml dH2O, 50ml 10xTBS, 500µl Tween20). This procedure was followed by 
blocking for 1 h with 5% w/v non-fat dry milk (Marvel™, Premier Foods, UK), 
prepared as solution in 1xTBS/0.1%Tween 20. Membranes were then incubated 
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with the primary antibody solution in dilutions as described in Table 2 overnight 
at 40C on a shaker.  
The following day, membranes were washed 3 times for 10 min in 
1xTBS/0.1%Tween 20, followed by incubation for 1h with secondary antibody 
conjugated to horseradish peroxidase (HRP) (Table 2.2). Primary and secondary 
antibodies were prepared in 5% w/v non-fat dry milk dissolved in 
1xTBS/0.1%Tween 20. Finally membranes were washed 3 times for 10 min and 
exposed for 5 min to SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific, Pierce Biotechnology, USA) or Immun-Star™ WesternC™ 
kit (Bio-Rad Lab.Inc.), both used as a working solution in volume ratio 1:1 from 
each stock reagent. For one membrane 2.5 ml from each stock solution was 
sufficient for the light sensitive reaction. Membranes were imaged with 
ChemiDoc XRS+ (Bio-Rad Lab.Inc.) or were exposed to High performance 
chemiluminescence film (Amersham Hyperfilm ECL, GE Healthcare Limited,  
 
 
 
 
 
 
 
                                                                                              Chapter 2 – Materials and Methods  
66 
 
Antigen/antibody Titre (Western Blot) Species Origin 
Decorin 1:500  Goat R&D – AF143 
Galectin-3 (D-20) 1:200 Goat Santa Cruz – SC19283 
GAPDH 1:5000  Mouse Meridian, Life Science, Inc. – H86504M 
IGFBP-5 1:500 Goat R&D Systems – AF875 
IGFBP-7 1:500 Goat R&D Systems – AF1334 
Lumican (H-90) 1:500 Rabbit Santa Cruz – SC33785 
PAI-1 1:500 Rabbit GeneTex – GX100550 
Secretogranin II (H-300) 1:200 Rabbit Santa Cruz – SC50290 
Serpin E2 (nexin) 1:500 Goat R&D Systems – AF2980 
TIMP-1 1:1000 Rabbit Chemicon – AB8112 
TIMP-2 1:5000 Rabbit Chemicon – AB8107 
TGFβig-h3 1:1000 Goat R&D – AF2935 
Anti-goat IgG 1:10 000 Rabbit Sigma A5420 
Anti-mouse 1:10 000 Goat Sigma A4416 
Anti-rabbit 1:10 000 Goat Santa Cruz SC-2004 
Table 2.2 Primary and secondary HRP-conjugated antibodies used in 
Western blot. 
 
UK). Films were developed with developer/replenisher and fixer/replenisher 
solutions (Sigma).  
 
2.2.4 Densitometry 
Densitometric analysis of the band intensities from Western blot analysis was 
performed using either ImageLab software v2.1 (Bio-Rad Lab, Inc.) for the film-
free developing method or Multi-Analyst v1.1 build 34 (Bio-Rad Lab, Inc., Life 
Science Group, USA) for films.  
 
2.2.5 Coefficient of variation 
To determine the intra-assay variability in Western blots, a single sample was 
loaded 5 times and run on an SDS polyacrylamide gel followed by protein 
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transfer to nitrocellulose membrane and blotting for TGFβig-h3. Densitometric 
analysis of the bands was performed and the data were used to calculate the 
coefficient of variation, which was 6% (Figure 2). Based on this, in subsequent 
studies differences in relative abundance of protein between two samples run on 
the same gel above 1.2 were considered informative as this allowed a further 
margin of error for other possible sources of variation.  
 
Figure 2 Coefficient of variation. 
Western blot analysis of TGFβig-
h3 of a single myofibroblast media 
sample, loaded 5 times on one 
SDS-PAGE gel in equal quantity. 
Densitometric analysis of the 
bands intensity determined 
coefficient of variation of 6% 
(Mean band intensity ± stand error, 
202.9x104 ± 2.7x104, n=5). 
 
2.2.6 Variability of biological response 
To determine biological variability across different experiments, identical 
stimulation experiments were conducted with IGF-II on separate days; media 
was processed via two different methods (see Section 2.2.1) and analysed by 
Western blot for TGFβig-h3 with subsequent densitometric analysis. Based on 
the band intensities the ratio of treated-to-control i.e. fold difference, was 
determined. The mean differences for IGF-II stimulation ± standard error were 
determined for two different myofibroblast cell lines using either filters or beads 
to concentrate the samples. For patient 14 (CAM), IGF-II stimulation of TGFβig-
h3 was estimated to be 1.47±0.06 (n=3) using filters compared with 1.54±0.10 
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(n=9) using beads to concentrate the samples; for patient 21 (NTM), the 
corresponding values were 2.01±0.39 (n=6) and 2.05±0.29 (n=3) respectively.   
 
2.2.7 Immunofluorescence 
Cells were harvested, counted and 1 x 104 plated on 4-well chamber slides (BD 
Flacon, Belgium) or on cover slips placed in 24-well plates. The following day 
cells received experimental treatments (see Section 2.1.4) followed by washing 
twice with PBS and fixation with 500 µl 4% v/v paraformalydehyde (PFA, Agar 
Scientific Ltd.) (30 min). Fixed cells were washed twice in PBS and 
permeabilised (30 min) using filtered PBS containing 0.1% triton X-100. 
Permeabilised cells were washed in PBS and incubated with 5% w/v BSA (30 
min) and then washed in PBS and incubated with 10% v/v donkey serum 
(Jackson ImmunoResearch Lab.) (30 min). Donkey serum was removed, cells 
were washed twice in PBS and primary antibody (diluted in PBS) was added 
overnight at 40C in a humidified atmosphere (Table 2.3).  
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Antigen/antibody Titre (Immunofluorescence) Species Origin 
Decorin 1:50  Goat R&D – AF143 
Galectin-1 1:400 Goat Santa Cruz – SC19277 
Galectin-3 1:400 Goat Santa Cruz – SC19283 
PAI-1 1:100 Goat Santa Cruz – SC6644  
Secretogranin II 1:1000 Rabbit Thermo Sci. – PA1-10838 
SPARC 1:200 Rabbit Santa Cruz – SC25574 
TGFβig-h3 1:50  Rabbit Cell Signalling – Cat.2719 
Fluorescein-
conjugated anti-rabbit 1:400 Donkey 
Jackson ImmunoResearch 
Lab. – 711-095-152 
Texas Red-conjugated 
anti-goat 1:400 Donkey 
Jackson ImmunoResearch 
Lab. – 705-075-147 
Fluorescein-
conjugated anti-goat 1:400 Donkey 
Jackson ImmunoResearch 
Lab. – 705-095-147 
Table 2.3 Primary and fluorescence dye-conjugated secondary antibodies 
used in Immunofluorescence. 
 
Cells were washed the following day, with NaCl at 0.14M, 0.5M and 0.14M (5 
min each) to minimise non-specific staining. The appropriate secondary antibody 
(prepared in 10mM HEPES pH7.5) was applied for 1 h in a dark, humidified, 
environment (Table 2.3). Secondary antibodies were removed and cells were 
washed 3 times in PBS (10min) and mounted with Vectashield containing 4',6-
diamidino-2-phenylindole DAPI (Vector laboratories, Peterborough, UK). For 
confocal imaging Vectashield without DAPI was used. Slides were observed 
using a Zeiss Axioplan-2 microscope (Zeiss Vision, Welwyn Garden City, UK) 
and images were taken using an Axiocam HRm camera (Carl Zeiss) and 
processed by AxioVision 4.5 (Carl Zeiss). Non-specific binding was determined 
in the absence of primary antibody. Confocal microscopy was performed using 
Leica SP2 AOBS confocal microscope (Leica Microsystems, Milton Keynes, 
UK) and images were processed by Leica confocal software (Leica 
Microsystems) with the help of Miss Nantaporn Lertkowit.  
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2.3 Silencing and overexpression of secretogranin II  
2.3.1Silencing RNA 
Mission® Silencing RNAs (SASI_Hs01 00132008, SASI_Hs02 00335724, and 
SASI_Hs01 00132010) for secretogranin II were purchased from Sigma-Aldrich 
(Table 5). Upon arrival RNA was resuspended in 100 µl Tris/EDTA buffer (TE) 
to give 100 µM and was stored in aliquots in a freezer at -200C. 
 
2.3.2 Plasmid DNA  
An expression vector encoding human secretogranin II (10 µg, NM_003469.3) 
was purchased from OriGene Tehcnologies, Inc (Rockville, USA) and stored 
dried at -200C. After reconstitution with 100 µl 5mM Tris-HCl to give 0.1µg/ml, 
secretogranin II plasmid was stored at -200C.  
 
2.3.3 Transformation of E.coli and extraction of plasmid 
Competent cells α-Select™ Gold efficiency (Bioline Ltd., London, UK) were 
kept at -800C. Cells were thawed at room temperature and secretogranin II 
plasmid corresponding to 10 µg DNA was added to 50 µl competent cells. Cells 
were incubated on ice (20 min), heat shocked at 420C for 45 sec, incubated on ice 
for a further 2 min, followed by addition of 450 µl Super Optimal Broth with 
Catabolite repression (SOC) medium (20g tryptone, 5g yeast extract, 0.5g NaCl, 
20ml 250mM KCl, 5ml sterile 2M MgCl2 and 20ml sterile 1M glucose for 
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1000ml solution pH 7.0). Samples were shaken on a roto-shaker at 370C for 60-
90min and the mixture plasmid/competent cells was plated onto ampicillin-
resistant agar plates and incubated overnight at 370C.  
For a Maxi-Prep inoculation, a single colony was picked the following day and 
grown in 1ml of freshly autoclaved Lysogeny broth (LB, 10g tryptone, 5g yeast 
extract,  10g NaCl for 1000ml solution of pH 7.0), containing ampicillin, for 8 h 
at 370C on a roto-shaker. The cultured colony was then added to 100ml 
ampicillin-containing LB and incubated overnight on a roto-shaker. Ampicillin 
10mg/ml was prepared fresh, stored at 40C and filter-sterilised prior to use. The 
stock solution was used at 0.5ml per 100ml LB. Finally the QIAGEN protocol 
for Plasmid DNA purification Maxi Kit was used (see manufacturer’s 
instructions). Concentration of the plasmid DNA was determined using 
NanoDrop 2000c device and NanoDrop2000 software. Secretogranin II plasmid 
concentration was 1139.8ng/ml and 260/280 ratio was 1.85. Reconstituted DNA 
plasmid was kept at 40C. 
 
2.3.4 Transient transfection 
Transfections were performed using Amaxa Human AoSMC Nucleofector kit 
(Lonza) or Amaxa Human Dermal Fibroblast Nucleofector kit (Lonza) on a 
Nucleofector® I device with the appropriate program for each kit following 
manufacturer’s instructions. Cells were counted and 12x106 cells were pulled 
down at 800g at 40C for 7 min. Media was decanted, the cell pellet gently dried 
and 800 µl of Nucleofector® solution was added, gently mixed and divided into 
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two fractions. Four transfections per fraction were done in volumes of 100 µl. 
Each nucleofection volume was transfected with 1µM siRNA or 3µg plasmid 
DNA. Control fraction was transfected either with a scrambled RNA or an empty 
vector pcDNA3 (a gift from Prof Rod Dimaline). After nucleofection 500 µl full 
media were added and samples were collected in clean sterilins, mixed and each 
fraction was equally plated into four 10cm dishes. Post-transfection cells were 
incubated for 96 h before release assays were performed and samples were 
processed as described earlier.  
 
2.4 Gene expression analysis  
Prior to this project, total RNA was extracted from primary myofibroblasts by 
Dr. Islay Steele, labelled and hybridised to a GeneChip©Human Genome U133 
Plus 2.0 array (Affymetrix, Santa Clara, CA, USA) at the Liverpool Genome 
Facility Unit by Dr. Lucille Rainbow, following the manufacturer’s instructions. 
The U133 Plus 2.0 array determines the relative expression of over 47,000 
transcripts. A GeneChip® Scanner 3000 (Affymetrix) was used to image the 
arrays. Data analysis was performed using Gene Spring GX v.10 (Agilent 
Technologies, USA).  
For the purpose of this project, the raw data were re-analysed. Gene expression 
profiles of myofibroblasts exhibiting regulated secretion of TGFβig-h3 were 
compared to those of myofibroblasts without regulated secretion. Firstly, data 
were normalised using the Affymetrix MAS5 normalization algorithm. 
Oligonucleotide probes marked as 100% present in all members of at least one of 
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the two groups were identified. Statistical analysis of the data was performed 
using unpaired t-test with no adjustments for multiple comparisons (i.e. No 
Correction false discovery rate).  Further analysis was performed to identify the 
corresponding gene products using MetaCore™, a data-mining tool developed by 
GeneGo (www.genego.com); and to annotate the gene products by cellular 
component using Gene Ontology database (www.geneontology.org).  
 
2.5 Proteomic analysis  
Prior to this project, a list with putative secretory proteins identified in gastric 
myofibroblasts (Patient 14) and in MSCs (Patient 37) was generated by Dr Chris 
Holmberg using the procedures briefly described below.  
 
2.5.1 SILAC labelling  
Gastric myofibroblasts from patient 14 and MSCs from patient 37 were cultured 
in media supplemented with either 12C6 lysine and 12C6 arginine (Light label), or 
13C6 lysine and 13C6 arginine (Heavy label) for at least 6 population doublings.  
 
2.5.2 Sample processing and identification of proteins  
Media protein was extracted using StrataClean™ Resin (Agilent Technologies, 
USA) following the manufacturer’s protocol, and further processed for HPLC-
MS/MS identification. SILAC data were searched and analysed using MaxQuant 
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1.1.1.36 (Cox and Mann, 2008) against the human Universal Protein Resource 
(UniProt) database v3.68. 
 
2.6 Statistics 
Statistical analysis was performed using Sigma Plot v11. Results were presented 
as mean ± standard error of the mean (SEM), where needed, and were considered 
statistically significant if p<0.05.  
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3.1 Introduction  
Recent work in a number of different cell types has suggested that regulated 
exocytosis might be a property of a wider range of cells than previously 
supposed (Borgonovo et al., 2002; Coorssen et al., 1996; Ninomiya et al., 1996). 
For example, in addition to neurons, endocrine and exocrine cells that have been 
studied in detail for many decades, emerging evidence from this laboratory 
suggests that myofibroblasts might also exhibit regulated secretion.  
Regulated exocytosis is calcium-dependent. Unpublished work in this laboratory 
has shown that rhIGF-II increased intracellular calcium concentration in gastric 
myofibroblasts and this required extracellular calcium (McCaig, Burdyga & 
Varro, unpublished observations). Subsequently it was shown that MMP-7 also 
increased intracellular calcium in these cells (McCaig, Burdyga & Varro, 
unpublished observations). Since increased intracellular calcium triggers 
secretory vesicle fusion with plasma membrane and hence exocytosis (Peters and 
Mayer, 1998), these observations raised the question of whether there might be 
regulated release of secretory proteins in gastric myofibroblasts. In other studies, 
a proteomic approach using stable isotope labeling with amino acids in cell 
culture (SILAC) identified increased abundance of the ECM protein TGFβ-
inducible protein (TGFβig-h3) in the media of gastric myofibroblasts after acute 
treatment with rhMMP-7 (Duval & Varro, unpublished observations); the same 
studies also raised the possibility of stimulated release of decorin.  
Based on these findings it was considered important to determine whether gastric 
myofibroblasts might exhibit regulated protein secretion, not least because this 
might be expected to be important in influencing the local tissue 
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microenvironment in health and disease. On the basis of previous studies it was 
therefore hypothesised that IGF- and MMP-7 stimulated protein secretion by 
gastric myofibroblasts and that TGFβig-h3 and decorin were putative markers of 
this process.   
 
3.1.1 Aims and Objectives 
The aim of this chapter was to characterise secretory mechanisms in gastric 
myofibroblasts and specifically: 
1. To characterise the secretion of the ECM proteins decorin and TGFβig-h3 
from gastric myofibroblasts. 
2. To assess the effects of calcium-free media, ionomycin, brefeldin A, 
cycloheximide and actinomycin D on secretion.  
3. To characterise the effects of MMP-7 in stimulating protein secretion.
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3.2 Materials and Methods 
3.2.1 Primary myofibroblasts   
The work in this chapter utilised gastric myofibroblasts from patients 14 and 21. 
These cells were characterised in previous immunocytochemical studies as 
positive for α-SMA and vimentin, and negative for cytokeratin and desmin (See 
Chapter 2). 
 
3.2.2 Immunocytochemistry 
Myofibroblasts were stained for decorin and TGFβig-h3 using goat anti-decorin 
at 1:50 (R&D, AF143) and rabbit anti-TGFβig-h3 at 1:50 (Cell signalling, 2719). 
Secondary antibodies were FITC-conjugated donkey anti-goat and donkey anti-
rabbit used in dilution 1:400 (Jackson ImmunoResearch Laboratories, 705-095-
147 and 711-095-152). 
 
3.2.3 Western blot analysis 
Primary antibodies used for Western blotting were goat anti-decorin at 1:500 
(R&D, AF143), goat anti-TGFβig-h3 at 1:1000 (R&D, AF2935) and mouse anti-
GAPDH at 1:5000 (Meridian Life Science, H86504M). Secondary antibodies 
were rabbit anti-goat and goat anti-mouse used at 1:10 000 (Sigma, A5420 and 
A4416).  
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3.2.4 Confocal microscopy  
Myofibroblasts from patient 21 were processed according to the 
immunofluorescence protocol in section 2.2.6 (Chapter 2) and mounted in 
Vectashield without DAPI prior to observation. Images were taken with the 
technical support of Dr Nantaporn Lertkowit.  
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3.3 Results 
3.3.1 Gastric myofibroblasts produce and secrete ECM proteins decorin and 
TGFβig-h3 
Intracellular localisation of decorin and TGFβig-h3 
Immunocytochemical studies showed expression of TGFβig-h3 and decorin in 
myofibroblasts from patient 21 (Figure 3.3.1.1). Typically, there was perinuclear 
localisation and staining of a reticular-like network that could correspond to the 
endoplasmic reticulum (ER) and Golgi apparatus. There was distinct punctate 
staining of both proteins compatible with localisation to vesicles, and in some 
cases small numbers of vesicles were observed close to the cell membrane 
(Figure 3.3.1.1). Using confocal imaging, TGFβig-h3 and decorin were found co-
expressed not only in regions correspond to the ER and Golgi complex, but also 
in secretory vesicles distributed through the cytosol and close to the plasma 
membrane (Figure 3.3.1.2). 
 
Corpus and antrum NTMs have similar profiles of decorin secretion 
To determine whether different populations of gastric myofibroblasts exhibited 
similar patterns of secretion, studies were initially made on cells from two 
anatomically different parts of stomach: the gastric corpus and pyloric antrum.  
Western blots revealed a band of approximately 90 kDa corresponding to 
glycosylated decorin in media in both cases. Moreover, media from both corpus 
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Figure 3.3.1.1 Gastric myofibroblasts express decorin and TGFβig-h3. 
Immunocytochemical localisation of TGFβig-h3 (A and C, green) shows 
punctate staining compatible with localisation in ER, Golgi or secretory vesicles. 
Immunocytochemical localisation of decorin (D and F, green) shows similar 
distribution. DAPI (B and E, blue) staining was used for the nuclei. 
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Figure 3.3.1.2 TGFβig-h3 and decorin localise to the same secretory vesicles 
in myofibroblasts with regulated secretion. Confocal microscopy of decorin 
(red) and TGFβig-h3 (green) in myofibroblasts with regulated secretion (see 
below). Myofibroblasts express decorin (A, D) and TGFβig-h3 (B, E) in regions 
corresponding to ER and Golgi complex (open arrow), and in the same 
secretory vesicles (closed arrow) (C, F). 
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Figure 3.3.1.4 IGF-II stimulation 
increases secretion of decorin. 
Western blot analysis of decorin in 
myofibroblast media (top panel) and 
cell lysates (middle and bottom 
panels). IGF-II (100ng/ml) increased 
decorin abundance in the media after 
incubation for 1 and 2 h. Decorin cell 
abundance was not influenced by 
IGF-II (middle panel. GAPDH was 
used as a loading control for the cell 
extracts (bottom panel). 
 
Figure 3.3.1.5 IGF-II stimulation 
increases secretion of TGFβig-h3. 
Western blot analysis of TGFβig-h3 
in myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panels). IGF-II (100ng/ml) increased 
TGFβig-h3 abundance in the media 
at 1 and 2 h. TGFβig-h3 cell 
abundance was unchanged (middle 
panel). GAPDH was used as a 
loading control for the cell extracts 
(bottom panel). 
 
 
Figure 3.3.1.3 Similar time course 
of decorin release from corpus and 
antrum myofibroblasts. Western 
blots of decorin in myofibroblast 
media (top panel) and cell lysates 
(middle and bottom panels) from 
corpus and antrum myofibroblasts. 
Abundance of a band corresponding 
to glycosylated decorin (90kDa) 
increased progressively in the media 
of corpus and antrum myofibroblasts 
up to 24 h. Cellular abundance of the 
decorin core protein of 
approximately 40 kDa was 
unchanged. GAPDH, shown in the 
bottom panel, was used as a loading 
control for the cell extracts. 
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and antrum myofibroblasts exhibited a similar progressive increase in intensity of 
this band from 8 to 24 h of incubation (Figure 3.3.1.3 top panel); at an early time 
point, 4 h, decorin was undetectable. There was no difference in this respect 
between cells originating from the antrum or the corpus. In cell extracts, decorin 
was detected mainly as a band corresponding to the 40kDa core protein and this 
remained unchanged over 24 h (Figure 3.3.1.3 - middle and bottom panel). In 
view of the similarity in decorin secretion in antrum and corpus myofibroblasts, 
further studies were focused on corpus myofibroblasts.  
 
IGF-II treatment increases secretion of decorin and TGFβig-h3  
In view of previous findings in the laboratory (see above), the effect of IGF-II on 
secretion of decorin and of TGFβig-h3 was examined. Recombinant human IGF-
II (rhIGF-II) was used in concentration of 100ng/ml, which was previously 
determined to increase proliferative and migratory responses of myofibroblasts 
(Hemers et al., 2005). Treatment of cells with IGF-II increased the abundance of 
decorin and TGFβig-h3 in media (Figure 3.3.1.4-3.3.1.5 top panels). Following 
pilot experiments to optimise conditions, secretion of decorin was detectable at 1 
h and there was a clear increase in abundance with IGF-II treatment. Cellular 
decorin remained unchanged with IGF-II treatment (Figure 3.3.1.4 - middle and 
bottom panel). Similarly, there was little or no detectable TGFβig-h3 in the 
media of unstimulated cells after 1 h in these experiments, but there were clearly 
detectable bands of approximately 68 and 74kDa after 2 h (Figure 3.3.1.5). 
Strikingly, after 1 h in the presence of IGF-II there was evidence of increased 
TGFβig-h3 abundance in media, and there was a further increase after 2 h. 
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Cellular TGFβig-h3 was detected as bands of 74 and 68kDa respectively, 
corresponding to bands in control samples of media. There was no change in 
abundance or size of cellular TGFβig-h3 with IGF-II treatment but interestingly, 
in the media IGF-II treatment generated a band of 60-62kDa in addition to higher 
molecular weight material. 
 
Actinomycin D does not change IGF-stimulated secretion of decorin and 
TGFβig-h3 
To determine whether IGF-II might act by increasing decorin and TGFβig-h3 
expression, the effect of actinomycin D (2µg/ml), which inhibits DNA 
transcription, was examined. There was no decrease in cellular decorin and only 
a slight reduction in cellular TGFβig-h3 over 2 h (Figure 3.3.1.6-3.3.1.7 middle 
and bottom panels). The abundance of decorin and TGFβig-h3 in the media was 
increased by IGF-II stimulation, regardless of whether actinomycin D was 
present or absent (Figure 3.3.1.6-3.3.1.7 top panel), suggesting that transcription 
was not required for secretory responses to IGF-II. 
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Figure 3.3.1.6 Actinomycin D 
does not influence decorin 
secretion in response to IGF-II. 
Western blot analysis of decorin in 
myofibroblast media collected after 
2 h (top panel) and cell lysates 
(middle and bottom panels). IGF-II 
increased protein secretion and this 
increase was still present after 
actinomycin D treatment (top 
panel). There was no decrease in 
decorin cellular abundance after 
actinomycin D treatment (middle 
panel). GAPDH was used as a 
loading control for the cell extracts 
(bottom panel). 
 
Figure 3.3.1.7 Actinomycin D 
does not influence TGFβig-h3 
secretion in response to IGF-II. 
Western blot analysis of TGFβig-h3 
in myofibroblast media collected 
after 2 h (top panel) and cell lysates 
(middle and bottom panels). IGF-II 
increased protein secretion and this 
increase was still present after 
actinomycin D treatment (top 
panel). TGFβig-h3 cell abundance 
was slightly decreased after 
actinomycin D treatment (middle 
panel). GAPDH was used as a 
loading control for the cell extracts 
(bottom panel). 
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Figure 3.3.1.8 Decreased 
intracellular decorin after 
cycloheximide treatment. Western 
blot analysis of decorin in 
myofibroblast media collected after 1 
and 2 h (top panel) and cell lysates 
(middle and bottom panels). IGF-II 
stimulation increased decorin in the 
media both with and without 
cycloheximide treatment (top panel). 
Cycloheximide decreased cellular 
glycosylated form of decorin more 
notably at 1 h. GAPDH was used as a 
loading control for the cell extracts 
(bottom panel). 
Figure 3.3.1.9 Decreased 
intracellular TGFβig-h3 after 
cycloheximide treatment. Western 
blot analysis of TGFβig-h3 in 
myofibroblast media collected after 1 
and 2 h (top panel) and cell lysates 
(middle and bottom panels). IGF-II 
stimulation increased media TGFβig-
h3 both with and without 
cycloheximide treatment (top panel). 
TGFβig-h3 cell abundance was 
decreased at 2 h (middle panel). 
GAPDH was used as a loading 
control for the cell extracts (bottom 
panel). 
 
Figure 3.3.1.10 Cycloheximide does 
not inhibit TGFβig-h3 secretion in 
response to IGF-II. Western blot 
analysis of TGFβig-h3 in 
myofibroblast media collected after 
30 min (top panel) and cell lysates 
(middle and bottom panels). 
Cycloheximide had no effect on the 
secretion in response to IGF-II (top 
panel). TGFβig-h3 cell abundance 
was unchanged (middle panel). 
GAPDH was used as a loading 
control for the cell extracts (bottom 
panel). 
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Cycloheximide does not change IGF-stimulated secretion of decorin and 
TGFβig-h3  
To further examine the role of protein synthesis in the secretory response to IGF-
II, myofibroblasts were treated with cycloheximide (10µg/ml), a reversible 
inhibitor of protein translation, and then stimulated with IGF-II. Both, decorin 
and TGFβig-h3 were detected in the media after 1h but in unstimulated cells 
there was decreased abundance after 2 h (Figure 3.3.1.8-3.3.1.9 top panel); at 
both time points, there was increased abundance in media in the presence of IGF-
II stimulation. Cycloheximide therefore inhibited basal secretion of decorin and 
TGFβig-h3, but it did not inhibit the response to IGF-II. In addition, 
cycloheximide decreased intracellular decorin, with a strong effect on the 
glycosylated form (Figure 3.3.1.8 middle and bottom panel). In contrast, 
TGFβig-h3 abundance in the cell was only slightly decreased at 2 h (Figure 
3.3.1.9 middle and bottom panel).The data support the idea that IGF-II evokes 
secretion from a store of preformed vesicles, while basal secretion was 
maintained by newly synthesised material. In order to minimise the different 
contributions of regulated and constitutively secreted proteins in the media, the 
possibility of studying release over even shorter periods of time was explored. It 
proved difficult to detect decorin in studies of release over a period of 30 min, 
but TGFβig-h3 release was detectable in response to IGF-II stimulation (Figure 
3.3.1.10 top panel) and this was resistant to treatment with cycloheximide 
(Figure 3.3.1.10 top panel). Cell protein abundance was unchanged (Figure 
3.3.1.10 middle and bottom panels).  
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control IGF-II 
 
 
 
cycloheximide cycloheximide + IGF-II 
Figure 3.3.1.11 Cell depletion for TGFβig-h3. Immunocytochemical analysis 
of TGFβig-h3 (green) in NTM treated with cycloheximide (10µg/ml) and IGF-II 
(100ng/ml). Nuclei were stained with DAPI (blue). Untreated controls expressed 
TGFβig-h3 as punctated staining throughout the cytoplasm (A). IGF-II 
stimulation decreased cytoplasmic TGFβig-h3 (B). Cycloheximide decreased cell 
TGFβig-h3 abundance (C). Cells were entirely depleted of TGFβig-h3 (D). 
Images of all four treatments were taken on the same day, using identical 
software settings for each channel, including time of exposure and picture 
brightness and contrast.  
 
 
 
 
 
 
 
                                                                                                                                            Chapter 3  
90 
 
Immunocytochemical studies of TGFβig-h3 after cycloheximide treatment 
Immunocytochemical analysis for TGFβig-h3 in myofibroblasts pre-treated with 
cycloheximide and IGF-II showed that TGFβig-h3 was expressed in several 
cellular compartments (Figure 3.3.1.11). Nearly all (98%) control cells had 
staining compatible with localisation to ER, Golgi apparatus and secretory 
vesicles (Figure 3.3.1.11 A). Cells treated with IGF-II had decreased cytoplasmic 
TGFβig-h3 fluorescence (Figure 3.3.1.11 B). A majority (89%) of the cells 
preincubated with cycloheximide exhibited decreased TGFβig-h3 abundance 
(Figure 3.3.1.11 C). IGF-stimulation of cycloheximide-treated cells was 
associated with even weaker staining, consistent with decreased cellular TGFβig-
h3 abundance (Figure 3.3.1.11 D). 
 
3.3.2 Characterisation of short term (30 min) IGF-stimulated TGFβig-h3 
secretion 
Both IGF-II and IGF-I stimulate TGFβig-h3 secretion 
In view of the data described above, it was considered that TGFβig-h3 offered 
advantages over decorin as a model protein for short term (30 min) secretion 
studies. To further explore the secretory response, a comparison was made of 
rhIGF-I and IGF-II. As noted previously, there was stimulation of TGFβig-h3 
secretion in response to IGF-II at 30 min compared to the control (Figure 3.3.2.1 
top panel); there was also comparable secretion of TGFβig-h3 at 30 min in 
response to 50 ng/ml rhIGF-I (Figure 3.3.2.1 top panel). There was no detectable 
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stimulation of secretion at 10 ng/ml rhIGF-I. Cellular TGFβig-h3 abundance was 
unchanged by both IGF-I and IGF-II (Figure 3.3.2.1 middle and bottom panels).  
 
IGF-stimulated TGFβig-h3 secretion is decreased in calcium-free media 
To define the role of extracellular calcium, experiments in the absence of 
extracellular calcium were then performed. IGF-stimulated TGFβig-h3 secretion 
was present in control media and decreased over 40% in calcium-free media 
(Figure 3.3.2.2 top panel). Cell protein abundance was unchanged by these 
treatments (Figure 3.3.2.2 middle and bottom panels).  
 
Ionomycin stimulates TGFβig-h3 secretion 
To further study the role of calcium in IGF-stimulated TGFβig-h3 secretion the 
calcium ionophore, ionomycin (1 µM), was employed. Myofibroblasts treated 
with ionomycin exhibited a small increase in TGFβig-h3 abundance in the media 
(Figure 3.3.2.3 top panel). The cell protein abundance was unchanged (Figure 
3.3.2.3 middle and bottom panels). 
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Figure 3.3.2.1 IGF-stimulated 
TGFβig-h3 secretion in NTM. 
Western blot analysis of TGFβig-h3 
myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panels). Both, IGF-II and IGF-I 
stimulated TGFβig-h3 secretion. 
TGFβig-h3 cell abundance was 
unchanged (middle panel). GAPDH 
was used as a loading control for 
the cell extracts (bottom panel). 
 
Figure 3.3.2.2 IGF-II-stimulated 
TGFβig-h3 secretion is inhibited 
in calcium-free media. A. Western 
blot analysis of TGFβig-h3 in 
myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panel). IGF-II stimulated secretion 
was inhibited in calcium-free media 
(top panel). TGFβig-h3 cell 
abundance was unchanged (middle 
panel). GAPDH was used as a 
loading control for the cell extracts 
(bottom panel). B. Densitometric 
analysis of media Western blot 
showing over 40% decrease in IGF-
stimulated secretion in the calcium-
free media (bar chart). 
Representative results from n=2 
separate experiments. 
 
 
 
 
 
 
 
A 
B 
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Brefeldin A does not inhibit IGF-stimulated TGFβig-h3 secretion 
In order to further define the pool of secreted TGFβig-h3, studies were 
undertaken using brefeldin A (BFA) which inhibits ER-to-Golgi and intra-Golgi 
vesicular transport (Donaldson et al., 1992; Fujiwara et al., 1988) and thus can 
separate constitutive secretion from release of a preformed pool of storage 
vesicles. Pilot experiments indicated that pre-incubation with 10µg/ml BFA for 
30 min was sufficient to reduce basal (constitutive) secretion of TGFβig-h3 
(Figure 3.3.2.4 top panel). However, myofibroblasts pre-incubated with BFA and 
treated with IGF-II retained stimulated TGFβig-h3 secretion comparable to IGF-
II treated control cells (Figure 3.3.2.4 top panel). Cell protein abundance 
remained unchanged (Figure 3.3.2.4 middle and bottom panels). 
 
3.3.3 MMP-7 and short term stimulation of TGFβig-h3 secretion 
MMP-7 stimulates TGFβig-h3 secretion through IGF-IR  
In view of findings from previous proteomic studies (see above) suggesting that 
MMP-7 might evoke TGFβig-h3 release, a direct analysis of the action of MMP-
7 was made. Thus the abundance of TGFβig-h3 in the media was shown to be 
increased after treatment with 0.2µg/ml rhMMP-7 (Figure 3.3.3.1 top panel). To 
determine if this effect was mediated by IGF-IR (which is the main receptor 
binding both IGF-I and IGF-II) the IGF-IR tyrosine kinase inhibitor AG1024 
(3.2µM) was used. The secretion of TGFβig-h3 in response to MMP-7 was  
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Figure 3.3.2.3 Ionomycin 
stimulates TGFβig-h3 release. A. 
Western blot analysis of TGFβig-h3 
in myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panel). Ionomycin slightly 
stimulated protein secretion in 
myofibroblasts (top panel). 
TGFβig-h3 cell abundance was 
unchanged (middle panel). GAPDH 
was used as a loading control for 
the cell extracts (bottom panel). B. 
Densitometric analysis of media 
Western blot showing ionomycin-
stimulated TGFβig-h3 secretion 
(bar chart).  
 
 
Figure 3.3.2.4 Brefeldin A does 
not inhibit IGF-stimulated 
TGFβig-h3 secretion. A. Western 
blot analysis of TGFβig-h3 in 
myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panel). Brefeldin A inhibited basal 
secretion, but not the IGF-
stimulated (top panel). TGFβig-h3 
cell abundance was unchanged 
(middle panel). GAPDH was used 
as a loading control for the cell 
extracts (bottom panel). 
Representative results from n=2 
separate experiments. B. 
Densitometric analysis of media 
Western blot showed lack of 
inhibition of IGF-stimulated 
TGFβig-h3 secretion by BFA (bar 
chart). 
 
 
 
 
A 
B 
A 
B 
                                                                                                                                            Chapter 3  
95 
 
reduced approximately 40% by AG1024 (Figure 3.3.3.1 top panel). Cellular 
abundance of TGFβig-h3 remained unchanged (Figure 3.3.3.1 middle and bottom 
panels).  
 
MMP-7-stimulated TGFβig-h3 secretion is decreased in calcium-free media 
The effect of MMP-7 in stimulating TGFβig-h3 secretion was decreased in 
calcium-free media (Figure 3.3.3.2 top panel). Cellular abundance of TGFβig-h3 
was unchanged (Figure 3.3.3.2 middle and bottom panels).  
 
Marimastat inhibits MMP-7 stimulated TGFβig-h3 secretion 
Lastly, the action of marimastat (5µM), a broad spectrum matrix 
metalloproteinase inhibitor, was examined. This fully inhibited MMP-7 evoked 
TGFβig-h3 secretion (Figure 3.3.3.3 top panel). Cell TGFβig-h3 abundance was 
unchanged (Figure 3.3.3.3 middle and bottom panels).  
 
3.3.4 Other proteases and short term stimulation of TGFβig-h3 secretion 
In addition, another proteolytic enzyme, urokinase-type plasminogen activator 
uPA, that has been shown previously by proteomic methods to increase TGFβig-
h3 in the media (Duval & Varro, unpublished observations), also stimulated 
secretion of TGFβig-h3 from myofibroblasts (Fig 3.3.4). Cell TGFβig-h3 
abundance was unchanged (Figure 3.3.4).  
 
Figure 3.3.3.1 IGF-IR inhibitor 
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decreases MMP-7 effect on 
stimulated TGFβig-h3 secretion. 
A. Western blot analysis of 
TGFβig-h3 myofibroblast media 
(top panel) and cell lysates (middle 
and bottom panel). AG1024 
decreased MMP-7 stimulated 
TGFβig-h3 secretion (top panel). 
TGFβig-h3 cell abundance was 
unchanged (middle panel). GAPDH 
was used as a loading control for 
the cell extracts (bottom panel). B. 
Densitometric analysis of media 
Western blot showed MMP-7-
stimulated secretion with and 
without AG1024 (bar chart). 
 
 
Figure 3.3.3.2 MMP-7-stimulated 
TGFβig-h3 secretion is decreased 
in calcium-free media. A. Western 
blot analysis of TGFβig-h3 in 
myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panel). MMP-7 stimulated secretion 
was decreased in calcium-free 
media (top panel). TGFβig-h3 cell 
abundance was unchanged (middle 
panel). GAPDH was used as a 
loading control for the cell extracts 
(bottom panel). B. Densitometric 
analysis of media Western blot 
showed some inhibition of MMP-7-
stimulated secretion in calcium-free 
media (bar chart). 
 
 
 
 
A 
A 
B 
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Figure 3.3.3.3 Marimastat 
inhibits MMP-7 stimulated 
TGFβig-h3 secretion. A. Western 
blot analysis of TGFβig-h3 in 
myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panel). Marimastat fully inhibited 
MMP-7 evoked TGFβig-h3 
secretion (top panel). TGFβig-h3 
cell abundance was unchanged 
(middle panel). GAPDH was used 
as a loading control for the cell 
extracts (bottom panel). B. 
Densitometric analysis of media 
Western blot showed full inhibition 
of MMP-7 stimulated secretion by 
marimastat (bar chart). 
 
 
 
Figure 3.3.4 TGFβig-h3 secretion 
is stimulated by uPA. A. Western 
blot analysis of TGFβig-h3 in 
myofibroblast media (top panel) 
and cell lysates (middle and bottom 
panel). TGFβig-h3 secretion was 
stimulated by uPA (500ng/ml) (top 
panel). TGFβig-h3 cell abundance 
was unchanged (middle panel). 
GAPDH was used as a loading 
control for the cell extracts (bottom 
panel). B. Densitometric analysis of 
media Western blot showed uPA-
stimulated secretion of TGFβig-h3 
(bar chart). 
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3.4 Discussion 
The present chapter provides evidence that normal gastric myofibroblasts exhibit 
stimulated secretion at least of the ECM proteins TGFβig-h3 and decorin. 
Regulated secretion is generally considered to be property of neurons, 
neuroendocrine, endocrine and exocrine cells although some cells with transitory 
secretory functions (eg sperm, egg) also have dense-core vesicles of the regulated 
secretory pathway. Even so, however, there is evidence that other cell types may 
exhibit evoked secretion too. For example, 3T3-L1 adipocytes secrete the 
adipokine apelin from a pre-formed pool after stimulation with 
eicosapentanenoic acid (Lorente-Cebrian et al., 2010); pancreatic stellate cells, a 
mesenchymal cell located in close proximity to the basolateral side of the acinar 
cells and playing role in maintenance of ECM, have CCK-stimulated 
acetycholine secretion (Phillips et al., 2010). The present work indicates that 
regulated release of ECM proteins occurs in response to IGF stimulation of 
gastric myofibroblasts.  
Immunofluorescence staining revealed that decorin and TGFβig-h3 are co-
expressed in compartments compatible with ER and Golgi and further studies to 
co-localise these proteins with ER, Golgi and trans-Golgi network (TGN) 
markers are now required. In this context, it is worth noting that in cornea there 
is perinuclear expression of TGFβig-h3 which was shown to co-localise with 
TGN38 staining, a marker for TGN (Kim et al., 2009). In some cases clusters of 
vesicles were observed in the cytoplasm and/or near the plasma membrane.  
Decorin and TGFβig-h3 were co-expressed in these vesicles, which, however, 
could correspond to vesicles of either the constitutive or regulated secretory 
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pathways. However, in cells treated with IGF-II there was decreased cellular 
TGFβig-h3 immunofluorescence which was more pronounced after 
cycloheximide treatment to inhibit new synthesis, compatible with depletion of a 
pool of storage vesicles.  
Initial studies showed that IGF-II increased secretion of decorin and TGFβig-h3, 
and since only the latter exhibited a relatively robust response at short time 
periods it was selected for further analysis. Two major bands of TGFβig-h3, 74 
and 68kDa, were identified in media together with a 60-62kDa band in some 
IGF-treated samples. TGFβig-h3 from whole corneal extracts migrated on 2-D 
gels as multiple spots of the same molecular weight, but different isoelectric 
points (Korvatska et al., 2000) and this was ascribed to posttranslational 
modifications particularly phosphorylation at multiple sites (threonine, tyrosine 
and serine). Jurkunas et al. used anti-TGFβig-h3 antibody binding to the C-
terminal of the protein and showed age-related differences in the TGFβig-h3 
turnover in normal corneal endothelium (Jurkunas et al., 2009). They identified 
three species (57, 39 and 29kDa), whose production was increased in disease. 
Another study showed rapid proteolytic degradation of TGFβig-h3 in the media 
and formation of multiple size bands (69, 62 and 60kDa) which was required for 
protein’s pro-apoptotic properties in human osteosarcoma cells (Zamilpa et al., 
2009). This report corroborated earlier studies that an integrin-binding sequence 
in the C-terminus of the molecule is implicated in triggering of apoptosis (Kim et 
al., 2003). In the present study, bands corresponding to the intact protein (74kDa) 
and two minor bands (68 and 60-62kDa) were identified, but there was no 
relation between the ages of the patients. Interestingly, there were no changes in 
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the size of the bands for TGFβig-h3 (74 and 68kDa) in cell extracts suggesting 
that there was some, limited, proteolytic degradation after secretion (Adlerz et 
al., 2007).  
Several different lines of evidence contribute to the view that IGF stimulated 
secretion of TGFβig-h3 is from preformed storage vesicles (Figure 3.4).  
 
Figure 3.4 Schematic outline of the experimental approach for studies of 
myofibroblast regulated secretion. Regulated TGFβig-h3 secretion was studied 
in calcium-free media, with an inhibitor of protein transport (brefeldin A) and 
with inhibitors of protein synthesis (cycloheximide, actinomycin D), after 
stimulation with exogenous IGF-I and IGF-II (recombinant proteins) and 
endogenous IGFs (released after MMP-7 cleavage of IGFBP-5).  
 
First, secretion was not dependent on protein synthesis; the transcriptional 
inhibitor actinomycin D did not alter either intracellular protein abundance or 
secretion, implying that rates of DNA transcription were relatively low in this 
system. However, the translational inhibitor cycloheximide inhibited basal 
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secretion, which is presumably constitutive, but had no effect on the secretion in 
response to IGF-II compatible with secretion from pre-existing storage vesicles. 
Second, an inhibitor of a GTP-exchange factor responsible for the recruitment of 
coat proteins for transport of vesicles from ER to Golgi namely brefeldin A 
(Jackson and Casanova, 2000) also inhibited basal (constitutive) TGFβig-h3 
secretion, but it did not inhibit the IGF-stimulated secretion. Again, this is 
compatible with the release of a pre-formed protein pool. Third, IGF-stimulation 
exhibited a partial requirement for extracellular calcium. It is known that both 
IGF-I and IGF-II interact with IGF-IR, a receptor tyrosine kinase (Baker et al., 
1993); the IGF-II receptor or type II IGF/mannose-6-phosphate receptor binds 
mainly IGF-II (Kar et al., 1997). Upon binding to IGF-IR the two IGFs activate 
downstream pathways including those related to calcium signalling leading to 
increased intracellular calcium (Kojima et al., 1988). In contrast, the IGF-II 
receptor has been suggested to have no functional activity but instead to be 
linked to receptor uptake and degradation (Jones and Clemmons, 1995) although 
a calcium influx was described in primed BALB/c3T3 fibroblast cells in which 
IGF-II receptor was found coupled to a calcium channel by a G protein 
(Nishimoto, 1993; Nishimoto et al., 1987). The present data suggest that both 
IGF-I and IGF-II evoke regulated secretion in gastric myofibroblasts and that 
while there was reduction of stimulated TGFβig-h3 secretion in the absence of 
extracellular calcium, it was not entirely inhibited. Conversely there was a 
relatively modest response to ionomycin.  
Cell types differ in respect to the source of calcium ions for regulated secretion, 
i.e. calcium from internal stores, external calcium, or both. For example, for 
                                                                                                                                            Chapter 3  
102 
 
regulated secretion adrenal chromaffin cells require calcium influx (Cheek and 
Thastrup, 1989; O'Sullivan et al., 1989), pancreatic exocrine cells - release of 
calcium from ER (Wasle and Edwardson, 2002), and pituitary corticotrophs – 
use both sources (Hille et al., 1999; Tse and Tse, 1999). In gastric myofibroblasts 
intracellular calcium was increased only in the presence of extracellular (personal 
communication, McCaig and Burdyga). Ionomycin triggers calcium influx in 
Xenopus oocytes by translocation from the smooth endoplasmic reticulum into 
the cytoplasm and by facilitating calcium entry (Cavarra et al., 2003). Similar 
dual mechanisms were demonstrated in other cell types like Ehrlich ascites 
tumour cells, murine peritoneal neutrophils, macrophages, and T-lymphocytes 
(Dedkova et al., 2000; Imboden and Weiss, 1987). Further studies are now 
required to define more precisely the mechanisms by which IGF controls 
intracellular calcium in myofibroblasts and to delineate the relevance for 
regulated secretion.  
The finding that MMP-7 stimulated TGFβig-h3 secretion was compatible with 
the previous proteomic studies (Duval & Varro, unpublished observations). 
Inhibition of MMP-7 stimulated secretion with IGF-IR inhibitor, although 
modest, was an expected effect considering the described effect of MMP-7 on 
IGFBP-5 secretion (Hemers et al., 2005). Secretion of TGFβig-h3 stimulated by 
MMP-7, like IGF stimulated secretion, was inhibited in calcium-free media 
suggesting that both occur via common mechanisms involving IGF-IR. Since 
inhibition of MMP-7 stimulated secretion in calcium-free media was not 
complete, further studies to clarify the Ca-independent effect are required. The 
broad spectrum matrix-metalloprotease inhibitor marimastat fully inhibited 
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MMP-7 stimulated TGFβig-h3 secretion suggesting that the observed effects 
were due to MMP-7 enzymatic activity (Hemers et al., 2005).  
 
3.5 Conclusions 
1. Myofibroblasts from anatomically different stomach parts (corpus and antrum) 
have similar secretion of the ECM protein decorin. 
2. TGFβig-h3 provides a useful model for studies of regulated secretion in 
response to IGF stimulation. 
3. IGF-stimulated secretion of TGFβig-h3 is not dependent on DNA 
transcription, mRNA translation or ER to Golgi transport, but is partially 
dependent on extracellular calcium. 
4. There is MMP-7 stimulated TGFβig-h3 secretion that appears to be mediated 
by IGF-IR. 
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4.1 Introduction 
Myofibroblasts from different tissues show functional heterogeneity (Powell et 
al., 1999). Moreover, there is increasing evidence for differences between 
myofibroblasts from tumour stroma compared with normal tissue including, for 
example, evidence of epigenetic changes in tumour-derived myofibroblasts 
(Jiang et al., 2008). Previous work in this laboratory using proteomic approaches 
showed decreased TGFβig-h3 abundance in the media of CAMs from patients 
with poor survival compared with their corresponding ATMs (Holmberg & 
Varro, unpublished observations). In view of the evidence presented in the 
previous chapter, it was therefore considered important to determine whether 
regulated secretion was a uniform property of all myofibroblasts. A unique 
opportunity to study this issue in detail was provided by the availability of a 
panel of primary myofibroblasts derived from normal tissue (stomach and 
oesophagus), from inflammatory, non-cancer, tissue (pernicious anaemia), as 
well as from two different cancers (gastric and oesophageal) and their adjacent 
tissues. Additionally, another stromal cell type was available for comparison, 
namely bone-marrow derived MSCs. 
 
4.1.1 Aims and Objectives 
The aims of the work in this chapter were: 
1. To study regulated secretion of TGFβig-h3 in myofibroblasts derived from 
normal stomach, gastric cancer and adjacent tissue.  
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2. To study regulated secretion of TGFβig-h3 in myofibroblasts derived from 
inflammatory gastric tissue (pernicious anaemia) and from normal oesophagus 
and oesophageal cancer. 
3. To characterise regulated secretion of TGFβig-h3 in MSCs. 
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4.2 Materials and methods 
4.2.1 Primary cell cultures 
The work in this chapter utilised human myofibroblasts and MSCs as described 
in Chapter 2 (Table 2.1).  
 
4.2.2 Release assay 
Secretory responses to IGF-II were studied using a method similar to the one 
described in Chapter 3.  
 
4.2.3 Immunocytochemistry 
Gastric myofibroblasts and MSCs were stained for TGFβig-h3 using rabbit anti-
TGFβig-h3 antibody at 1:50 (Cell signalling, 2719) and donkey anti-rabbit at 
1:400 (Jackson ImmunoResearch Laboratories, 705-095-147 and 711-095-152). 
Deconvolution of the images was performed using the AxioVision 4.5 software 
(Carl Zeiss). 
 
4.2.4 Transmission electron microscopy (TEM) 
Myofibroblasts and mesenchymal stem cells were cultured in 10cm dishes at 
80% confluency and processed for TEM by Simon Oliver (EM Unit, Physiology 
Department, University of Liverpool) using a resin pellet embedding protocol as 
published previously (Taylor et al., 2010). Multiple images were taken of 5-10 
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cells from three myofibroblast lines: one exhibiting (Patient 14) and two lacking 
regulated secretion (Patient 2 and 11), and one MSC line (Patient 37); the 
analysis of images for the presence of dense core secretory vesicles was 
conducted by an observer who was blind to the identity of the cells. Size of the 
secretory vesicles was measured using AnalySIS Pro 3.2 (Build 678) program.  
 
4.2.5 Statistics 
Results were presented as mean ± SEM, as appropriate. The Fisher exact 
statistical test was used to compare groups of patients segregated on the basis of 
survival after surgery with regard to the proportion of CAMs exhibiting regulated 
secretion in each group; the difference was considered significant if p<0.05.  
 
 
 
 
 
 
 
 
 
                                                                                                                                            Chapter 4  
109 
 
4.3 Results 
4.3.1 Gastric myofibroblasts and regulated secretion  
Regulated secretion of TGFβig-h3 is a property of some gastric myofibroblasts 
Initially, studies of regulated secretion of TGFβig-h3 were performed on 
myofibroblasts derived from normal stomach, gastric cancer and from tissue 
adjacent to tumours, using protocols based on the work described in the previous 
chapter. Stimulation of TGFβig-h3 secretion in response to IGF-II (100ng/ml) 
was defined as an increase of >20% compared with control; examples of cells 
either exhibiting stimulated secretion, or not, are presented in Figure 4.3.1.1 A 
and B. On this basis, regulated secretion was identified in 7 out of 8 NTMs 
(88%), in 10 out of 14 ATMs (71%) and in 6 out of 14 CAMs (43%) (Table 
4.3.1, Figure 4.3.1.1C).  
To further explore the properties of cells that did not exhibit regulated secretion 
of TGFβig-h3 in response to IGF-II, experiments were performed using the 
calcium ionophore ionomycin; there was no stimulation of TGFβig-h3 secretion 
in this experiment (Figure 4.3.1.2).  
It was considered possible that if rates of constitutive secretion were high this 
might mask a relatively modest response to IGF-II. To test this possibility, 
myofibroblasts that appeared not to exhibit regulated secretion were studied 
using BFA to inhibit constitutive secretion. After BFA treatment there was no 
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Patient No. Type of cells Relative abundance IGF/control Stimulation 
1 ATM 1.57 Y CAM 0.95 N 
2 ATM  1.31 Y CAM 0.85 N 
3 ATM 4.00 Y CAM 1.17 N 
4 ATM 1.40 Y CAM 1.71 Y 
5 CAM 1.80 Y 
6 ATM 1.22 Y CAM 1.33 Y 
7 ATM  5.50 Y CAM 0.98 N 
8 ATM 1.06 N CAM 0.94 N 
9 
ATM (proximal) 1.80 Y 
ATM (distal) 0.91 N 
CAM 5.00 Y 
10 ATM  3.68 Y CAM 1.17 N 
11 ATM  0.92 N CAM 0.88 N 
12 ATM 0.91 N CAM 0.95 N 
13 CAM 3.00 Y 
14 CAM 1.98 Y 
15 ATM 1.89 Y 
16 ATM 1.33 Y 
17 NTM Corpus 1.25 Y 
18 NTM Corpus 1.27 Y 
19 NTM Corpus 1.45 Y 
20 NTM Antrum 1.17 N 
21 NTM Corpus 3.00 Y NTM Antrum 2.33 Y 
22 NTM Corpus 3.50 Y NTM Antrum 1.27 Y 
30 PA Antrum  1.02 N 
31 PA Antrum  3.25 Y 
32 PA Antrum  1.39 Y 
Table 4.3.1 Responses of gastric myofibroblasts to IGF-II stimulation. 
Densitometric analyses of band intensities from Western blots were used to 
calculate relative abundance between IGF-II treated and control samples. A 
relative abundance above 1.2 was considered as stimulation (see Materials & 
Methods section 2.2.4. for more information) 
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Figure 4.3.1.1 Comparison of different types of gastric myofibroblasts. 
Representative Western blots of TGFβig-h3 in media from NTMs, ATMs and CAMs 
with (A) and without (B) regulated secretion. Bar chart indicates the proportion of 
gastric myofibroblasts exhibiting regulated secretion of TGFβig-h3 from normal, 
adjacent and cancer tissues (C). 
 
Figure 4.3.1.2 Lack of calcium 
sensitive TGFβig-h3 secretion in 
myofibroblasts without regulated 
secretion. Representative Western 
blot showing lack of ionomycin 
stimulated TGFβig-h3 release.  
 
A 
B 
C 
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Figure 4.3.1.3 BFA inhibits 
secretion of TGFβig-h3 in the 
absence or presence of IGF-II in 
myofibroblasts that do not exhibit 
regulated secretion. Western blot 
analysis of TGFβig-h3 in 
myofibroblast media (top panel) and 
cell lysates (middle and bottom 
panel). BFA inhibited TGFβig-h3 
secretion in both absence and 
presence of IGF-II in a 
myofibroblast line that failed to 
exhibit regulated exocytosis. 
TGFβig-h3 cell abundance was 
unchanged (middle panel). GAPDH 
was used as a loading control for the 
cell extracts (bottom panel). 
 
 
detectable release of TGFβig-h3 in either control or IGF-treated samples (Figure 
4.3.1.3). Cell protein abundance was unchanged (Figure 4.3.1.3). 
 
Regulated secretion of TGFβig-h3 correlates with patient survival 
Interestingly, six out of 9 CAMs that came from patients with good survival (>22 
months) exhibited a secretory response to IGF-II (Figure 4.3.1.4). In contrast, in 
the group of patients with poor survival (<22 months) none of the 5 CAMs 
exhibited regulated secretion of TGFβig-h3 (Fisher exact, p<0.05) (Figure 
4.3.1.4). There were no co-relations between regulated secretion of TGFβig-h3 
and patient gender or the pathology in adjacent tissue (data not shown). 
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Regulated secretion of TGFβig-h3 in gastric myofibroblasts from pernicious 
anaemia   
The presence of inflammatory and immune cells in solid tumours raised the 
possibility that differences in stromal cell function might be a reflection of an 
inflammatory/immune response. It was therefore considered interesting to see 
whether myofibroblasts from patients with pernicious anaemia in whom there is 
chronic atrophic gastritis would exhibit regulated secretion of TGFβig-h3. 
Regulated secretion of TGFβig-h3 was exhibited by two of three pernicious 
anaemia-derived myofibroblasts (67%) (Figure 4.3.1.5).  
 
4.3.2 Oesophageal myofibroblasts and regulated secretion  
To investigate further the role of tissue microenvironment in determining the 
capacity for regulated secretion, a panel of primary oesophageal myofibroblasts 
was studied, from normal tissue (n=6) and from adenocarcinoma (n=3) (Table 
4.3.2). Surprisingly, only one out of 6 oesophageal NTMs exhibited regulated 
secretion of TGFβig-h3 (Figure 4.3.2.1A), whereas the remaining five NTMs had 
no signs of regulated secretion (Figure 4.3.2.1B). In contrast, all ATMs and 
CAMs from oesophageal adenocarcinoma exhibited regulated secretion of 
TGFβig-h3 (Figure 4.3.2.2).  
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Figure 4.3.1.4 Demonstration of 
regulated TGFβig-h3 secretion in 
CAMs correlates with patient survival. 
A. Representative Western blots of 
TGFβig-h3 in myofibroblast media from 
CAMs from patients with good (>22Mo, 
left) and poor survival (<22Mo, right). B. 
CAMs from 6 out of 9 patients with good 
survival (>22 months) had regulated 
TGFβig-h3 secretion compared with 0 
out of 5 patients with poor survival (<22 
months) (Fisher exact, p<0.05). 
 
 
 
Figure 4.3.1.5 Secretion of TGFβig-h3 
in pernicious anaemia-derived gastric 
myofibroblasts. A. Representative 
Western blot analysis of TGFβig-h3 in 
media from pernicious anaemia-derived 
antral myofibroblast. Examples of a 
myofibroblast with (A) and without (B) 
regulated secretion of TGFβig-h3. 
 
 
 
 
 
 
 
 
 
 
B 
A 
B 
A 
                                                                                                                                            Chapter 4  
115 
 
Patient No. Type of cells Relative abundance 
 IGF/control Stimulation 
17 NTM 0.79 N 
18 NTM 0.93 N 
19 NTM 0.63 N 
20 NTM 1.91 Y 
21 NTM 0.97 N 
22 NTM 1.06 N 
27 ATM 1.28 Y CAM 1.30 Y 
28 ATM 3.39 Y CAM 1.25 Y 
29 ATM 1.48 Y CAM 2.56 Y 
Table 4.3.2 Responses of oesophageal myofibroblasts to IGF-II stimulation. 
Densitometric analysis of band intensities from Western blots was used to calculate 
relative abundance between IGF-II treated and control samples. Relative abundance 
above 1.2 was considered as stimulation. 
 
 
Figure 4.3.2.1 Secretion of TGFβig-h3 
by normal oesophageal myofibroblasts. 
Representative Western blot analysis of 
TGFβig-h3 in media from oesophageal 
myofibroblast. Only 1 out of 6 (17%) of 
oesophageal normal myofibroblasts 
exhibited regulated secretion of TGFβig-
h3 (A), and five did not (B).  
 
Figure 4.3.2.2 Secretion of TGFβig-h3 
by myofibroblasts from oesophageal 
adenocarcinoma. Representative 
Western blot analysis of TGFβig-h3 in 
media from oesophageal cancer 
myofibroblasts. All CAMs 
(representative example in A) and all 
ATMs (representative example in B) 
exhibited regulated secretion of TGFβig-
h3 after stimulation with IGF-II (mean 
increase 1.70±0.43, n=3 and 2.05±0.67, 
n=3 respectively). 
 
 
 
 
A 
B 
A 
B 
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4.3.3 MSCs and regulated secretion  
Human MSCs exhibit regulated TGFβig-h3 secretion 
To further characterise the capacity of mesenchymal cells to exhibit regulated 
secretion a set of six human MSC lines was examined. Using 
immunofluorescence, TGFβig-h3 was found to be localised to a perinuclear zone 
with some cytoplasmic, possibly vesicular, localisation (Figure 4.3.3.1). All six 
MSC lines exhibited increased secretion of TGFβig-h3 in response to stimulation 
with IGF-II (Table 4.3.3, Figure 4.3.3.2).  
Since all lines of MSCs showed evidence of regulated secretion of TGFβig-h3, 
further studies were performed to characterise the response. In a pilot experiment 
studying a range of IGF-I concentrations (10ng/ml, 50ng/ml and 100ng/ml), there 
was stimulation of TGFβig-h3 secretion, as compared with the 100ng/ml IGF-II 
stimulation, and the secretory response to IGF-I was dose-dependent (Figure 
4.3.3.3).  
 
Regulated secretion of TGFβig-h3 by MSCs is decreased in calcium-free media 
There was a decrease in IGF-stimulated TGFβig-h3 secretion in calcium-free 
media compared with normal media (Figure 4.3.3.4). Cell TGFβig-h3 abundance 
was unchanged (Figure 4.3.3.4). Additionally, the calcium ionophore, 
ionomycin, stimulated TGFβig-h3 secretion from MSCs comparable to that by 
both IGF-II and IGF-I (Figure 4.3.3.4). Cell abundance was unchanged (Figure 
4.3.3.4). 
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Regulated secretion of TGFβig-h3 by MSCs is present after BFA treatment 
Basal secretion of TGFβig-h3 in MSCs was almost entirely blocked by BFA 
(Figure 4.3.3.5). IGF-stimulated TGFβig-h3 secretion, however, was still present 
(Figure 4.3.3.5). Cell protein abundance was unchanged (Figure 4.3.3.5). 
 
Regulated secretion of TGFβig-h3 by MSCs is present after cycloheximide 
treatment  
Finally, cycloheximide was used to inhibit protein synthesis before stimulation 
with IGF-II. IGF-stimulated secretion of TGFβig-h3 was slightly lower, but still  
 
Patient No. Type of cells Relative abundance 
 IGF/control Stimulation 
33 MSC 2.75 Y 
34 MSC 4.00 Y 
35 MSC 16.00 Y 
36 MSC 1.32 Y 
37 MSC 3.33 Y 
38 MSC 2.51 Y 
Table 4.3.3 Responses of human MSCs to IGF-II stimulation. Densitometric 
analysis of band intensities from Western blots was used to calculate relative 
abundance between IGF-II treated and control samples. Relative abundance above 
1.2 was considered as stimulation. 
 
 
 
                                                                                                                                            Chapter 4  
118 
 
 
 
Figure 4.3.3.1 TGFβig-h3 
expression in MSC. 
Immunocytochemical images 
of TGFβig-h3 (green) in MSCs 
showed perinuclear and some 
vesicular localisation. Nuclei 
were stained with DAPI (A, B, 
C). 
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Figure 4.3.3.2 Regulated 
TGFβig-h3 secretion in 
MSCs. Representative Western 
blots of TGFβig-h3 in MSC 
media. All MSCs had 
increased TGFβig-h3 secretion 
after IGF-II treatment (mean 
fold increase 4.98±2.23, n=6).   
 
 
Figure 4.3.3.3 IGF-
stimulated TGFβig-h3 
secretion in MSC. Western 
blot analysis of TGFβig-h3 in 
MSC media. Both, IGF-II and 
IGF-I stimulated TGFβig-h3 
secretion. There was dose-
dependent stimulation of 
secretion by IGF-I. 
 
 
Figure 4.3.3.4 Regulated 
TGFβig-h3 secretion is 
inhibited in calcium-free 
media. *Western blot analysis 
of TGFβig-h3 in media from 
MSC. IGF-II stimulated 
secretion was inhibited in 
calcium-free media (A). 
Calcium ionophore, ionomycin 
stimulated TGFβig-h3 
secretion comparable to IGF-I 
and IGF-II (B). *Data were 
obtained jointly with Mr Jin Rui 
Liang. 
 
 
 
 
 
A 
B 
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present after preincubation with cycloheximide (Figure 4.3.3.6). There was no 
observable change in cell protein abundance (Figure 4.3.3.6). 
 
4.3.4 Dense-core secretory vesicles in the cytoplasm of myofibroblasts with 
regulated secretion and MSCs  
Based on the findings described above, it was reasoned that in myofibroblasts 
exhibiting regulated exocytosis it might also be possible to identify dense-cored 
secretory vesicles using TEM, while it was not expected to find these structures 
in cells that did not exhibit regulated secretion. In myofibroblasts with regulated 
secretion (Patient 14, panel A) and in an MSC line (Patient 37, panel B) there 
were dense-cored secretory vesicles in the close vicinity of the Golgi complex 
(Figure 4.3.4). Typically the electron dense core occupied a relatively small 
proportion of the vesicle. Similar vesicles were occasionally found scattered 
throughout the cytosol. The diameter of the secretory vesicles was similar in both 
myofibroblasts and MSCs, respectively 197.4 ± 10.3 nm and 219.9 ± 11.2 nm 
(Table 4.3.4). Rough ER and Golgi stacks were observed routinely in all cells 
whether they exhibit regulated exocytosis or not. Dense cored secretory vesicles 
with diameter 202.5 ± 13.1nm were occasionally observed in a myofibroblast 
line that did not exhibit regulated secretion (Patient 11, Table 4.3.4). However, 
no secretory vesicles were observed either close to the Golgi, or in the cytosol of 
another myofibroblasts that did not exhibit regulated secretion (panel C, Figure 
4.3.4; Patient 2, Table 4.3.4). 
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Figure 4.3.3.5 Regulated TGFβig-
h3 secretion is maintained after 
brefeldin A treatment. *Western 
blot analysis of TGFβig-h3 in MSC 
media (top panel) and cell lysates 
(middle and bottom panel). 
Brefeldin A had no effect on the 
secretion in response to IGF-II (top 
panel). TGFβig-h3 cell abundance 
was unchanged (middle panel). 
GAPDH was used as a loading 
control for the cell extracts (bottom 
panel).* Data were obtained jointly with 
Mr Jin Rui Liang. 
 
Figure 4.3.3.6 Regulated TGFβig-
h3 secretion is maintained after 
cycloheximide treatment. 
*Western blot analysis of TGFβig-
h3 in MSC media (top panel) and 
cell lysates (middle and bottom 
panel). Cycloheximide had no effect 
on the secretion in response to IGF-
II (top panel). TGFβig-h3 cell 
abundance was unchanged (middle 
panel). GAPDH was used as a 
loading control for the cell extracts 
(bottom panel).* Data were obtained 
jointly with Mr Jin Rui Liang. 
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Figure 4.3.4 Transmission electron microscopy (TEM) identifies dense core secretory 
vesicles in myofibroblats exhibiting regulated secretion and in MSCs. Representative 
photomicrographs taken at magnification of 60,000 x showing dense core secretory vesicles 
(closed arrows) in myofibroblasts (A) and MSCs (B) exhibiting regulated secretion. Lack of 
dense core secretory vesicles in myofibroblasts without regulated secretion (C) while the Golgi 
apparatus is clearly visible (open arrows). Scale bar 500nm. 
 
Patient 
No. 
Cell 
type 
No. of 
cells 
counted 
No. of 
fields 
counted 
No. of 
secretory 
vesicles 
counted 
Mean diameter of 
secretory vesicles 
Patient 2 CAM 9 14 0 - 
Patient 11 ATM 15 31 3 202.5 ± 13.1nm 
Patient 14 CAM 6 7 17 197.4 ± 10.3nm 
Patient 37 MSC 5 8 37 219.9 ± 11.2nm 
Table 4.3.4 Similar diameter of dense core secretory vesicles from 
myofibroblasts and from MSCs. The diameter of secretory vesicles was measured 
from photomicrographs taken at magnification of 60,000 x. For vesicles with a not 
round shape average diameter was calculated on the basis of diameter via long and 
short axis. For each cell type mean diameters were calculated ± SEM. Myofibroblasts 
with regulated secretion were taken from Patient 14 and without - from Patient 2 & 
11. 
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4.4 Discussion 
The work in this chapter describes differences between myofibroblast lines in the 
ability to respond to IGF with increased secretion of TGFβig-h3. The differences 
were apparent in myofibroblasts from distinct regions of gastrointestinal tract 
(stomach vs oesophagus), from the same region but from normal and cancerous 
tissue, as well as between different mesenchymal cell types (e.g. MSCs). In 
addition, electron microscopy images of myofibroblasts with regulated secretion 
showed dense core secretory vesicles in their cytosol whereas these were not 
identified in myofibroblasts that did not exhibit regulated secretion. 
There is increasing evidence that myofibroblasts play an important role in tissue 
organization in health and in disease (Powell et al., 1999) includes roles for 
myofibroblasts from skin (Darby et al., 1990; Hebda et al., 1993), brain (Mucke 
and Eddleston, 1993), heart and pericardium (Weber et al., 1997), and small 
intestine and colon (Joyce et al., 1987). These studies showed local regulation 
exerted by myofibroblasts with respect to their respective tissue or organ of 
origin. For example, subepithelial intestinal myofibroblasts participate in the 
modulation of intestinal motility, in the regulation of intestinal water and 
electrolyte transport and in tissue responses to inflammation (Powell, 2005). The 
present data now suggest, conversely, that the local tissue microenvironment 
plays a role in determining the secretory phenotype of myofibroblasts. Thus, this 
study showed that almost all of the normal gastric myofibroblasts exhibited 
regulated secretion while normal oesophageal myofibroblasts did not, raising the 
possibility that differences in secretory pattern may be related to functional 
differences within the gastrointestinal tract. This is the first demonstration of 
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differences in secretory function in myofibroblasts from normal upper 
gastrointestinal tract and the functional significance, in vivo, will require further 
study.  
Less than half of CAMs exhibited regulated secretion and, surprisingly, these 
cells were from patients with good survival. There is increasing evidence that 
changes occur in stromal cells alongside changes in tumour cells as cancers 
progress; for example, altered gene expression was detected in breast cancer 
stromal cells with tumour progression (Ma et al., 2009). Moreover, comparisons 
using microarray analysis between intestinal myofibroblasts from normal, 
adenomatous and adenocarcinomatous human colonic tissues found quite 
distinctive gene expression profiles (Powell, 2005). Furthermore, Jiang et al. 
showed epigenetic changes in myofibroblasts from gastric adenocarcinoma, 
which were not associated with genomic instability but with an altered gene 
expression instead (Jiang et al., 2008). Thus, the data raise the possibility that 
stromal myofibroblasts acquire changes during cancer development that modify 
their phenotype, including their secretory capacity. More generally, the 
observations with CAMs support the idea that the cellular microenvironment in 
cancer, as well as normal tissue, is a determinant of myofibroblast functional 
properties.  
Based on these findings a test for regulated secretion in cancer stromal 
myofibroblasts could be used as a disease biomarker. Use of cancer stroma-
derived markers to define cancer progression has been already discussed in the 
literature. For example, analysis of the fibrotic focus in the tumour was used as a 
useful histological prognostic marker for patients with breast cancer (Van den 
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Eynden et al., 2007). In the case of regulated secretion of TGFβig-h3, a possible 
biomarker assay might assess, for example, TGFβig-h3 abundance in the blood 
before and after local administration of IGF-II (Urbanek et al., 2005). Urbanek et 
al. injected a mixture of growth factors in the hearts of infarcted mice to trigger 
migration and growth, and proliferation of the cardiac stem cells and early 
committed cells to the damaged area, thus improving myocardial regeneration 
and increasing survival of the mice. This approach could be applied with some 
modifications in the staging of gastric tumours, and therefore in the assessment 
of therapeutic options. In addition, plasma proteomics in an experimental cancer 
model identified differentially abundant proteins derived from both cancer itself 
and cancer stroma (Hung et al., 2006). The latter study employed mass 
spectrometry to compare plasma from mice with moderate to high intestinal 
adenoma burden to healthy control mice of the same age. Despite the complex 
protein content of the plasma, the analysis identified differentially secreted 
proteins, including from the stromal cells, hence suggesting that the proteome of 
the cancer stromal cells could be used as a source of biomarkers in conjunction 
with the classic tumour markers; and to increase sensitivity and specificity of 
disease identification (Zhang et al., 2004). 
Regulated secretion in myofibroblasts was associated with the presence of dense 
cored secretory vesicles in the cytosol. These vesicles were relatively large in 
size and exhibited an electron opaque core resembling the dense core secretory 
vesicles identified in endocrine, neuroendocrine and exocrine cells. Recently, 
astrocytes from brain were reported to exhibit ultrastructural features similar to 
the dense core vesicles of the neuronal cells (Prada et al., 2011). In contrast, 
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myofibroblasts without regulated secretion occasionally exhibited dense core 
secretory vesicles in their cytosol, if any at all. Additionally, the higher number 
of secretory vesicles per field in the MSCs was consistent with the higher rate of 
regulated secretion from these cells. 
There is substantial work relating chronic inflammation with cancer development 
(Balkwill and Mantovani, 2001). For example, there is a direct relation between 
stomach infection with H.pylori and gastric cancer (Parsonnet et al., 1991), 
between inflammatory bowel disease and colorectal carcinoma (Coussens and 
Werb, 2002), between Hepatitis C infection and liver carcinoma (Tsukuma et al., 
1993) and between chronic pancreatitis and pancreatic cancer (Lowenfels et al., 
1993). Pernicious anaemia is a condition of chronic inflammation in the gastric 
antrum related to changed mucosal morphology and hypergastrinaemic 
environment. Two of three myofibroblast lines taken from pernicious anaemia 
stomachs exhibited regulated secretion of TGFβig-h3. Due to the small group 
size it would be speculative to draw any other conclusions besides that these 
myofibroblasts resembled the normal cells from the gastric antrum in terms of 
their capacity for regulated secretion. 
Bone marrow-derived MSCs have some features of fibroblast morphology 
(Majumdar et al., 1998). MSCs cultured in special supplemented medium to 
remain undifferentiated express and secrete TGFβig-h3, as shown by 
immunofluorescence and Western blot. These findings are consistent with data 
from proteomic studies on the media of human embryonic stem cell (hESC)-
derived MSCs (Sze et al., 2007) which identified 201 unique proteins in the 
secretome of hESC-MSCs, including TGFβig-h3 and other ECM proteins, 
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growth factors and their binding proteins, and matrix proteases and their 
inhibitors. 
In the present study, MSCs were shown to exhibit regulated secretion of TGFβig-
h3 that was triggered by IGFs; the response was partially dependent on 
extracellular calcium and occurred from a preformed store. Mesenchymal stem 
cells are reported to express IGF-IR (Ponte et al., 2007) and are able to respond 
to IGF-I treatment (Worster et al., 2001). Based on the relative changes in 
abundance of protein in the media, the secretory response of MSCs was stronger 
than that of myofibroblasts, suggesting that MSCs may have a larger pool of 
stored protein (see above). Growth factor-triggered regulated secretion by MSCs 
arriving at a peripheral destination, including for example in preneoplastic 
stomach, could be functionally significant. In this context it is interesting that 
Houghton et al. showed that bone-marrow derived MSCs contribute to the 
development of gastric tumours in mice with chronic H.felis infection (Houghton 
et al., 2004). Moreover, there is evidence that myofibroblasts develop from 
MSCs in the same model (Quante et al., 2011). These studies suggest an active 
role for bone marrow-derived MSCs in gastric cancer progression, and further 
suggest a functional link to myofibroblasts; the secretory phenotype of these cells 
might therefore help to define the identity of the cellular niches following growth 
factor stimulation.  
In conclusion, the results described in this chapter show consistent differences in 
the secretion of myofibroblasts derived from different tissues, thus providing 
further evidence of their heterogeneity. The data are consistent with a role for the 
local tissue microenvironment in defining myofibroblast phenotype in normal 
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and in cancer tissue; however, the relevant factors remain to be determined. In 
the meantime, differences in the secretory phenotype between normal and 
cancer-associated gastric myofibroblasts might become useful as a diagnostic 
disease marker. Additionally, the presence of a regulated secretion in the bone-
marrow derived MSCs might be important in the studies of their emerging 
tumour-promoting role.  
 
4.5 Conclusions 
1. Myofibroblasts from gastric tissue tend to exhibit regulated secretion if they 
are from normal tissue and from tumours from patients with good survival.  
2. Myofibroblasts from normal oesophageal tissue tend not to exhibit regulated 
secretion of TGFβig-h3, but do so when from oesophageal adenocarcinoma.   
3. MSCs exhibit regulated secretion of TGFβig-h3 that requires extracellular 
calcium and occurs from a preformed vesicle pool.  
4. Regulated secretion of myofibroblasts is not a ubiquitous cell property as it 
may vary depending on different local tissue factors. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
IDENTIFICATION OF PROTEINS IN THE 
SECRETOMES OF GASTRIC 
MYOFIBROBLASTS AND MSCS THAT 
EXHIBIT REGULATED AND 
CONSTITUTIVE SECRETION 
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5.1 Introduction  
In recent years, secretome studies have become increasingly important in 
understanding both mechanisms of intercellular communication and the way that 
cells define their extracellular niche. Based on the findings described in the 
previous chapter it was considered important to identify the range of proteins in 
the secretomes of gastric myofibroblasts and MSCs that exhibited stimulated 
release in response to IGF-II (termed here “the regulated secretome”) and by 
exclusion those that were released via constitutive secretory pathways (and so 
could be used as controls in mechanistic studies).  
There are multiple possible approaches to defining secretomes (Skalnikova et al., 
2011). The work in this chapter is based on previous experience in the group that 
utilised a mass spectrometry-based proteomic method, namely Stable Isotope 
Labelling by Amino Acids in Cell Culture (SILAC) combined with identification 
and relative quantification of proteins in IGF-treated compared to control 
samples using LTQ OrbitrapVelos mass spectrometer.  
Although relatively new, the method has been successfully applied to secretome 
studies of several different primary cell types (Greco et al., 2010; Spellman et al., 
2008). Amongst the various bioinformatic tools available for the analysis of mass 
spectrometry datasets, the MaxQuant software package has proven advantageous 
when applied to SILAC data (Cox and Mann, 2008) and was used to generate the 
information used here.   
Thus, this chapter makes use of data from an analysis of the regulated secretome 
of myofibroblasts and MSCs performed by Dr Chris Holmberg; the validation of 
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these datasets is described with a particular focus on the identification of proteins 
that might act as markers of either the regulated or constitutive secretory 
pathways. 
 
5.1.1 Aims and Objectives 
The specific aim of the work in this chapter was:  
To identify putative constitutive and regulated secretory proteins in the 
secretomes of gastric myofibroblasts and MSCs, thereby validating targets 
identified by proteomic methods. 
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5.2 Materials and methods 
5.2.1 Identification of proteins for validation studies 
A list of putative secreted proteins in the media of myofibroblasts (Patient 14) 
and MSCs (Patient 37) was generated by Dr Chris Holmberg and provided for 
this study (Appendix). Candidate proteins for release by the constitutive and 
regulated pathway were selected from this list and validated using Western blot. 
 
5.2.2 Sample generation  
Cells were plated at 1x106 cells in 10cm dishes and left to attach overnight. On 
the following day cells were washed 3 times with PBS, serum-starved for 1 h and 
treated with 100ng/ml IGF-II for 30 min. Media was collected, centrifuged (800g 
40C, 7 min) and processed with StrataClean™ Resin (10µl resin for ml sample) 
for extraction of proteins. The resin suspension was vortexed for 1 min and 
centrifuged (2000rpm 40C, 1 min) to separate waste media from the resin. After 
removal of waste, resin was washed twice with 500µl 50mM ammonium 
bicarbonate ((NH4)2CO3), resuspended in 100µl (NH4)2CO3, aliquoted and stored 
at -800C until further processed.  
 
5.2.3 Western blot analysis 
Media samples processed with StrataClean™ Resin were analysed by Western 
blot without the boiling step with Laemmli buffer. A full list of the primary 
antibodies used in this chapter is presented in Chapter 2 Table 2.2. 
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5.3 Results 
The secretomes of gastric myofibroblasts and MSCs 
Proteomic analysis initially identified approximately 250 proteins in the media of 
myofibroblasts and MSCs and from this a list of 143 putative secreted proteins 
had been generated (see Appendix). Using the Universal Protein Resource 
(UniProt) database the 143 proteins were manually identified as (a) soluble 
secretory proteins, (b) shed membrane proteins, i.e. plasma membrane proteins 
with a sequence exposed on the extracellular surface providing a target for 
shedding mechanisms, or (c) existing in both forms (membrane/secreted). 
There were 106 putative secreted proteins in the media of gastric myofibroblasts, 
and co-incidentally there was exactly the same number of putative secreted 
proteins in the media of MSCs. More than half of the secretomes of the two cells 
were shared between them (~60%). Thus of the total of 143 proteins that had 
been identified, there were 69 present in the media of both cell types (Table 
5.3.1). From the pool of common proteins, 63 belonged to the group of soluble 
secretory proteins and 51 out of these exhibited increased relative abundance in 
IGF vs control media of >1.2, i.e. were considered to be secreted via the 
regulated pathway. None of the common secreted proteins exhibited a relative 
abundance in IGF vs control media of <1.2 in both cell types; in other words, 
there were no common proteins that were candidates for secretion by the 
constitutive pathway. However, 12 proteins were identified as exhibiting a 
relative abundance in IGF vs control media of <1.2 in either myofibroblasts or 
MSCs and were therefore candidates for constitutive release in one or other of 
these cells. 
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Protein category Number of proteins 
Common secretome  69 
Common soluble secretory proteins  63 
Common soluble secretory proteins with relative abundance >1.2   51 
Common soluble secretory proteins with relative abundance <1.2   0 
Common soluble secretory proteins with relative abundance <1.2  
in either myofibroblasts or MSCs 12 
Table 5.3.1 The secretomes of gastric myofibroblasts and MSCs. From all 
identified proteins a list of 143 putative secreted proteins was generated (see 
Appendix I). There were 106 putative secreted proteins present in the media of 
myofibroblasts, and the same number of different proteins was present in the 
media of MSCs. The two secretomes shared 69 proteins, 63 of these were 
secreted soluble factors and 51 of the latter exhibited relative abundance of IGF 
to control >1.2. The remaining 12 exhibited secretion by a different pathway in 
the two cell types, leaving none shared proteins with relative abundance <1.2. 
 
The secretome of gastric myofibroblasts 
Based on the UniProt database, 92 of 106 proteins in the gastric myofibroblast 
secretome were identified as soluble secreted proteins, 12 as membrane-
associated and 2 as membrane/secreted proteins (see above). From the 92 
secreted proteins, 79 exhibited an increased relative abundance in IGF vs control 
media of >1.2, while 13 exhibited <1.2 (Appendix). As outlined in Chapter 2, a 
difference >1.2 was considered to be indicative of regulated secretion.  
Individual proteins in the myofibroblast secretome were then assigned to 
different functional groups namely ECM proteins, binding proteins, ligands, 
proteases, protease inhibitors, receptors, enzymes, other and unknown, again 
using the UniProt database (Figure 5.3.1). The analysis was conducted separately 
for proteins potentially released by regulated and constitutive pathways. 
Although the number of protein candidates for secretion by the constitutive 
pathway was relatively low, there were examples in all the main functional 
classes.  
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Validation of the secretome data of gastric myofibroblasts 
Validation of the proteomic data was performed on ten secreted proteins using 
Western blot. These proteins were selected on the basis of representation in 
different functional classes, with examples drawn from both putative regulated 
and constitutively secreted proteins.  
Table 5.3.2 shows the relative abundance in the media and some cell extracts 
from samples treated with IGF-II compared to the control samples from both 
mass spectrometry and Western blot. Eight proteins exhibited an increased 
relative abundance after IGF treatment of >1.2 in both proteomic studies and 
Western blots namely decorin, IGF-binding protein (IGFBP)-5, IGF-binding 
protein (IGFBP)-7, lumican, nexin, tissue inhibitor of matrix metalloproteinase-1 
(TIMP-1), TIMP-2 and TGFβig-h3 (Table 5.3.2, Figure 5.3.2). Two proteins, 
galectin-3 and plasminogen activator inhibitor-1 (PAI-1), exhibited relative 
abundance of <1.2 in response to IGF treatment determined by both mass 
spectrometry identification and Western blot, compatible with constitutive 
release (Figure 5.3.3).  
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Figure 5.3.1 Separation by protein class of the secretome of gastric 
myofibroblasts. Nine functional categories were identified amongst proteins 
secreted via regulated secretion (RS) with the two predominant classes being 
ECM proteins and binding proteins. Proteins secreted via constitutive secretion 
(CS) belonged to seven categories. Allocation to different classes was based on 
UniProt protein database.  
Protein name Media Cell extracts SILAC-MS Western Blot SILAC-MS Western Blot 
Decorin 1.23 2.94 NI 0.98 
Galectin-3 0.88 0.84 1.29 0.95 
IGFBP-5 1.48 4.67 NI 1.01 
IGFBP-7 1.72 1.50 NI ND 
Lumican 1.78 2.84 NI ND 
Nexin 2.47 1.59 1.69 ND 
PAI-1 1.02 1.10 NI ND 
TIMP-1 1.54 1.36 1.15 ND 
TIMP-2 1.80 2.35 NI ND 
TGFbigh-3 2.00 1.56 NI 1.09 
Table 5.3.2 Relative abundance of selected proteins in the media and cell 
extract from myofibroblasts after IGF-II stimulation. Relative abundance of 
ten selected proteins from SILAC and Western blot identifications. Relative 
abundance for SILAC analysis was average of n=3 (n-number of replicates). NI-
Not Identified, ND-Not Done. 
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Only three out of ten of the selected proteins were identified in cell extracts by 
mass spectrometry. Western blot analysis of one of these and of three other 
proteins in cell extracts indicated no change in relative abundance with IGF 
stimulation (Table 5.3.2). 
 
The secretome of MSCs 
Based on the UniProt database, 94 of 106 proteins in the secretome of MSCs 
were identified as soluble secreted proteins, 9 as membrane-associated and 3 as 
membrane/secreted proteins (see Appendix). From the 94 secreted proteins, 87 
exhibited an increased relative abundance in IGF vs control media >1.2, while 7 
exhibited <1.2 (Appendix).  
Individual proteins in the MSCs secretome were then assigned to the same 
functional groups as above: ECM proteins, binding proteins, ligands, proteases,   
protease inhibitors, receptors, enzymes, other and unknown (Figure 5.3.4). The 
analysis was conducted separately for proteins potentially released by the 
regulated and constitutive pathways, and taking into account of the relatively low 
number of protein candidates for secretion by the constitutive pathway.  
 
Validation of the secretome data of MSCs 
Validation of the proteomic data was performed on seven secreted proteins using 
Western blot. These proteins were selected on the basis of representation in  
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Protein 
name 
Western Blot Protein 
name 
Western Blot 
Decorin Nexin 
IGFBP-5 TIMP-1 
IGFBP-7 TIMP-2 
Lumican TGFβigh-3 
Figure 5.3.2 Representative Western blots of media from myofibroblasts 
after 30 minutes IGF-II stimulation. Eight proteins were chosen for validation 
after proteomic analysis suggested they were released via regulated secretion. 
Western blot identification confirmed the proteomic data. 
 
Protein 
name 
Western Blot Protein 
name 
Western Blot 
Galectin-3 PAI-1 
Figure 5.3.3 Representative Western blots of media from myofibroblasts 
after 30 minutes IGF-II stimulation. Two proteins were chosen for validation 
after proteomic analysis suggested they were secreted via constitutive secretion. 
Western blot identification confirmed the proteomic data. 
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different functional classes, with examples drawn from the putative regulated 
secreted proteins. 
Table 5.3.3 shows the relative abundance in the media and some cell extracts 
from samples treated with IGF-II compared to the control samples from both 
mass spectrometry and Western blot. All seven proteins exhibited an increased 
relative abundance after IGF treatment of >1.2 in both proteomic studies and 
Western blots namely decorin, IGFBP-5, IGFBP-7, lumican, PAI-1, TIMP-2 and 
TGFβig-h3 (Table 5.3.3). Interestingly, PAI-1 exhibited relative abundance >1.2 
in the media of MSCs, but <1.2 in the media of gastric myofibroblasts. An eighth 
protein, galectin-3, had not been identified by mass spectrometry in the media of 
MSCs, but in view of its identification as a candidate for constitutive release by 
myofibroblasts it was also studied by Western blot in MSC media. Interestingly, 
galectin-3 exhibited relative abundance in IGF-treated vs control media ˃1.2, 
suggesting that it is secreted in a regulated fashion by MSCs (Table 5.3.3, Figure 
5.3.5). 
Only one out of seven of the selected proteins was identified in the cell extracts 
by mass spectrometry. Western blot analysis of TGFβig-h3 in cell extracts 
indicated no change in relative abundance with IGF stimulation (Table 5.3.3). 
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Figure 5.3.4 Separation by protein class of the secretome of MSCs. Nine 
functional categories were identified amongst proteins secreted via regulated 
secretion (RS) with the dominant being ECM proteins and binding proteins. 
Proteins secreted via constitutive secretion (CS belonged to four functional 
categories. Allocation to different classes was based on UniProt protein database. 
 
Protein name 
Media Cell extracts 
SILAC Western Blot SILAC Western blot 
Decorin 1.72 3.98 NI ND 
Galectin-3 NI 3.01 NI ND 
IGFBP-5 2.05 1.52 NI ND 
IGFBP-7 2.59 2.20 1.28 ND 
Lumican 2.37 1.70 NI ND 
PAI-1 2.05 1.71 NI ND 
TIMP-2 2.28 2.16 NI ND 
TGFβig-h3 1.74 3.44 NI 1.03 
Table 5.3.3 Relative abundance of selected proteins in the media and cell 
extract from MSCs after IGF-II stimulation. Relative abundance of seven 
specifically selected proteins from SILAC and Western blot identifications. 
Galectin-3 was identified in the media only by Western blot. Relative abundance 
for SILAC analysis was average of n=3 (n-number of replicates). Key: NI-Not 
Identified, ND-Not Done. 
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Protein 
name 
Western Blot Protein 
name 
Western Blot 
Decorin Lumican 
Galectin-3 PAI-1 
IGFBP-5 TIMP-2 
IGFBP-7 TGFβig-h3 
Figure 5.3.5 Representative Western blots of media from MSCs after 30 
minutes IGF-II stimulation. Eight proteins were chosen for validation after 
proteomic analysis suggested they were released via regulated secretion. Western 
blot identification confirmed the proteomic data. 
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5.4 Discussion 
The present chapter describes for the first time data from a secretome-wide 
analysis of proteins exhibiting stimulated release by gastric myofibroblasts and 
MSCs after acute exposure to IGF-II. The study identifies candidates for release 
by both regulated and constitutive mechanisms. Interestingly, the former 
predominate. The data also reveal unexpected differences between 
myofibroblasts and MSCs in the capacity for regulated release of individual 
proteins.  
Overlap in the secretomes of gastric myofibroblasts and MSCs (about 60% of 
each cell type) was not unexpected since these are both mesenchymal cell types. 
Moreover, there is evidence that myofibroblasts can develop from bone marrow-
derived MSCs in murine gastric tumours with chronic H.felis infection (Quante 
et al., 2011). However, it was unexpected to see that 80% of the shared 
secretome was sensitive to IGF stimulation, and there were no examples of 
constitutively secreted proteins released by both cell types. It seems, then, that 
proteins released via the constitutive pathway in one cell type can be released via 
regulated secretion in a related cell type. It is of course, entirely feasible that 
further studies will indeed identify common constitutively released proteins. 
However, the finding that the same protein may exhibit IGF-stimulated release in 
one cell type but not the other, raises questions about the mechanisms 
determining release routes which will be taken up in the next chapter. 
It is important to note that all proteins selected for validation exhibited relative 
abundance in the Western blot analysis consistent with the proteomic data, 
thereby showing robustness of the performed secretome analysis.  
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Separation by functional class for both myofibroblasts and MSCs demonstrated 
that secreted proteins represented a wide range of protein classes associated with 
the constitution and maintenance of the extracellular environment. These data are 
consistent with the large body of evidence indicating the role of myofibroblasts 
in secreting a range of different proteins involved in the formation of 
extracellular matrix, and in the repair and regeneration processes in inflammation 
and tissue injury (Powell et al., 1999). Similarly, utilising two different 
proteomic approaches, a recent study has identified a number of factors involved 
in tissue repair and regeneration in the media of human embryonic stem cells-
derived MSCs (Sze et al., 2007). Additionally, our analysis showed for no 
particular preferences of protein functional class for a cell type or a release route.  
Interestingly, although many similarities were identified between the 
myofibroblasts and MSCs, these were related to proteins exhibiting regulated 
release. In the first place it was unexpected to observe that shared secretome did 
not include any proteins potentially exhibiting constitutive release. There were, 
however, proteins with relative abundance <1.2, but not in the both cell types. 
For example, PAI-1 was found not to exhibit increase in abundance in response 
to IGF stimulation of myofibroblasts, indicative for a non-regulated secretion, 
whereas there was increased abundance in response to IGF in MSCs compatible 
with release via regulated secretion. Multiple reports on human umbilical cord 
endothelial cells give evidence for a constitutive secretion of PAI-1 (Diamond et 
al., 1989; MacGregor and Booth, 1988; Stiko-Rahm et al., 1990). Conversely, a 
recent report found PAI-1 to be targeted to catecholamine storage vesicles of 
chromaffin cells and co-released with catecholamines in regulated fashion (Jiang 
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et al., 2011). These studies therefore support the idea that the same protein can be 
secreted via different release routes in different cell types. 
Furthermore, in the validation studies galectin-3 exhibited relative abundance in 
response to IGF stimulation <1.2 in the media of myofibroblasts, but >1.2 in the 
media of MSCs. To understand this observation, however, it is important first to 
understand the release mechanism of galectin-3. As opposed to secreted proteins 
containing N-terminal signal sequence which targets them to ER (Kelly, 1985), 
galectins are known to lack N-terminal signal sequences, and thus they are 
example of an unconventional secretion (Muesch et al., 1990). A number of other 
proteins are known to exhibit unconventional secretion e.g. interleukin-1β 
(Rubartelli et al., 1990), fibroblast growth factor-2 (Mignatti and Rifkin, 1991; 
Schafer et al., 2004) and annexins (Christmas et al., 1991), however, the 
molecular mechanisms remain poorly understood. Galectin-3 has been found in 
culture supernatants entrapped within cytoplasmic vesicles, and hence it has been 
suggested that secretion occurs via membrane blebbing or ectocytosis (Mehul 
and Hughes, 1997; Stein and Luzio, 1991); it has also been found entrapped 
within exosomes secreted by dendritic cells (Thery et al., 2001). In both cases, 
galectin-3 was released inside vesicles and subsequently liberated after their 
lysis. Further, some reports show that galectin-1, another member of the lectin 
family, is secreted constitutively by Chinese hamster ovary (CHO)-K1 line (Cho 
and Cummings, 1995a; Cho and Cummings, 1995b). Conversely, there are cells 
where galectin-3 secretion is regulated to varying extents (Lindstedt et al., 1993; 
Sato and Hughes, 1994). Results from our study indicated that galectin-3 
secretion was not regulated in gastric myofibroblasts, and thus raising the 
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possibility to use galectin-3 as a secretion control for these cells in further 
research.   
In conclusion, the work in this chapter identified a number of proteins that are 
released in response to IGF and some that were not sensitive to IGF suggesting 
release by the constitutive pathway. Furthermore, this chapter presented 
similarities in the secretion profile of myofibroblasts and MSCs, along with some 
interesting differences.   
 
5.5 Conclusions 
1. A high proportion of proteins identified in the secretomes of both gastric 
myofibroblasts and MSCs exhibit increased abundance in response to IGF 
stimulation. 
2. Individual proteins can exhibit IGF-stimulated secretion in one cell type, but 
not in another.  
3. Protein markers for release by constitutive secretion were identified that can 
be used in future studies. 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
INVESTIGATION OF THE MOLECULAR 
MECHANISMS DETERMINING 
REGULATED SECRETION  
BY MYOFIBROBLASTS 
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6.1 Introduction 
Previous chapters reported that gastric myofibroblasts exhibited regulated 
secretion that tended to be absent in CAMs from patients with poor survival. 
However, the factors determining the presence or absence of regulated secretion 
in these cells are unknown.  
Studies of secretory incompetent clones of neuroendocrine PC12 cells showed 
that the capacity for regulated secretion was associated with a specific gene and 
protein expression profile (Grundschober et al., 2002). Thus, in order to 
understand why some myofibroblasts exhibited regulated secretion while others 
did not, an obvious starting point was to study the gene expression profiles of 
these cell lines. The expression profile was therefore scanned for genes 
specifically associated with the regulated exocytotic machinery, including ones 
involved in biogenesis of the secretory granules, also known as regulated 
secretory proteins. The latter are known to be markers of both regulated secretion 
and disease progression in neuroendocrine tumours (Ischia et al., 2000; O'Connor 
and Deftos, 1986).  
The results reported in this chapter utilised gene expression data from a previous 
microarray analysis performed within the group of all available lines of gastric 
myofibroblasts with the aim of identifying differences in expression profiles that 
would inform experimental studies of the underlying mechanisms. The 
experimental work in this chapter focuses on the characterisation of one specific 
protein, secretogranin II, which may play a role in determining the regulated 
secretory phenotype of gastric myofibroblasts.  
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6.1.1 Aims and Objectives 
The specific aims of this chapter were: 
1. To compare the transcriptomes of myofibroblasts exhibiting regulated 
secretion with those that do not, in order to identify differentially expressed 
genes. 
2. To characterise secretogranin II and its role in the stimulated secretion of 
selected proteins. 
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6.2 Materials and methods 
6.2.1 Experimental grouping 
For the purpose of this study, myofibroblasts exhibiting regulated secretion 
(termed “responders”) were compared with myofibroblasts without regulated 
secretion (termed “non-responders”). To increase accuracy of the analysis 
responders were defined on the basis of relative abundance of TGFβig-h3 in 
media in response to IGF of >1.5 compared with control, and non-responders as 
≤1.17, thereby avoiding edge effects for cells that were on the margins (Table 
6.2.1). 
 
6.2.2 Data analysis 
Using transcriptome data obtained by Dr Islay Steele (see section 2.4 Chapter 2) 
analysis of the data presented in this chapter was performed using Gene Spring 
GX v.10 (Agilent Technologies, USA). This included normalisation of gene 
expression data by the MAS5 algorithm, followed by checks for hybridisation 
and data quality, and identification of an “All Entities” list. Only transcripts 
flagged as “present” in all samples from one of the groups were used in the 
subsequent analysis. Given the experimental grouping, differentially expressed 
genes were identified using an unpaired t-test with no adjustment for multiple 
comparisons. A list of the genes regarded as significantly expressed (p<0.05) was 
refined by focussing on those with differential abundance of >2 in responders vs 
non-responders. Gene lists were uploaded into the Metacore™ database (Ekins et 
al., 2007) to generate corresponding protein lists. Differentially expressed  
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Responders Non-Responders 
Patient 
ID Cell Type  
Relative 
abundance 
IGF/Control 
Patient 
ID Cell Type 
Relative 
abundance 
IGF/Control 
 
Patient 3 
Patient 5 
Patient 7 
Patient 9 
Patient 9 
Patient 10 
Patient 13 
Patient 14 
Patient 15 
Patient 21 
Patient 21 
Patient 22  
Patient 31 
ATM  
CAM 
ATM  
CAM  
ATM  
ATM  
CAM  
CAM  
ATM  
NTM  
NTM  
NTM  
ATM 
4.00 
1.80 
5.50 
5.00 
1.80 
3.68 
3.00 
1.98 
1.89 
3.00 
2.33 
3.50 
3.25 
Patient 1 
Patient 2 
Patient 3 
Patient 7 
Patient 8 
Patient 8 
Patient 9 
Patient 10 
Patient 11 
Patient 11 
Patient 12 
Patient 12 
Patient 30 
CAM  
CAM  
CAM  
CAM  
CAM  
ATM  
ATM  
CAM  
CAM  
ATM  
CAM  
ATM  
ATM 
0.95 
0.85 
1.17 
0.98 
0.94 
1.06 
0.91 
1.17 
0.88 
0.92 
0.95 
0.91 
1.02 
Table 6.2.1 Myofibroblasts used for gene expression analysis. Gastric 
myofibroblasts were divided into two groups (n=13 each3 according to the 
presence or absence of regulated secretion (responders vs non-responders), 
regardless the sample origin (NTM, ATM or CAM). 
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proteins were annotated by cellular localisation using the Gene Ontology 
database (www.geneontology.org).  
 
6.2.3 Transfection  
Myofibroblasts were transfected with siRNA or plasmid DNA using 
Nucleofection™ (Gresch et al., 2004). Protein secretion was studied 96 h post-
transfection of myofibroblasts from Patient 14 (CAM, responder) and Patient 11 
(ATM, non-responder).  
 
6.2.4 Deconvolution analysis 
Immunofluorescence images were analysed using an algorithm-based 
deconvolution method in the AxioVision 4.5 software, which reduced optical 
distortion and achieved sharper images.  
 
6.2.5 Confocal microscopy 
Myofibroblasts were prepared for confocal imaging and images were taken as 
described in section 3.2.4 (Chapter 3).  
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6.3 Results 
6.3.1 Transcriptomic analysis of myofibroblasts with regulated secretion  
To identify the gene expression profiles of responder and non-responder 
myofibroblasts, microarray data that had already been generated in the group 
were re-analysed. The designation of responder and non-responder cells was 
made regardless of tissue origin i.e. normal, adjacent or tumour tissue (Table 
6.2.1).  
The analysis identified a total of 18,861 expressed oligonucleotides flagged as 
“present”. These oligonucleotides coded for 10,597 gene products, and 1,178 of 
them were significantly expressed by responders, i.e. passed the statistical test 
with p<0.05. Only 30 out of 1,178 differentially expressed genes were identified 
using a cut-off of 2-fold difference in abundance in the two datasets (Table 
6.3.1). Of these differentially expressed genes 19 were up-regulated and the 
remaining 11 were down-regulated. Differentially expressed genes were 
identified from Metacore™ as coding for proteins belonging to nine different 
functional classes: metalloprotease (1), generic kinase (1), generic binding 
protein (11), generic enzyme (3), generic protein (3), transcription factor (3), 
generic receptor (3), generic protease (2), RNA (1) and receptor ligand (2). 
However, 8 out of 30 differentially expressed transcripts encoded soluble 
secreted proteins (in bold, Table 6.3.1). Two of the 8 transcripts (mannan- 
binding lectin serine protease 1 and stanniocalcin-1) were decreased in the 
responder dataset, while the remaining six were increased: disintegrin and 
metalloprotease domain-containing protein 12 (ADAM-12), glia-derived nexin,   
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# Protein name Protein class Fold 
change P-value 
1 Disintegrin and metalloproteinase domain-containing protein 12 Metalloprotease 2.88 0.025 
2 Adenylate kinase isoenzyme 4, 
mitochondrial Generic kinase 2.28 0.003 
3 Cadherin-2 Generic binding protein 2.16 0.017 
4 Calponin-1 Generic binding protein 2.16 0.033 
5 Cystathionine gamma-lyase Generic enzyme 2.14 0.018 
6 DENN domain-containing protein 2A Generic protein -2.06 0.025 
7 ETS translocation variant 3 Transcription factor 2.41 0.002 
8 Protein FAM65C Generic protein -2.09 0.027 
9 FLJ35700 (gene symbol) Generic protein -3.16 0.034 
10 Polypeptide N-
acetylgalactosaminyltransferase 12 Generic enzyme 2.08 0.033 
11 Transcription factor GATA-6 Transcription factor 2.15 0.047 
12 Interleukin-17 receptor D Generic receptor 2.35 0.043 
13 Integrin beta-like protein 1 Generic receptor 2.38 0.033 
14 Mannan-binding lectin serine protease 1 Generic protease -2.64 0.015 
15 MEG3 (gene symbol) RNA 2.44 0.026 
16 Neuron navigator 3 Generic binding protein 2.16 0.006 
17 Protein naked cuticle homolog 2 Generic binding protein -2.35 0.015 
18 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Generic enzyme -2.28 0.011 
19 PDZ and LIM domain protein 3 Generic binding protein 2.83 0.013 
20 Trypsin-3 Generic protease 2.20 0.010 
21 Protein S100-A4 Generic binding protein -2.12 0.012 
22 Secretogranin-2 Receptor ligand 3.03 0.014 
23 Plasminogen activator inhibitor 1 Receptor ligand 2.24 0.005 
24 Glia-derived nexin Generic binding protein 2.25 0.001 
25 SH3-containing GRB2-like protein 3-interacting protein 1 Generic binding protein -2.11 0.009 
26 Stanniocalcin-1 Generic binding protein -2.95 0.036 
27 Transcription factor 21 Transcription factor -2.09 0.012 
28 Transmembrane 4 L6 family member 1 Generic receptor -2.53 0.037 
29 Tensin-1 Generic binding protein 2.02 0.016 
30 Versican core protein Generic binding protein 2.45 0.008 
Table 6.3.1 Differentially expressed genes in responder compared with non-
responder cells. Gene expression analysis indentified 30 differentially expressed 
genes defined as exhibiting a 2-fold difference in abundance in responders and non-
responders (unpaired t-test, p<0.05, no adjustment for multiple comparisons); these 
encoded proteins in nine different functional classes. There were eight soluble 
secretory proteins (in bold). 
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integrin beta-like protein 1, PAI-1, trypsin-3, versican and secretogranin II. The 
latter exhibited the greatest difference between the two datasets (3.03).  
 
6.3.2 Secretogranin II and its role in the regulated secretion of 
myofibroblasts 
Myofibroblasts express secretogranin II 
On the basis of the transcriptomic analysis, secretogranin II was selected for 
further study at the protein level using immunofluorescence and Western blot. 
Secretogranin II distribution in myofibroblasts exhibiting regulated secretion was 
predominantly punctuate consistent with vesicular localisation (Figure 6.3.2.1, 
A-D). Secretogranin II was present throughout the cell although in varying 
intensity in different cell lines. However, in non-responder myofibroblasts it was 
difficult to identify secretory vesicles (Figure 6.3.2.1, E-H). Consistently, 
Western blot analysis revealed that cellular secretogranin II abundance was 
higher in responder myofibroblasts than non-responders (unpaired t-test, p<0.05, 
n=6, n-number of cell lines in each group) (Figure 6.3.2.2). Additionally, 
responder myofibroblasts exhibited increased secretogranin II secretion after 
stimulation with IGF-II for 30 min (Figure 6.3.2.3) whereas non-responders did 
not (see below, Figure 6.3.2.9).  
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Figure 6.3.2.1 Responder myofibroblasts express secretogranin II. 
Immunocytochemical localisation with deconvolution analysis of secretogranin II 
(green) showed punctuate and vesicular staining (white arrows) throughout the 
cytosol in responder myofibroblasts (A-D) but not in non-responder myofibroblasts 
(E-H). 
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Figure 6.3.2.2 Increased 
expression of secretogranin II in 
responder myofibroblasts. A. 
Representative Western Blot 
analysis of cellular secretogranin II 
in two responder and two non-
responder myofibroblasts (top 
panel). GAPDH was used as a 
loading control (bottom panel). B. 
Cumulative densitometric analysis 
(n=6 in each group; reference 
samples were loaded on every gel 
for normalization) of cellular 
secretogranin II showed 
significantly higher relative protein 
abundance in the responders (paired 
t-test, p<0.05).  
 
 
Figure 6.3.2.3 Stimulated 
secretion of secretogranin II in 
responder myofibroblasts. 
Representative Western Blot 
analysis of media from a responder 
myofibroblast showed increased 
abundance of secretogranin II after 
IGF-II treatment (100 ng/ml)  for 
30 min.  
 
Consequences of inhibition of secretogranin II expression in responder 
myofibroblasts  
To study the role of secretogranin II in regulated secretion, secretory responses to 
IGF-II were examined after secretogranin II gene was knocked down using 
siRNA. Using a myofibroblast cell line (Patient 14, CAM) that consistently 
exhibited robust secretory responses to IGF-II, and a short doubling time, the 
most effective of three siRNA molecules (siRNA3) in down-regulating 
secretogranin II gene expression was identified. With this construct there was 
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approximately 72% reduction in secretogranin II cellular protein reduction 
(Figure 6.3.2.4).  
 
Figure 6.3.2.4 Decreased 
expression of secretogranin II in 
response to siRNA silencing. A. 
Western Blot analysis of 
secretogranin II after gene silencing 
with three different siRNAs (top 
panel). GAPDH was used as a 
loading control (bottom panel). B. 
Densitometric analysis of 
corresponding band intensities 
showed that secretogranin II 
expression was reduced by 72% 
with siRNA3, 26% with siRNA1 
and 12% with siRNA2. (n=2) 
 
 
Responses to IGF-II stimulation of myofibroblasts after secretogranin II knock 
down were then studied by monitoring release of three representative proteins. 
Secretogranin II itself, TGFβig-h3 and galectin-3 were selected for this purpose: 
TGFβig-h3 because it had previously been shown to exhibit regulated secretion, 
galectin-3 because it had previously been shown not to exhibit regulated 
secretion and secretogranin II to indicate the efficacy of knockdown. After 
secretogranin II silencing there was inhibition of the stimulated secretion of 
secretogranin II (Figure 6.3.2.5), and secretion of TGFβig-h3 was completely 
blocked (Figure 6.3.2.6). There was no change, however, in galectin-3 secretion 
(Figure 6.3.2.7). 
 
A 
B 
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Figure 6.3.2.5 Decreased 
stimulated release of 
secretogranin II from 
myofibroblasts treated with 
siRNA3. A. Representative 
Western Blot analysis of 
secretogranin II in the media from 
responder myofibroblasts. There 
was a decrease in the secretory 
response to IGF-II after gene 
silencing. B. Densitometric analysis 
of the Western blot showed that 
IGF-stimulated secretion of 
secretogranin II was inhibited in 
siRNA3-treated cells. (n=2)  
 
 
Figure 6.3.2.6 Inhibition of 
stimulated release of TGFβig-h3 
from myofibroblasts treated with 
siRNA3. A. Representative 
Western Blot analysis of TGFβig-
h3 in the media from responder 
myofibroblasts. There was 
inhibition of the secretion response 
to IGF-II after gene silencing. B. 
Densitometric analysis of the 
Western blot showed that IGF-
stimulated secretion of TGFβig-h3 
was inhibited in siRNA3-treated 
cells. (n=2)  
 
 
Figure 6.3.2.7 No change of 
galectin-3 release from 
myofibroblasts treated with 
siRNA3.A. Representative Western 
Blot analysis of galectin-3 in the 
media from responder 
myofibroblasts. There was no 
change in the secretion response to 
IGF-II after gene silencing.  B. 
Densitometric analysis of the 
Western blot showed no change in 
the secretion of galectin-3. (n=2) 
 
A 
B 
A 
A 
B 
B 
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Consequences of overexpression of secretogranin II gene in non-responder 
myofibroblasts  
To further explore the role of secretogranin II in the regulated secretion of gastric 
myofibroblasts, secretogranin II was then overexpressed in non-responder 
myofibroblasts. Many non-responder lines exhibited low levels of secretogranin 
II expression and for this experiment the line with the lowest protein expression 
according to Western blot analysis was chosen (Patient 11, ATM).  
Using Western blot, cellular secretogranin II abundance after transfection with a 
secretogranin II expressing plasmid, was about 1.8 times greater than control 
untransfected cells (Figure 6.3.2.8). The secretory response to IGF-II after 
overexpressing secretogranin II was assessed using Western blot of secretogranin 
II itself, TGFβig-h3 and galectin-3 (see above). There was a substantial increase 
in secretogranin II stimulated secretion (Figure 6.3.2.9), and a modest increase in 
TGFβig-h3 stimulated secretion (Figure 6.3.2.10) in the transfected cells. 
However, there was no change in the galectin-3 secretion after secretogranin II 
overexpression (Figure 6.3.2.11).   
 
6.3.3 Co-localisation studies of selected secreted proteins in myofibroblasts 
exhibiting regulated secretion 
Finally, the sub-cellular localisation of proteins exhibiting regulated and non-
regulated secretion was examined by confocal microscopy. Secretogranin II and 
galectin-3 were found to be co-expressed in the ER and Golgi region, while they 
were expressed in different secretory vesicles in the cytosol (Figure 6.3.3).  
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Figure 6.3.2.8 Increased cellular 
protein abundance after 
overexpression of secretogranin 
II gene. A. Western Blot analysis 
of cellular secretogranin II in 
control and transfected 
myofibroblasts (top panel). 
GAPDH was used as a loading 
control (bottom panel). B. 
Densitometric analysis of 
corresponding band intensities 
showed increased secretogranin II 
protein expression after 
secretogranin II overexpression  
(n=2).  
 
 
Figure 6.3.2.9 Stimulated release 
of secretogranin II in non-
responder myofibroblasts after 
secretogranin II overexpression. 
A. Representative Western Blot 
analysis of secretogranin II in the 
media from myofibroblasts without 
RS. There was an increase in the 
secretion response to IGF-II after 
secretogranin II overexpression. B. 
Densitometric analysis of the 
Western blot showed the presence 
of IGF-II stimulated secretion after 
secretogranin II overexpression 
(n=2). 
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Figure 6.3.2.10 Stimulated release 
of TGFβig-h3 in non-responder 
myofibroblasts after 
secretogranin II overexpression. 
A. Representative Western Blot 
analysis of TGFβig-h3 in the media 
from myofibroblasts without RS. 
There was an increased secretion 
response to IGF-II after 
secretogranin II overexpression. B. 
Densitometric analysis of the 
Western blot showed the presence 
of IGF-II stimulated secretion of 
TGFβig-h3 after secretogranin II 
overexpression. (n=2) 
 
 
 
Figure 6.3.2.11 No change of 
galectin-3 release from non-
responder myofibroblasts 
transfected with secretogranin II. 
A. Representative Western Blot 
analysis for galectin-3 in the media 
from myofibroblasts without RS. 
There was no change in the 
secretion response to IGF-II after 
secretogranin II overexpression. B. 
Densitometric analysis of the 
Western blot showed no change in 
the secretion of galectin-3 after 
IGF-II stimulation. (n=2)  
 
 
A 
B 
B 
A 
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Figure 6.3.3 Secretogranin II and galectin-3 localise to different secretory 
vesicles in myofibroblasts with regulated secretion. Confocal microscopy of 
secretogranin II (green, green arrow) and galectin-3 (red, red arrow) in 
myofibroblasts with regulated secretion. Galectin-3 (A, D) and secretogranin II (B, 
E) co-localise in ER and Golgi (white arrow), but they belong to different types of 
secretory vesicle (C, F).  
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6.4 Discussion 
The work in this chapter focuses on differences in the transcriptomes of 
responder and non-responder myofibroblasts and identifies the regulated 
secretory protein secretogranin II as a differentially expressed secretory protein. 
The results suggest that expression of secretogranin II plays a role in determining 
the regulated secretory phenotype and that there are distinct vesicular 
compartments for this protein and for galectin-3, which does not exhibit 
regulated exocytosis. 
Based on the results presented in Chapter 4, it was not unexpected to identify 
differences in the gene expression profiles of responder and non-responder 
myofibroblasts. Given the functional difference between the two groups it was 
anticipated that differential genes might encode proteins related to the regulated 
exocytotic machinery including t-SNAREs and v-SNAREs, chromogranins and 
secretory peptides. Surprisingly, of 30 differentially expressed genes only one 
was directly associated with the regulated exocytotic phenotype – secretogranin 
II. Thus, secretogranin II is a member of the granin family (as called 
chromogranin C) and has been previously proposed as a marker for the 
neuroendocrine secretory phenotype (Ozawa and Takata, 1995; Rosa et al., 
1985).  
In PC12 cells there is a considerable body of research on the differences between 
secretory competent and secretory incompetent clones. The results indicate that 
regulated exocytosis is a complex program that includes regulation at multiple 
levels: transcriptional (Grundschober et al., 2002), post-transcriptional (Bruce et 
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al., 2006; Knoch et al., 2004), translational (Courel et al., 2010) and protein 
turnover or degradation (Kim and Loh, 2006; Kim et al., 2003).  
Chromogranins (granins) are acidic soluble proteins that were initially identified 
to be co-secreted with catecholamines (Banks and Helle, 1965). It is now known 
that chromogranins are implicated in the biogenesis of secretory granules and in 
sorting them at the trans-Golgi network. Two mechanisms have been 
investigated: “sorting-for-entry” (based on specific primary structure of the 
granin molecules) and “sorting-by-retention” (based on protein aggregation 
under certain conditions). During the latter, in the lumen of the trans-Golgi high 
concentrations of calcium and low pH promote the aggregation of granins 
(chromogranin A, chromogranin B and secretogranin II) to generate the electron 
dense core of secretory vesicles (Chanat and Huttner, 1991). During aggregation 
granins may serve as chaperones for recruitment of other regulated secretory 
proteins (Gerdes et al., 1989; Gorr et al., 1989). “Sorting-for-entry” hypothesis is 
based on the amino acid sequence of the granin molecules. A N-terminal 
hydrophobic disulfide-bonded loop in the primary structure of chromogranin B 
was identified to serve as a sufficient sorting motif to direct this granin into the 
dense core vesicles (Chanat et al., 1993). An additional amphipathic α-helix was 
needed for chromogranin A to direct it to the regulated pathway (Taupenot et al., 
2002). The primary structure of secretogranin II, however, lacks the N-terminal 
hydrophobic disulfide-bonded loop (Taupenot et al., 2003). It was reported that 
sorting information of secretogranin II to the regulated pathway was contained 
within both N- and C-terminals of the molecule, and involved specific α-helix-
containing amino acid sequences (Courel et al., 2008).  
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Down-regulation of the chromogranin A and chromogranin B was associated 
with the loss of secretory granules in PC12 cells, whereas their overexpression, 
including in non-secretory cells, has triggered granule biogenesis (Huh et al., 
2003; Kim et al., 2001). Mice with deletion of either the chromogranin A or 
chromogranin B genes nevertheless still exhibit regulated exocytosis, due to 
activation of compensatory mechanisms (Borges et al., 2010). In a secretory-
deficient pheochromocytoma PC12 cells that are unable to store and release 
catecholamines via regulated secretion, expression of secretogranin II was 
sufficient to rescue the secretory phenotype (Courel et al., 2010). This was 
consistent with the data from the present study showing that expression of 
secretogranin II in responder myofibroblasts correlates with a distinct secretory 
response to IGF-II, which, however, was depressed after silencing of 
secretogranin II expression. Interestingly, the non-responder phenotype was 
associated with a low level of secretogranin II expression, which was not 
sufficient to generate a secretory response to IGF-II.   
Initially, Kim et al. suggested that chromogranin A controls the stability of dense 
core granules by regulating degradation of granule proteins (Kim et al., 2003). 
Further they showed that overexpression of protease nexin-1 stabilised dense 
core granule proteins in the Golgi apparatus and thus promoted granulogenic 
properties and stimulated the regulated secretory phenotype (Kim and Loh, 
2006). Based on these observations, they proposed a mechanism by which 
chromogranin A up-regulated protease nexin-1 expression, which further 
supported the granulogenic properties of chromogranin A and inhibited the 
proteolytic degradation of granule proteins in Golgi. It is important to note that 
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our analysis also identified protease nexin amongst the nine differentially 
expressed genes alongside secretogranin II (and in previous chapters regulated 
release of protease nexin was demonstrated), so that a similar stabilising effect 
might exist between protease nexin and secretogranin II in myofibroblasts.  
Notwithstanding the evidence discussed above, there is nevertheless a view that 
chromogranin A and chromogranin B are simply cargo proteins, and thus their 
overexpression may not be sufficient to reinstall the regulated secretion (Day and 
Gorr, 2003; Malosio et al., 2004). Malosio et al. demonstrated that the newly 
formed organelles held features of lysosomes, but not secretory vesicles, thus 
raising the need to study the exact nature of the secretory vesicles of gastric 
myofibroblasts. 
Based on the data from Chapter 5 galectin-3 was successfully employed as a 
control protein, i.e. protein secreted by non-regulated secretion. In this sense, it 
was not unexpected to see that secretogranin II and galectin-3 did not co-localise 
to the same vesicles.  
Interestingly, the secretogranin II gene was expressed by all gastric 
myofibroblasts regardless of the capacity for regulated secretion, but it was 
considerably higher in responders, thereby implying transcriptional down-
regulation in non-responder myofibroblasts. Recent studies identified 
transcriptional repressor RE-1–silencing transcription factor (REST)/neuron-
restrictive silencer factor (NRSF) as suppressing the regulated secretory 
phenotype in astrocytes (Bruce et al., 2006; Prada et al., 2011), but it was not 
identified as present in our microarray data, suggesting that other transcriptional 
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factors may regulate secretogranin II in myofibroblasts, and hence may influence 
the secretory phenotype. 
The results of the current chapter indicate that a defect in secretrogranin II 
expression, occurring at transcriptional, translational and/or post-translational 
level influences the regulated secretory phenotype. Together with the evidence 
presented in the previous chapters, the data suggest that the non-responder 
phenotype might be a result of multiple defects in the regulated exocytotic 
machinery of these cells, and specifically due to defective secretogranin II 
expression as well as impaired intracellular calcium signalling. The present data 
suggest that secretogranin II expression in gastric myofibroblasts might provide a 
marker for the responder phenotype and its loss an indicator of cancer 
progression similar to that in some malignant neuroendocrine tumours (Schmid 
et al., 1994).  
 
6.5 Conclusions 
1. Differentially expressed genes in responder myofibroblasts included at least 
one encoding a protein involved in regulated exocytotic machinery - 
secretogranin II. 
2. Loss of secretogranin II expression was associated with impaired regulated 
secretion of an independent protein, TGFβig-h3, and overexpression – with 
restored secretion.   
3. Lack of regulated secretion capacity in myofibroblasts appears to be 
determined by defects in multiple levels. 
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7.1 Overview  
The main findings of this thesis are (a) that gastric myofibroblasts exhibit 
calcium-dependent secretion in response to stimulation by IGF; (b) the capacity 
for regulated secretion depends on the tissue microenvironment, since normal 
gastric myofibroblasts exhibited regulated secretion while those from the 
oesophagus did not; (c) some gastric CAMs, particularly from patients with poor 
survival, lack regulated secretion; (d) the secretory response to IGF includes the 
release of many different types of protein including ECM proteins, ligands, 
binding proteins, carbohydrate-binding proteins, proteases and protease 
inhibitors; (e) the capacity for regulated secretion of gastric myofibroblasts is 
associated with the expression of secretogranin II, which in turn may provide a 
useful biomarker for the regulated secretory phenotype of myofibroblasts.  
 
7.1.1 Myofibroblasts exhibit regulated secretion  
A growing body of literature indicates that in addition to neuronal, endocrine and 
exocrine cells a wide variety of other cell types exhibit regulated secretion; 
examples include 3T3-L1 adipocytes (Lorente-Cebrian et al., 2010) and Chinese 
hamster ovary cells (Chavez et al., 1996; Coorssen et al., 1996) in which 
secretion occurs from Golgi-derived vesicles, but in addition pancreatic stellate 
cells (which resemble myofibroblasts) (Phillips et al., 2010) and hippocampal 
astrocytes (Bezzi et al., 2004; Kreft et al., 2004; Zhang et al., 2004) exhibit 
regulated secretion by small, clear synaptic-like vesicles (Table 7.1.1). In all 
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cases, the cells respond to a range of stimuli with increase in intracellular 
calcium triggering release of small neurotransmitters or proteins. 
The evidence is based on the use of a wide range of methods, including ELISA, 
subcellular fractionation, liquid chromatography with mass spectrometry and 
calcium signalling measurements (Table 7.1.1). Thus, secretion by 3T3-L1 
adipocytes of the neuropeptide apelin was demonstrated before and after 
treatment with actinomycin D and cycloheximide using ELISA. Alternatively, 
Philips et al. used liquid chromatography with mass spectrometric analysis to 
study secreted acetylcholine (Phillips et al., 2010), and Chavez et al. used 
subcellular fractionation of different secretory vesicles to separate the vesicles of 
the regulated and constitutive pathways (Chavez et al., 1996). Electron 
microscopy studies of pancreatic stellate cells (Phillips et al., 2010) and 
immunogold labelling in hippocampal astrocytes (Bezzi et al., 2004) revealed 
secretory vesicles resembling synaptic-like vesicles. Some of the techniques used 
in these studies were employed in the present project, and the application of 
others (e.g. sub-cellular fractionation, EM immunogold labelling, pulse-chase 
labelling: see below) to the study of regulated secretion of myofibroblasts is now 
required.   
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Cell type Marker of 
secretion 
Type 
of 
vesicles 
Stimulus Methods Reference 
3T3-L1 
adipocytes 
Neuropeptide 
apelin 
Golgi-
derived 
Eicosapentaenoic 
acid 
ELISA, actinomycin 
D and cycloheximide  
(Lorente-
Cebrian et 
al., 2010) 
CHO cells [35S]SO4-
labeled 
glycosaminogly
can chains 
Golgi-
derived 
Ionophore 
A23187 and 
phorbol esters 
N-ethylmaleiimide, 
subcellular 
fractionation, WB, 
indirect 
immunofluorescence 
(Chavez et 
al., 1996) 
CHO cells, 
3T3 
fibroblasts 
Membrane 
capacitance 
Golgi-
derived 
Different 
concentrations of 
calcium 
Calcium signalling  (Coorssen et 
al., 1996) 
Pancreatic 
stellate cells 
Neurotransmitte
r acetylcholine  
Clear 
synaptic
-like 
vesicles 
Cholecystokinin  LC-MS/MS, EM (Phillips et 
al., 2010) 
Hippocampal 
astrocytes 
Gliotransmitter 
glutamate 
Clear 
synaptic
-like 
vesicles 
Different stimuli Total internal 
reflection 
fluorescence imaging 
(TIRF)c, immunogold 
labelling 
(Bezzi et al., 
2004) 
Table 7.1.1 Methods used in studies of regulated secretion. Examples of non-
specialised for regulated secretion cells and of approaches utilised to study their  
regulated secretion.  
 
7.1.2 Characteristics of regulated secretion by gastric myofibroblasts 
7.1.2.1 Role of the tissue microenvironment  
Myofibroblasts from different tissues are phenotypically diverse. Initially, 
myofibroblasts were described as a sub-type of fibroblasts expressing smooth 
muscle-like features (Gabbiani et al., 1971), localised either close to epithelial 
cells as in the intestine (Pascal et al., 1968) or further away as in the stomach 
(Wu et al., 1999). The first studies of gastric myofibroblasts derived from the 
lamina propria established that these retained the phenotype seen in vivo with 
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respect to the expression of the cytoskeletal markers α-SMA and vimentin (but 
negative for desmin) and functional enzymes such as cyclooxygenase(COX)-1 
and -2 (Wu et al., 1999). In addition, studies on cultured colonic myofibroblasts 
demonstrated expression of collagen type IV, laminin-β1 and γ1, and fibronectin 
resembling that in vivo (Mahida et al., 1997). The present project was based on 
cells obtained by the method used by Wu et al. (1999) coupled with 
immunocytochemical characterisation. These cells are thought to be identical to, 
or at least closely resemble, those studied by others (Mahida et al., 1997; Wu et 
al., 1999).   
The heterogeneity of myofibroblasts has been associated with their role in tissue 
organisation (Powell et al., 1999). For example, myofibroblasts from small and 
large intestine form tight pericryptal sheath below the epithelial cells (Mutoh et 
al., 2005), gastric myofibroblasts are scattered throughout all levels of gastric 
mucosa (Wu et al., 1999), while there are no myofibroblasts in the normal heart 
tissue (Baum and Duffy, 2011). Moreover, stromal CAMs are shown to acquire 
genetic mutations including loss of heterozygosity (Hill et al., 2005; Patocs et al., 
2007) and epigenetic changes like global DNA hypomethylation and focal gain 
of DNA methylation (Jiang et al., 2008). These observations suggest that the 
phenotype of gastric myofibroblasts, including secretory phenotype, might be 
influenced by factors from tissue microenvironment such as type and function of 
the organ, physiological and pathophysiological status. The present study is the 
first to identify differences in the secretory phenotype of myofibroblasts from the 
upper gut, as well as between cancer and normal tissue, but the factors 
determining this need to be further studied.  
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7.1.2.2 Expression of dense core secretory vesicles  
The regulated secretory phenotype of myofibroblasts is associated with the 
expression of dense core secretory vesicles with diameter about 100nm and 
located close to the Golgi apparatus (Table 7.1.2). Two previous studies using 
TEM show abundant rough endoplasmic reticulum, stress fibres (longitudinal 
bundles of actin microfilaments), Golgi apparatus and mitochondria, but give no 
information on dense core secretory vesicles (Mahida et al., 1997; Valentich et 
al., 1997). Dense core vesicles are not mentioned by these authors, but 
interestingly some dense core vesicle-like structures can be seen in the cytosol of 
the colonic myofibroblasts in the photomicrographs, and it would be interesting 
to study the secretory phenotype of these cells (Mahida et al., 1997).   
 
7.1.2.3 Regulated release of ECM proteins  
Regulated secretion by myofibroblasts was not found to be associated with 
specific classes of proteins, but there were many examples of regulated secretion 
of proteins associated with ECM assembly, organisation and maintenance. This 
presumably reflects the role of myofibroblasts as a major cell type responsible 
for ECM remodelling after tissue damage and in cancer (Desmouliere et al., 
2004). However, the high proportion of all identified secretory proteins released  
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Type of 
vesicle 
Cell 
types 
Origin Morpholo
gy 
Diamet
er 
Content Examples of markers 
(Reference) 
Constituti
ve 
vesicles 
All cells Golgi-
derived 
Small and 
clear 
~100nm Plasma 
membrane 
proteins, 
proteoglyc
ans 
Glycosaminoglycan 
(Burgess and Kelly, 1984), 
plasma membrane proteins 
(Holcomb et al., 1988) 
Synaptic 
vesicles 
Neurons, 
neuroendo
crine cells 
Non-
Golgi-
derived 
Small and 
clear 
~40nm Neuro-
transmitte
rs 
Vesicular transporters 
(Sudhof, 2004), 
ATP-dependent proton 
pump (Stadler and Tsukita, 
1984) 
 
Zymogen 
granules 
Exocrine 
cells e.g. 
pancreatic 
acinar 
cells 
Golgi-
derived 
Varying 
electron 
density 
≥1µm Inactive 
forms of 
digestive 
enzymes, 
water, 
ions 
Pancreatic membrane 
protein GP2 (Hoops et al., 
1993) 
Dense 
core 
secretory 
vesicles 
Neuroend
ocrine 
cells, 
endocrine 
cells 
Golgi-
derived 
Electron-
dense core 
~100nm Neuropept
ides, 
hormones 
Granins (Huttner et al., 
1991), 
prohormone convertases 
PC2 and PC1/3 (Steiner, 
1998)   
 
Myofibro
blast 
secretory 
vesicles 
Gastric 
myofibrob
lasts, bone 
marrow-
derived 
MSCs 
Golgi-
derived 
Electron-
dense core 
~200nm ECM 
proteins 
Secretogranin II 
Table 7.1.2 Types of exocytotic vesicles in classical pathway of secretion. 
Table of main features of different types of secretory vesicles in the classical 
pathway of secretion, and comparison with the secretory vesicles of gastric 
myofibroblast. 
 
via regulated pathway is a new observation indicating a higher level of 
complexity for the role of myofibroblasts in tissue organisation compared to that 
previously described by Powell et al. (Powell et al., 1999). For example, 
regulated secretion of gastric myofibroblasts at the sites of tissue injury, infection 
or cancer in response to autocrine and/or paracrine soluble factors would mean 
rapid release of substances re-shaping the microenvironment to support or 
suppress host defence systems.  
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Regulated secretion by myofibroblasts involves a rise in intracellular calcium. 
Previously, increased cytosolic calcium was observed in cultured rat lamina 
propria fibroblasts following stimulation with endothelins, substance P, 
angiotensin II, ATP, bradykinin and 5-hydroxytryptamine, and was associated 
with the contractile properties of these cells (Furuya et al., 1994). In the earlier 
literature distinction between fibroblasts and myofibroblasts was sometimes 
obscure. Therefore, it is important to mention that Furuya et al. used the term 
fibroblast, but actually referred to the myofibroblast, as per nowadays definition. 
In the present project, IGF-II stimulation was used since (a) it has previously 
been shown to increase intracellular calcium in gastric myofibroblasts (McCaig, 
Burdyga & Varro, unpublished observations), (b) has previously been shown to 
be produced by these cells, and (c) is known to stimulate myofibroblast 
proliferation and migration (Hemers et al., 2005). Taken together the two studies 
raise the question of whether, as seems likely, there are many other potential 
physiological secretagogues for gastric myofibroblasts; a systematic study of this 
question is now needed.  
 
7.1.2.4 Expression of secretogranin II  
Chromogranin A and B, and secretogranin II, are prominent members of the 
granin family that are present in large dense core secretory granules in many 
neuroendocrine and endocrine cell types (Wiedenmann and Huttner, 1989). 
Several functions have been attributed to the granins, including in the biogenesis 
of dense core granules, as they aggregate at low pH and millimolar calcium 
concentrations in TGN, and thereby contribute to the formation of the electron 
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dense core (Courel et al., 2010; Helle et al., 1985). Also, granins are shown to act 
as chaperones via binding other soluble molecules e.g. catecholamines and thus 
improving the packaging of the latter inside the dense core granules (Helle et al., 
1985). Recent report, however, showed that chromogranin B unlike 
chromogranin A can bind the inositol 1,4,5-triphosphate receptor at the neutral 
pH of the ER lumen (Yoo and Lewis, 2000). Schmidt et al. further identify a C-
terminal domain within the molecule of chromogranin B that is crucial for the 
induction of calcium release from ER stores and thus capable of modulating 
intracellular calcium signals from within the ER lumen (Schmidt et al., 2011). 
This thesis showed that the regulated phenotype of gastric myofibroblasts is 
associated (a) with expression of secretogranin II, that (b) knockdown of 
secretogranin II inhibited regulated secretion, while (c) over-expression induced 
the capacity for regulated secretion in cells that otherwise lacked this phenotype. 
Based on previous work with this family of proteins, it now seems possible that 
secretrogranin II might determine the regulated secretory phenotype either by 
contributing to the formation of dense cored secretory vesicles, or by influencing 
intracellular calcium concentrations, or both. Further experimental work in this 
area should address these issues. Regardless of the outcome, the present data 
raise the possibility that in vivo identification of secretogranin II could be used as 
a marker for the regulated secretion phenotype that might be used, for example, 
in assessing cancer progression.  
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7.2 Methodology 
Primary cell cultures, such as used in this study, have been very widely 
employed for studies of secretory mechanisms. Even so, there are limitations in 
interpreting the physiological relevance of the findings. For example, in 
introducing them to culture, the cells are taken out of their normal physiological 
environment and in the process of adapting to a new environment they may 
undergo changes in gene expression that influence the results of subsequent 
experimental studies. To extrapolate these findings to physiological conditions an 
in vivo model system needs to be employed. One possibility would be to use 
targeted expression in transgenic animals of secretogranin II to cells that do not 
normally express it (e.g. oesophageal myofibroblasts), or alternatively to 
selectively delete secretogranin II. The effects on secretion in isolated 
myofibroblasts could subsequently be studied together with examination of in 
vivo phenotypes and with studies of in vivo secretion mechanisms (in the case of 
secretogranin II expressing animals). A conditional knockout of secretogranin II 
has been already described in the literature and used to study the biological role 
of the secretogranin II product secretoneurin (Leierer, 2008). Knockout mice for 
chromogranin A or B are described as viable, although they exhibit 
compensatory expression of the opposite granin (Borges et al., 2010). These 
strains retained the capacity for granule biogenesis and secretion, but with 
impaired accumulation of vesicular catecholamine content. Another report 
described upregulated expression of a few secretogranins, including 
secretogranin II, and chromogranin B in a chromogranin A null mice (Hendy et 
al., 2006). Although much is still unknown about the biology of secretogranin II, 
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these studies demonstrate a close relation between expressions of different 
granins. 
Cells exhibit both constitutive and regulated secretion because secretory vesicles 
of the two pathways exhibit different fusion machinery proteins, as well as 
different mechanisms of biogenesis. Tooze et al. showed distinct classes of 
vesicles using pulse-chase labelling with [35S]sulphate of marker molecules of 
each pathway (Tooze et al., 1991). Subsequently, some samples of supernatant 
were immunoprecipitated for quantification of radiolabelled proteins, while other 
samples were subjected to velocity and equilibrium gradient centrifugation to 
characterise the fractions of secretory granules according to their density and 
size. In another study, formation, docking and fusion of the constitutive vesicles 
and immature vesicles of the regulated pathway were studied also using sulphate 
labelling, but in permeabilised, semi-intact cells (Grimes and Kelly, 1992). 
Besides studies that segregate proteins released via the constitutive and regulated 
pathways, multiple studies have employed in vitro and in vivo imaging 
approaches to visualise secretory vesicles and their fusion kinetics. The imaging 
techniques used in this project included fluorescence microscopy, confocal 
microscopy and TEM. However, these are limited insofar as they provide only a 
single time point snap-shot of localisation and have not localised proteins to 
specific vesicle types. There is now a need to perform immunogold labelling of 
two or three proteins using different sizes of gold particle to establish the 
localisation to vesicular structures of these proteins. As an example of this 
approach, Bezzi et al. used double-labelling with immunogold to co-localise 
glutamate transporters VGLUT1 and VGLUT2 to vesicles containing the v-
                                                                                                                      Chapter 7 - Discussion  
179 
 
SNARE cellubrevin, but not VAMP2 (Bezzi et al., 2004). They also employed a 
live cell imaging technique, total internal reflection fluorescence microscopy 
(TIRF), to determine whether VGLUT-positive vesicles underwent regulated 
exocytosis and to determine their kinetics in response to different stimuli. This 
was possible, because vesicles lying just below the plasma membrane (Tsuboi et 
al., 2000) were double-labelled with fluorescent markers that allowed 
observations of their movement before and after the fusion event (Steyer and 
Almers, 2001).  
Finally, although there have been some direct studies of calcium signalling in 
gastric myofibroblasts more needs to be done to link this to regulated secretion. 
Both IGF-I and IGF-II are known to trigger calcium influx in primed competent 
cells and this is associated with their mitogenic effects (Kojima et al., 1988; 
Nishimoto et al., 1987); however a similar transduction pathway may well be 
activated when IGFs act as secretagogues for myofibroblasts. These two studies 
followed the same experimental pattern with the main difference being the type 
of IGF investigated. They determined cytoplasmic calcium concentration and 
measured calcium influx rate at rest and after stimulation using radioactive 
calcium 45Ca, and further identified the relevant plasma membrane calcium 
channels. With regard to the relation of secretogranin II and calcium increase, it 
would be interesting to see if secretogranin II could modify calcium levels in the 
ER lumen similarly to chromogranin B (Schmidt et al., 2011). This group studied 
calcium peaks in different transfected cell lines as a function of chromogranin B 
expression using calcium chemical indicators (fura-2 or fluo-4). Calcium 
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signalling experiments like these would be informative and could be performed 
in the cells used in this project. 
 
7.3 Future perspectives 
This project identified that some gastric CAMs tend not to exhibit regulated 
secretion. Therefore, it is important to consider whether these gastric CAMs have 
never exhibited regulated secretion, like their oesophageal counterparts, or 
whether this capacity is lost, and even more what could be the significance in 
cancer. It is now known that CAMs differ from normal myofibroblasts (for more 
details see section 7.1.2.1). Since gastric CAMs without regulated secretion 
exhibited transcriptional downregulation of the secretogranin II gene it is 
tempting to speculate that this is a consequence of epigenetic changes. However, 
other mechanisms are possible. In the recent years, short RNA molecules or 
microRNAs are gaining increasing attention, as they act as post-transcriptional 
regulators leading to gene silencing (Lee et al., 1993), however, there is no 
evidence yet of microRNAs regulating expression of any granin.  
Also, it would be useful to study the influence of the secretory phenotype of 
myofibroblasts on cancer cell function for example using a co-culture system, 
and furthermore to translate this knowledge into an in vivo model system such as 
a xenograft model. For example, only cancer-associated myofibroblasts co-
injected with breast carcinoma cell line into immunodeficient mice were 
promoting tumour growth but not the normal myofibroblasts (Orimo et al., 
2005).  
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Additionally, the link between patients survival and regulated secretion of gastric 
CAMs suggests the latter could be used as a marker in determining cancer 
progression. Secretogranin II immunofluorescence studies would be useful in this 
context, although their validation for clinical use would need to be established. 
Since secretogranin II may be cleaved to any of a variety of different peptide 
fragments it may well be that there is cleavage pattern which is specific to 
myofibroblasts, in which case specific antibodies for particular peptide products 
could be especially useful. Taking into consideration that generated protein 
products are biologically active (Anouar et al., 1998; Fischer-Colbrie et al., 1995; 
Yajima et al., 2004), it would be interesting to explore their effects on 
myofibroblasts or on cancer cells.  
To conclude, regulated secretion by gastric myofibroblasts is a newly identified 
property of these cells, the molecular basis of which needs to be further explored. 
There is preliminary data that it may impact myofibroblast cell function in 
promoting tumour progression and that it may provide novel markers for cancer 
progression. The prognosis of gastric cancer remains poor in spite of research 
over many years. Focusing on the novel phenotypes of stromal cells in this 
tumour may yield new insights leading to benefits for patients with this 
condition. 
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Protein name UniProt ID Localisation 
Myofibroblast 
(Patient 14) 
IGF-II/Cont 
MSC 
(Patient 37) 
IGF-II/Cont 
200 kDa protein;Laminin 
subunit beta-1;95 kDa protein 
P07942;Q8TAS6 Secreted 1.79 NI 
28 kDa heat- and acid-stable 
phosphoprotein;Putative 
uncharacterized protein PDAP1 
Q13442;C9J8N2 Secreted 1.24 NI 
45 kDa calcium-binding 
protein;stromal cell derived 
factor 4 isoform 1 
precursor;Isoform 3 of 45 kDa 
calcium-binding 
protein;Stromal cell derived 
factor 4 
Q9BRK5-
1;Q9BRK5;Q9BRK5-
4;B1AME6;Q9BRK5-
3;B1AME7 
Secreted 0.93 2.40 
5'-nucleotidase;cDNA 
FLJ90527 fis, clone 
NT2RP4001467, highly similar 
to 5'-nucleotidase;5'-
nucleotidase, ecto (CD73), 
isoform CRA_c;5'-nucleotidase, 
ecto 
P21589;B2RBH2;B3KQK1;Q5
3Z63;Q6NZX3;B3KQI8;Q5JR
Q2;Q96B60;Q5JRQ1 
Membrane 1.28 NI 
72 kDa type IV 
collagenase;matrix 
metalloproteinase 2 isoform b 
P08253;B4DWH3;Q2EF79 Secreted 1.70 2.07 
ADM P35318 Secreted 2.96 NI 
Aminopeptidase N P15144;B4DP01;B4DP96;B4D
PH5;B4DV63;Q59E93;Q71E4
6;Q8IVL7 
Membrane NI 1.73 
Annexin A1;cDNA FLJ51887, 
highly similar to Annexin A1 
P04083;B5BU38;Q05BR2;Q5T
ZZ9;B4DL19 
Secreted 1.27 2.05 
Annexin A2;Isoform 1 of 
Annexin A2;24 kDa 
protein;Putative annexin A2-
like protein;cDNA FLJ59138, 
highly similar to Annexin A2 
P07355-2;P07355;P07355-
1;A6NMY6;B4DNH8 
Secreted 1.33 1.81 
Annexin A5;Putative 
uncharacterized protein 
ANXA5 (Fragment) 
P08758;B4DNG6;Q6FHB3;A8
MTE3 
Secreted 1.70 1.72 
annexin IV;Annexin A4 Q6LES2;P09525;B4DDF9;B4
DDZ4;B4DE02;B4E1S2;Q59F
K3;Q6MZI0;Q6P452 
Secreted? 1.07 1.62 
Apolipoprotein B-100 P04114;A8K479;C0JYY2;P78
482;Q13789;Q13828;Q4ZG63;
Q53QC8;Q59HB3;Q9UE51;Q9
UE52;Q9UE53 
Secreted 9.37 5.70 
Basement membrane-specific 
heparan sulfate proteoglycan 
core protein;Basement 
membrane-specific heparan 
sulfate proteoglycan core 
protein variant 
P98160;B6EU51;Q2VPA1;Q59
EG0 
Secreted 1.54 1.99 
Biglycan;cDNA FLJ35635 fis, 
clone SPLEN2011805, highly 
similar to BONE/CARTILAGE 
PROTEOGLYCAN I;Putative 
uncharacterized protein 
BGN;cDNA FLJ59360, 
moderately similar to 
Biglycan;cDNA FLJ35704 fis, 
clone SPLEN2020183, highly 
similar to Biglycan;cDNA 
FLJ598 
P21810;A8K7E0;B4DDQ2;Q5
3FI4;Q53HU6;Q8NAB7;A6NL
G9;B4DNL4;B3KS75;B4DDN
7;B4DQD6 
Secreted NI 1.53 
Bone-derived growth factor Q13876;O00391- Secreted NI 2.26 
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(Fragment);Isoform 1 of 
Sulfhydryl oxidase 1;Putative 
uncharacterized protein 
QSOX1;Isoform 2 of 
Sulfhydryl oxidase 1 
1;O00391;A8K477;A8K4C2;A
8MXT8;O00391-2 
Calpain-2 catalytic 
subunit;cDNA FLJ58224, 
highly similar to Calpain-2 
catalytic subunit 
P17655;B2RCM3;B4DN77;B4
E1R7 
Membrane 0.74 NI 
CALUMENIN;Isoform 1 of 
Calumenin;Isoform 2 of 
Calumenin 
B3KPG9;B3KQF5;O43852-
1;O43852;Q6IAW5;O43852-
2;B3KNG6;B3KQK3 
Secreted 1.45 1.96 
Cathepsin B;cDNA FLJ58073, 
moderately similar to Cathepsin 
B;cDNA FLJ40065 fis, clone 
TESOP2000400, highly similar 
to CATHEPSIN B 
P07858;A8K2H4;B4DMY4;Q6
LAF9;B4DL49;Q5HYG5;B3K
UJ8;Q8TAC7 
Secreted 1.26 2.47 
Cathepsin D;Putative 
uncharacterized protein 
CTSD;Putative uncharacterized 
protein CTSD 
P07339;C9JTL0;C9JIH9 Secreted 1.44 1.93 
Cathepsin K P43235;Q6FHN2;Q6FHS6 Secreted 1.96 NI 
Cathepsin L1;Cathepsin L1 P07711;A5PLM9;B3KQK4;Q6
LAF7;Q9HBQ7;Q5K630;Q5T8
F0;Q8NG13 
Secreted 1.92 NI 
C-C motif chemokine 2 P13500 Secreted 1.82 NI 
CD166 antigen;cDNA, 
FLJ79012, highly similar to 
CD166 antigen;Isoform 2 of 
CD166 antigen;Activated 
leukocyte cell adhesion 
molecule soluble 
isoform;cDNA FLJ52980, 
highly similar to CD166 
antigen 
Q13740-
1;Q13740;B3KNN9;B4DTU0;
Q13740-2;Q6PEY4;B4DX43 
Membrane 1.20 NI 
CD44 antigen;Isoform 5 of 
CD44 antigen;Isoform 7 of 
CD44 antigen;Isoform 3 of 
CD44 antigen;Isoform 4 of 
CD44 antigen;Isoform 6 of 
CD44 antigen;Isoform 17 of 
CD44 antigen;Isoform 8 of 
CD44 antigen;Isoform 16 of 
CD44 antigen;Isoform 10 of 
CD4 
P16070-1;P16070;P16070-
5;P16070-7;P16070-3;P16070-
4;C1PHC2;Q9H5A7;Q9P2Z2;P
16070-6;P16070-17;P16070-
8;B4XHE2;C1PHE6;P16070-
16;P16070-
10;B4E2X0;Q9H5A6;P16070-
11;P16070-13;P16070-
14;A6NDN4;P16070-
12;A8K309;Q9H5A4;B6EAT9;
B4DN59 
Membrane 0.95 1.89 
CD59 glycoprotein P13987;Q6FHM9 Membrane NI 3.96 
Cell proliferation-inducing 
protein 41;73 kDa protein 
P27658;A1KY36 Secreted NI 1.29 
Chitinase-3-like protein 1 P36222 Secreted NI 1.40 
Chondroitin sulfate 
proteoglycan 4 
Q6UVK1;A2VCL1 Membrane 1.32 NI 
Clusterin;54 kDa 
protein;Isoform 1 of 
Clusterin;CLU 
P10909-2;P10909;P10909-
1;B3KSE6;B4DW11;Q6LDQ3;
Q8IWL5;Q8IWM0 
Secreted 31.52 1.43 
Coatomer subunit 
alpha;Isoform 1 of Coatomer 
subunit alpha 
P53621-2;P53621;P53621-1 Secreted? NI 1.62 
Coiled-coil domain-containing 
protein 80;Isoform 1 of Coiled-
coil domain-containing protein 
80;Putative uncharacterized 
protein CCDC80;cDNA 
Q76M96-
2;Q76M96;A3KC71;A8KA16;
Q76M96-1;C9JDY9;Q76M96-
3;B4E342 
Secreted 1.54 1.60 
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FLJ54405, highly similar to 
Homo sapiens steroid sensitive 
gene 1 (URB), transcript variant 
2, mRNA 
COL6A3 protein;alpha 3 type 
VI collagen isoform 4 
precursor;132 kDa protein 
B7ZW00;C9JNG9;B4E0A4;B7
ZMJ7;Q59F25;Q6MZG6;Q8N
4Z1 
Secreted NI 2.54 
Collagen alpha-1(I) chain P02452;Q14042;Q6LAN8;Q9U
MA6 
Secreted 1.27 2.15 
Collagen alpha-1(V) chain P20908;B2ZZ86;Q59EE7;Q96
HC0;Q9UML4 
Secreted NI 1.81 
Collagen alpha-1(VI) chain P12109;B4DRR8;Q05BT9;Q8
TBN2 
Secreted 1.70 1.89 
Collagen alpha-1(VII) 
chain;Isoform 2 of Collagen 
alpha-1(VII) chain 
Q02388-
1;Q02388;Q59F16;Q02388-
2;A9Z119;B0LXL0 
Secreted 1.62 NI 
Collagen alpha-1(XII) 
chain;Isoform 4 of Collagen 
alpha-1(XII) chain 
Q99715-
1;Q99715;B9EJB8;Q99715-4 
Secreted 1.73 1.81 
Collagen alpha-1(XXII) 
chain;Isoform 2 of Collagen 
alpha-1(XXII) chain;Isoform 3 
of Collagen alpha-1(XXII) 
chain 
Q8NFW1-
1;Q8NFW1;Q8NFW1-
2;Q8NFW1-3;C9K0G4 
Secreted 1.75 NI 
Collagen alpha-2(I) chain P08123;A2TIK1;Q75N18;Q7K
Z71 
Secreted 1.30 2.14 
Collagen alpha-2(V) chain;110 
kDa protein;COL5A2 
protein;cDNA FLJ53096, 
highly similar to Collagen 
alpha-2(V) chain 
P05997;B4DNJ0;Q5PR22;B4D
TC0 
Secreted 1.44 1.55 
Collagen alpha-2(VI) chain P12110-1;P12110;Q9BUM6 Secreted 1.77 1.93 
Collagen alpha-2(VI) 
chain;Isoform 2C2A' of 
Collagen alpha-2(VI) chain 
P12110-2;P12110;P12110-3 Secreted  1.64 
Collagen alpha-3(VI) 
chain;COL6A3 protein;322 
kDa protein;Isoform 2 of 
Collagen alpha-3(VI) 
chain;alpha 3 type VI collagen 
isoform 4 precursor;325 kDa 
protein;132 kDa protein 
P12111-
1;P12111;B7ZW00;C9JNG9;P
12111-
2;B4E0A4;B7ZMJ7;Q59F25;Q
6MZG6;Q8N4Z1 
Secreted 1.76 1.93 
Complement C1r 
subcomponent;cDNA 
FLJ54318, highly similar to 
Complement C1r 
subcomponent 
P00736;A8K5J8;B4DPQ0;Q53
HT9;Q53HU9;B4E1B0 
Secreted 1.50 2.10 
Complement C1s 
subcomponent;Putative 
uncharacterized protein C1S 
P09871;A8K2N0;B3KNX0;A6
NG18 
Secreted 1.66 2.37 
Connective tissue growth 
factor;Isoform 2 of Connective 
tissue growth factor 
P29279-
1;P29279;B2RCP7;B3KRV6;B
3KWK5;Q5M8T4;Q6FHL8;P2
9279-2;Q9UDL6 
Secreted 0.79 1.41 
Cystatin-C P01034 Secreted 1.46 2.18 
Decorin;Isoform B of 
Decorin;Isoform D of Decorin 
P07585-
1;P07585;Q6FH10;P07585-
2;P07585-4 
Secreted 1.23 1.72 
Deleted in malignant brain 
tumors 1 protein;Isoform 7 of 
Deleted in malignant brain 
tumors 1 protein;Isoform 1 of 
Deleted in malignant brain 
tumors 1 protein;261 kDa 
Q9UGM3-
6;Q9UGM3;A6ND64;Q9UGM
3-7;Q9UGM3-1;Q9UGM3-
3;Q9UGM3-5;Q9UGM3-
2;B6V682;B7Z8Y2;Q9UGM3-
8;Q9UGM3-
Secreted 2.24 NI 
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protein;Isoform 3 of Deleted in 
malignant brain tumors 1 
protein;Isoform 5 of 
4;A6NFE0;A6NDZ5;A8MYK5 
Dermcidin isoform 
2;Dermcidin 
A5JHP3;P81605;Q53YJ2 Secreted 4.67 1.22 
EGF-containing fibulin-like 
extracellular matrix protein 
1;Isoform 3 of EGF-containing 
fibulin-like extracellular matrix 
protein 1;Isoform 4 of EGF-
containing fibulin-like 
extracellular matrix protein 
1;Isoform 2 of EGF-containing 
fibulin-like 
Q12805-
1;Q12805;A8KAJ3;B2R6M6;Q
59G97;Q12805-3;Q12805-
4;Q12805-
2;Q53TA7;B4DW75;B4DWH0
;B3KS53 
Secreted 1.54 1.95 
EGF-like repeat and discoidin 
I-like domain-containing 
protein 3;Isoform 2 of EGF-like 
repeat and discoidin I-like 
domain-containing protein 3 
O43854-
1;O43854;Q8N610;O43854-
2;B7Z865 
Secreted NI 1.56 
EMILIN-1 Q9Y6C2 Secreted 1.40 NI 
Endosialin Q9HCU0-1;Q9HCU0 Membrane NI 1.65 
Extracellular matrix protein 
1;Isoform 1 of Extracellular 
matrix protein 1 
Q16610-4;Q16610;Q16610-
1;C8CHS3 
Secreted 1.88 2.77 
Fibrillin-1 P35555;B4E3I6;Q75N88;Q75
N89;Q9NP01 
Secreted 1.57 2.07 
Fibroleukin Q14314;A4D1B8;Q53GD2;Q8
WWE4 
Secreted 1.31 NI 
fibronectin 1 isoform 2 
preproprotein 
Q14328 Secreted 1.04 NI 
fibronectin 1 isoform 4 
preproprotein;FN1 protein;263 
kDa protein 
P02751-
4;P02751;A6YID3;Q5CZ99;Q
9UQS6;P02751-
10;B4DN21;B7ZLE5;B7ZLF0 
Secreted 1.35 1.73 
fibronectin type III domain 
containing 1;Isoform 2 of 
Fibronectin type III domain-
containing protein 1;FNDC1 
protein;179 kDa protein 
Q4ZHG4-
1;Q4ZHG4;B3KXM5;B7ZBR5
;B9EK49;Q4ZHG4-
2;A6H8X2;B7ZBR4 
Secreted NI 0.96 
Fibronectin;Isoform 3 of 
Fibronectin;Isoform 15 of 
Fibronectin;Isoform 7 of 
Fibronectin;Isoform 5 of 
Fibronectin;Isoform 8 of 
Fibronectin;Isoform 14 of 
Fibronectin;Isoform 9 of 
Fibronectin;Isoform 11 of 
Fibronectin;Isoform 13 of 
Fibronectin;Is 
P02751-
1;P02751;A6YID6;P02751-
3;A6YID2;O95617;Q68CX6;P
02751-15;P02751-
7;Q6MZM7;P02751-
5;A6YID5;P02751-8;P02751-
14;A6YID4;Q59G22;Q6N084;
P02751-9;B4DU16;P02751-
11;P02751-13;P02751-
6;P02751-12 
Secreted NI 1.93 
Fibulin 1;Isoform C of Fibulin-
1 
B0QY41;P23142-
4;P23142;B0QY42;B4DUV1 
Secreted 6.82 12.46 
Fibulin-1;Isoform B of Fibulin-
1;fibulin 1 isoform B 
precursor;Isoform A of Fibulin-
1 
P23142-
1;P23142;Q8NBH6;P23142-
3;B0QY43;P23142-2;B1AHM7 
Secreted NI 1.87 
Fibulin-1;Isoform D of Fibulin-
1;fibulin 1 isoform B 
precursor;Isoform A of Fibulin-
1 
P23142-3;P23142;P23142-
1;Q8NBH6;B0QY43;P23142-
2;B1AHM7 
Secreted 1.75 NI 
Follistatin;Isoform 3 of 
Follistatin;Isoform 2 of 
Follistatin 
P19883-
1;P19883;Q6FHE1;P19883-
3;P19883-2;B5BU94 
Secreted 1.11 1.62 
Follistatin-related protein 
1;cDNA FLJ50214, highly 
Q12841;A8K523;B4DTT5;B4
DTZ8;Q9BZQ0 
Secreted 1.64 2.16 
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similar to Follistatin-related 
protein 1 
Galectin-1 P09382;B2R5E8;Q15954 Secreted 0.90 1.78 
Galectin-3 P17931;Q59FR8;Q6FGL0;Q6I
BA7;Q6NVH9;Q86TY5;Q8IX
B9 
Secreted 0.88 NI 
Galectin-3-binding 
protein;cDNA FLJ53509, 
highly similar to Galectin-3-
binding protein;cDNA 
FLJ54583, highly similar to 
Galectin-3-binding protein 
Q08380;B4DVE1;B4DWA8;B
4DI70;B3KP88;B4DDG4 
Secreted 2.09 2.28 
Gelsolin;gelsolin isoform 
c;Isoform 2 of Gelsolin;cDNA 
FLJ53327, highly similar to 
Gelsolin;cDNA FLJ35478 fis, 
clone SMINT2007796, highly 
similar to Gelsolin 
P06396-
1;P06396;B7Z6N2;B7Z9A0;Q
5T0I2;B7Z373;B7Z5V1;Q5T0I
1;Q69YR8;P06396-
2;A2A418;B7Z4U6;B7Z992;B
7Z2X4;Q5T0H8;B3KS49;Q5T
0H9 
Secreted 1.23 NI 
Gremlin-1;Isoform 2 of 
Gremlin-1 
O60565-
1;O60565;A6XAA7;O60565-2 
Secreted 1.53 NI 
Growth arrest-specific protein 
6;Isoform 2 of Growth arrest-
specific protein 6;Isoform 3 of 
Growth arrest-specific protein 
6;growth arrest-specific 6 
isoform 2;growth arrest-specific 
6 isoform 3 
Q14393-1;Q14393;Q14393-
2;Q14393-
3;B4DZY7;B3KRQ7;B3KVL4;
Q658L2 
Secreted 1.57 NI 
Hepatoma-derived growth 
factor;hepatoma-derived growth 
factor isoform b;Hepatoma-
derived growth 
factor;hepatoma-derived growth 
factor isoform c 
B7Z525;Q5SZ07;P51858;B2R
DE8;A8K8G0;B3KU21;B7Z95
8;Q5SZ08 
Secreted NI 4.21 
Hyaluronan and proteoglycan 
link protein 1 
P10915 Secreted NI 2.87 
Immunoglobulin superfamily 
containing leucine-rich repeat 
protein;Putative 
uncharacterized protein ISLR 
O14498;C9J667 Secreted NI 1.53 
insulin-like growth factor 2 
isoform 2;Isoform 1 of Insulin-
like growth factor II;Isoform 2 
of Insulin-like growth factor II 
A8K6C9;C9JAF2;P01344-
1;P01344;B2MUX6;P01344-2 
Secreted 98.75 116.24 
insulin-like growth factor 
binding protein 3 isoform a 
precursor;Insulin-like growth 
factor-binding protein 3;cDNA 
FLJ45630 fis, clone 
CHONS2001287, moderately 
similar to INSULIN-LIKE 
GROWTH FACTOR 
BINDING PROTEIN 3;cDNA 
FLJ52568, highly similar to 
Insulin 
P17936;A6XND0;A6XND1;B3
KVF9;B4DN53;A6XNC9;B3K
TQ0;B3KWK7;B4DP07;B3KR
Z1;B3KTS0;B3KVY6;Q6ZSD
0;C9JMX4 
Secreted NI 2.15 
Insulin-like growth factor-
binding protein 4 
P22692;B4E351 Secreted 1.69 1.59 
Insulin-like growth factor-
binding protein 5 
P24593 Secreted 1.48 2.05 
Insulin-like growth factor-
binding protein 6 
P24592;Q9H2B5 Secreted 2.34 3.33 
Insulin-like growth factor-
binding protein 7 
Q16270;B4E1N2;B7Z9W7 Secreted 1.72 2.59 
Integrin beta-1 P05556-1;P05556 Membrane 1.35 NI 
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Integrin beta-like protein 
1;cDNA FLJ59733, highly 
similar to Homo sapiens 
integrin, beta-like 1 (with EGF-
like repeat domains) (ITGBL1), 
mRNA;Osteoblast specific 
cysteine-rich protein 
O95965;B3KTP1;B4DN32;B4
DQ02;O14549 
Secreted  2.47 
Lactadherin;milk fat globule-
EGF factor 8 protein isoform b 
Q08431;B3KTQ2;B4E396;Q7
Z3D2;Q9BTL9 
Membrane NI 1.58 
Laminin subunit gamma-1 P11047;Q6NVY8 Secreted 1.78 1.28 
Latent-transforming growth 
factor beta-binding protein 
1;173 kDa protein;Isoform 
Short of Latent-transforming 
growth factor beta-binding 
protein 1;latent transforming 
growth factor beta binding 
protein 1 isoform 4 
precursor;Isoform 3 of Lat 
Q14766-1;Q14766;Q14766-
2;B7ZLY3;C9J9Y0;Q14766-
3;B4DNR7;B4DRF7;B4DST8;
B4DZD1;C9JCG4;C9JD84 
Secreted 1.97 NI 
Latent-transforming growth 
factor beta-binding protein 2 
Q14767;Q59EE6;Q6AZ94 Secreted 1.86 0.77 
Lumican P51884;Q53FV4 Secreted 1.78 2.37 
Lysyl oxidase homolog 
2;cDNA FLJ53707, highly 
similar to Lysyl oxidase 
homolog 2 
Q9Y4K0;B2R5Q0;Q53HV3;B
4DDQ4 
Secreted NI 1.30 
Macrophage migration 
inhibitory factor 
P14174;A6MUU8 Secreted 1.48 2.57 
matrix metalloproteinase 14 
preproprotein;Matrix 
metalloproteinase-14 
B2R6P3;Q9UHK5;P50281 Membrane 0.98 2.12 
mesencephalic astrocyte-
derived neurotrophic 
factor;Mesencephalic astrocyte-
derived neurotrophic 
factor;Putative uncharacterized 
protein MANF 
A8K878;P55145;C9J3P1 Secreted 1.15 NI 
Metalloproteinase inhibitor 
1;TIMP metallopeptidase 
inhibitor 1;TIMP 
metallopeptidase inhibitor 1 
P01033;B3KQF4;Q58P21;Q6F
GX5;Q5H9A7;Q5H9A8 
Secreted 1.32 2.00 
Metalloproteinase inhibitor 
2;22 kDa protein;cDNA 
FLJ57920, highly similar to 
Metalloproteinase inhibitor 2 
P16035;B4DFW2 Secreted 1.80 2.28 
Metalloproteinase inhibitor 
3;TIMP metallopeptidase 
inhibitor 3 
P35625;B4DNZ4;Q6LEP5;B1
AJV7 
Secreted NI 1.67 
Mimecan;Osteoglycin P20774;A8K0R3;B4DI63;Q7Z
532;Q5TBF5 
Secreted 1.67 NI 
Mucin-16;1518 kDa 
protein;mucin 16 
Q8WXI7;B5ME49 Secreted/mem
brane 
NI 0.09 
Mutant p53 binding protein 1 
variant (Fragment);EGF-
containing fibulin-like 
extracellular matrix protein 2 
Q59GI8;O95967;A8K7R4;B2R
CM5;B3KM31;Q6FH22;Q96T
F5;Q9H3D5 
Secreted NI 1.73 
Neuropilin-2;Isoform A17 of 
Neuropilin-2;Isoform A0 of 
Neuropilin-2;neuropilin 2 
isoform 4 precursor;neuropilin 
2 isoform 5 
precursor;neuropilin 2 isoform 
6 precursor 
O60462-
1;O60462;B7ZL68;Q7LBX7;Q
7Z3T9;O60462-
3;Q7LBX6;O60462-
2;Q9H2D4;Q9H2E3;A8K4G9;
Q9H2D5;Q9H2E4;Q9H2E2 
Membrane 1.32 NI 
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Nidogen-1;Isoform 2 of 
Nidogen-1 
P14543-1;P14543;P14543-2 Secreted 1.84 NI 
Nidogen-2;NID2 
protein;Putative 
uncharacterized protein 
DKFZp686D12108 (Fragment) 
Q14112;A8K6I7;B4DPX8;B4
DU19;Q8IV28;Q5CZI2 
Secreted 1.74 NI 
Nucleobindin-2;Isoform 2 of 
Nucleobindin-2 
P80303-1;P80303;P80303-2 Membrane 1.33 1.82 
Olfactomedin-like protein 
3;Isoform 2 of Olfactomedin-
like protein 3 
Q9NRN5-
1;Q9NRN5;Q9NRN5-
2;B4DNG0 
Secreted 1.37 1.30 
Pentraxin-related protein PTX3 P26022 Secreted 1.49 1.54 
Periostin, osteoblast specific 
factor;Isoform 4 of Periostin 
B1ALD9;Q15063-
4;Q15063;B7Z6G1;C0IMJ4 
Secreted NI 1.73 
Periostin;Periostin, osteoblast 
specific factor;Isoform 2 of 
Periostin 
Q15063-
1;Q15063;C0IMJ1;Q15063-
3;B1ALD8;B4E3A7;C0IMJ3;Q
15063-2;B7Z4V4;C0IMJ2 
Secreted NI 0.16 
Pigment epithelium-derived 
factor;25 kDa protein 
P36955;Q2TU83 Secreted NI 0.96 
Plasminogen activator inhibitor 
1;plasminogen activator 
inhibitor-1 isoform 2 precursor 
P05121;B7Z1D9;B7Z4S0;B7Z
4X6;B7ZAB0;C9J272 
Secreted 1.02 2.05 
plasminogen activator inhibitor 
type 1, member 2 isoform c 
precursor;45 kDa 
protein;Isoform 1 of Glia-
derived nexin;Isoform 2 of 
Glia-derived nexin;Putative 
uncharacterized protein 
SERPINE2;Putative 
uncharacterized protein 
SERPINE2 
B4DIF2;P07093-
1;P07093;P07093-
2;B4DMR3;C9JYC8;C9JN98 
Secreted 1.74 1.96 
Procollagen C-endopeptidase 
enhancer 1;cDNA FLJ55126, 
highly similar to Procollagen C-
endopeptidase enhancer 1 
Q15113;A4D2D2;B4DPJ4 Secreted NI 2.59 
Proenkephalin-A;25 kDa 
protein 
P01210;Q3B7B1 Secreted 1.67 3.64 
Protein CYR61;cDNA 
FLJ58182, highly similar to 
Protein CYR61;CYR61 protein 
O00622;Q53FA4;Q6FI18;B4D
I61;Q9UID7 
Secreted 1.26 NI 
Protein disulfide-
isomerase;cDNA FLJ59430, 
highly similar to Protein 
disulfide-isomerase 
P07237;B2RDQ2;B4DJS0;B4
DNL5;B3KTQ9;B4DLN6;B4D
UA5;Q96C96 
Membrane 1.35 1.72 
Protein S100-A13 Q99584 Secreted 1.07 3.05 
Protein-lysine 6-oxidase P28300;B0AZT2;B4DN04;B4
DQF8;B7ZAJ4;D0PNI2;Q71V
04;Q96PQ9 
Secreted 1.58 1.72 
Putative killer cell 
immunoglobulin-like receptor-
like protein KIR3DX1;Isoform 
1 of Putative killer cell 
immunoglobulin-like receptor-
like protein KIR3DX1;Putative 
uncharacterized protein 
KIR3DX1;Putative 
uncharacterized protein 
KIR3DX1 
Q9H7L2-2;Q9H7L2;Q9H7L2-
1;C9JDH6;C9JJY8 
Secreted NI 1.45 
Putative uncharacterized 
protein CD81;CD81 antigen 
A6NMH8;P60033 Membrane 1.38 NI 
Putative uncharacterized 
protein COL5A1 
A6NNQ0;Q5JR39 Secreted NI 0.79 
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Putative uncharacterized 
protein GPC1;Glypican-
1;Putative uncharacterized 
protein GPC1;Glypican 1, 
isoform CRA_a 
C9JGZ5;P35052;Q53EX3;C9J
1L8;B3KTD1;Q59GI7 
Membrane/sec
reted 
1.70 1.49 
Retinol-binding protein 
4;Retinol binding protein 4, 
plasma, isoform 
CRA_b;Retinol binding protein 
4, plasma 
P02753;A6NCP9;Q5VY30 Secreted NI 8.00 
Semaphorin-7A;semaphorin 7A 
isoform 2 
preproprotein;semaphorin 7A 
isoform 3 
O75326;B4DDP7;B3KMH6 Secreted 1.39 2.13 
Serine protease 23;cDNA 
FLJ51190, highly similar to 
Serine protease 23 
O95084;B3KQQ9;B4E2J3 Secreted 1.20 1.21 
Serine protease HTRA1;cDNA 
FLJ34625 fis, clone 
KIDNE2015244, highly similar 
to Serine protease HTRA1 
Q92743;B3KRN4 Secreted NI 2.03 
small inducible cytokine 
subfamily E, member 1 isoform 
b precursor;Aminoacyl tRNA 
synthetase complex-interacting 
multifunctional protein 1;cDNA 
FLJ52127, highly similar to 
Multisynthetase complex 
auxiliary component p43 
B4E1S7;Q12904;B4DNK3 Secreted 1.66 NI 
SPARC P09486;B2RDL6;B4DRV4;Q6
QE20 
Secreted 2.17 1.17 
Stanniocalcin-2 O76061;B3KNF2;Q6FHC9 Secreted NI 1.89 
Sulfhydryl oxidase 1;Putative 
uncharacterized protein 
QSOX1;Isoform 2 of 
Sulfhydryl oxidase 1 
O00391-
1;O00391;A8K477;A8K4C2;A
8MXT8;O00391-2 
Secreted 1.67 NI 
Sushi, von Willebrand factor 
type A, EGF and pentraxin 
domain-containing protein 
1;polydom;Isoform 3 of Sushi, 
von Willebrand factor type A, 
EGF and pentraxin domain-
containing protein 1 
Q4LDE5-1;Q4LDE5;Q4LDE5-
3;B3KQM1 
Secreted 1.61 NI 
Target of Nesh-SH3 precursor 
(Tarsh) (Nesh-binding protein) 
(NeshBP) (ABI gene family 
member 3-binding protein). 
Isoform 2;Isoform 1 of Target 
of Nesh-SH3;Putative 
uncharacterized protein 
ABI3BP 
(Fragment);Protein;cDNA 
FLJ56632, moderately similar 
to Targe 
Q7Z7G0-3;Q7Z7G0;Q7Z7G0-
1;C9J0V1;B4DSV9;Q7Z7G0-
4;Q7Z7G0-2 
Secreted? NI 1.69 
Tenascin;Isoform 4 of 
Tenascin;Isoform 3 of 
Tenascin;Isoform 2 of 
Tenascin;Isoform 5 of 
Tenascin;TNC protein;Isoform 
6 of Tenascin 
P24821-
1;P24821;Q4LE33;Q5T7S3;P2
4821-4;C9J848;P24821-
3;C9J6D9;P24821-2;P24821-
5;C9J575;A7MBN2;P24821-
6;C9IYT7 
Secreted 1.40 2.50 
Testican-1 Q08629;O60400 Secreted 1.34 1.60 
Thrombospondin-1 P07996;A0PJG0;B4E3J7;Q59E
99;Q7KYY3 
Secreted 1.66 1.49 
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Thrombospondin-
2;Thrombospondin 2 
P35442;Q6MZL6;Q5RI53 Secreted 1.44 1.55 
Thrombospondin-4 P35443;B7Z832 Secreted 0.79 NI 
Thy-1 membrane 
glycoprotein;Thy-1 cell surface 
antigen variant (Fragment) 
P04216;B0YJA4;Q59GA0 Membrane NI 0.89 
Tissue factor pathway inhibitor 
2 
P48307;Q8NAK6;Q8NE89;Q9
6QP2 
Secreted 1.64 NI 
Tissue-type plasminogen 
activator;Isoform 3 of Tissue-
type plasminogen 
activator;cDNA FLJ59440, 
highly similar to Tissue-type 
plasminogen activator;cDNA 
FLJ59355, highly similar to 
Tissue-type plasminogen 
activator;cDNA FLJ59358, 
highly simila 
P00750-
1;P00750;B4DRD3;B8ZX62;P
00750-
3;B2R8E8;Q5HYM8;B4DV92;
B4DN26;Q6LBF5;P00750-
4;B4DNJ1 
Secreted 0.93 1.76 
Transforming growth factor-
beta-induced protein ig-h3;60 
kDa protein;Transforming 
growth factor, beta-induced, 
68kDa, isoform CRA_a 
Q15582;Q53GU8;Q53XM1;B9
ZVW9;C7FFS5 
Secreted 2.00 1.74 
Tubulointerstitial nephritis 
antigen-like;cDNA FLJ55020, 
highly similar to 
Tubulointerstitial nephritis 
antigen-like 
Q9GZM7-
1;Q9GZM7;B4DVG5;B4DPK6 
Secreted NI 0.26 
Tumor necrosis factor receptor 
superfamily member 11B 
O00300 Secreted 1.43 NI 
UPF0027 protein 
C22orf28;cDNA FLJ58027 
Q9Y3I0;B4DNA0 Membrane? 1.87 NI 
Vasorin Q6EMK4 Membrane/Sec
reted 
1.34 2.83 
Versican core protein;Isoform 
Vint of Versican core 
protein;Isoform V1 of Versican 
core protein;Isoform V2 of 
Versican core protein;Isoform 
V3 of Versican core protein 
P13611-
1;P13611;Q59FG9;P13611-
5;P13611-
2;B7Z638;Q6MZK8;P13611-
3;B7Z3R6;P13611-4;Q86W61 
Secreted 1.55 2.66 
Table 1. List of putative secreted proteins in the media of gastric myofibroblasts and of 
MSCs. From approximately 250 proteins that were initially identified, a list of 143 predicted 
secreted proteins was generated. Of these, 106 proteins were predicted as secreted into the 
media of myofibroblasts. An identical number of proteins were predicted to be secreted into 
the media of MSCs. The information provided in this Table includes protein name, unique 
UniProt identification number(s), predicted localisation and relative abundance in IGF-
treated vs control media for both cell types. NI-Not Identified.  
 
 
 
